Stapled peptide-antibody conjugates (SPACs) and their uses

Stapled peptide-antibody conjugates (SPACs) address the issues of linker instability and low cell penetration in ADCs by targeting stapled peptides to cancer cells with high selectivity and reduced off-target toxicity, enhancing the efficacy of therapeutic delivery.

JP2024545161APending Publication Date: 2024-12-05LYTICA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024534450
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-17
Filing Date
2022-12-09
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Antibody-drug conjugates (ADCs) face challenges such as non-specific toxicity due to linker instability, leading to unintended damage of healthy tissues, and low cell penetration rates of stapled peptides, which hinder targeted delivery of therapeutic agents.

Method used

Development of stapled peptide-antibody conjugates (SPACs) that conjugate stapled peptides to antibodies or their fragments via linkers, enabling targeted delivery of therapeutic agents to cells with high selectivity and low off-target toxicity.

Benefits of technology

SPACs achieve targeted delivery of stapled peptides to cancer cells with high potency and reduced off-target toxicity, overcoming the limitations of traditional ADCs by utilizing the internalization of the conjugate for selective cell entry.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545161000001_ABST
    Figure 2024545161000001_ABST
Patent Text Reader

Abstract

Provided herein are stapled peptide-antibody conjugates (SPACs) comprising a stapled peptide conjugated to an antibody or antigen-binding fragment thereof. In some embodiments, the stapled peptide is conjugated to the antibody or antigen-binding fragment thereof via a linker. In some embodiments, the SPACs provided herein can be used to deliver the stapled peptide to cells (e.g., cancer cells) with relatively high selectivity and relatively low off-target toxicity. Also provided herein are pharmaceutical compositions and kits comprising the SPACs described herein, methods of using them (e.g., to treat cancer and / or inhibit tumor growth in a subject), and methods of preparing them.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Nos. 63 / 288,498, filed December 10, 2021; 63 / 321,968, filed March 21, 2022; and 63 / 353,275, filed June 17, 2022, the entire contents of which are incorporated herein by reference. [Background technology]

[0002] background Antibody-drug conjugates (ADCs) are a unique class of oncology drugs that can deliver highly cytotoxic payloads directly into cells (e.g., cancer cells). This advance in precision medicine has enabled the use of highly potent chemotherapeutics that previously had very narrow therapeutic windows. ADCs have been described, for example, in Drago et al., Nature Reviews Clinical Oncology, 2021, vol. 18, 327-344; Baah et al., Molecules, 2021, 26(10), 2943; Khongorzul et al., Mol. Cancer Res., 2020, 18(1): 3-19; and Beck et al., Nature Reviews Drug Discovery, 2017, vol. 16, 315-337.

[0003] Interestingly, ADCs can be used to treat cancer patients who have been heavily pretreated with other chemotherapeutic agents, including those in the same therapeutic class, and even with the same unconjugated antibodies, due to the high potency of their cargo. However, despite the great advances in the field, some serious liabilities of ADCs still need to be resolved. One of these issues is the non-specific toxicity of ADC cargoes, for example due to linker instability. As these cargoes tend to be highly cytotoxic, they may damage healthy tissues if unintentionally released outside of tumor cells. Efforts to solve this problem have mainly focused on creating new linkers with higher stability and release selectivity. Summary of the Invention

[0004] SUMMARY OF THE PRESENT APPLICATION Described herein is a new class of therapeutic agents that overcomes many of the problems of current antibody-drug conjugates (ADCs) and expands the payload beyond current highly cytotoxic drugs. The conjugates described herein rely on a unique class of peptides known as stapled peptides, which offer distinct advantages without many of the drawbacks of current ADCs.

[0005] Stapled peptides are synthetic peptides that contain at least two unnatural amino acids connected via a bridge (i.e., a "staple"). For example, a stapled peptide can contain at least two unnatural olefin-bearing amino acids that are cyclized via metathesis to form an internal hydrocarbon bridge (i.e., a "hydrocarbon staple"). This process of cyclization, or "stapling," can help fold the peptide into an alpha-helical conformation or other secondary structure, thereby restoring the native three-dimensional orientation of protein structures to mimic their biological function. Examples of stapled peptide technology can be found, for example, in International PCT Application Publication No. WO 2017 / 004591, published January 5, 2017; WO 2019 / 018499, published January 24, 2019; and WO 2021 / 126827, published June 24, 2021, the entire contents of each of which are incorporated herein by reference. See also, for example, Mourtada et al., Nature Biotechnology, 2019, vol. 37, 1186-1197, the entire contents of which are incorporated herein by reference.

[0006] Since their development in the early 2000s, stapled peptides have been shown to be able to disrupt protein-protein interactions (PPIs) both extracellularly and intracellularly. Currently, Aileron Therapeutics has a stapled peptide drug candidate, ALRN-6924, in Phase 2 clinical trials as a preventative treatment for chemotherapy-induced neutropenia. Although stapled peptides themselves are promising therapeutic agents, a challenge in some development efforts is the inability to deliver stapled peptides intracellularly without triggering lysis of off-target cells. This is because many stapled peptides exhibit poor cell penetration.

[0007] However, in the context of antibody conjugates, the low cell penetration rate of some stapled peptides can be an asset rather than a drawback. By conjugating stapled peptides to antibodies or antigen-binding fragments, cargo / payload (i.e., stapled peptide) can be delivered into cells by exploiting the internalization of the conjugate, which would otherwise be inactive or have low activity outside the cell. Similarly, the ability of antibodies to aggregate payloads at the plasma membrane of receptor-positive cells may allow targeted delivery of otherwise nonspecifically lytic stapled peptides. Leveraging the unique properties of stapled peptides in these systems allows for the delivery of therapeutic agents with high potency but without the off-target toxicity of previous ADCs.

[0008] Provided herein are stapled peptide-antibody conjugates (SPACs) comprising a stapled peptide conjugated to an antibody or antigen-binding fragment thereof. In some embodiments, the stapled peptide is conjugated to the antibody or antigen-binding fragment thereof via a linker. In some embodiments, the SPACs provided herein can be used to deliver the stapled peptide to cells (e.g., cancer cells, bacterial cells) with relatively high selectivity and / or relatively low off-target toxicity.

[0009] The SPACs provided herein include antibodies or antigen-binding fragments, including intact antibodies and antigen-binding fragments, variants, and derivatives thereof, including, but not limited to, polyclonal, monoclonal, multispecific, human, humanized, primatized, or chimeric antibodies, heteroconjugate antibodies (e.g., bi-, tri-, and tetraspecific antibodies, diabodies, triabodies, and tetrabodies), single domain antibodies (sdAbs), epitope-binding fragments (e.g., Fab, Fab', and F(ab')2, Fd, Fvs, single chain Fvs (scFv), rIgG, single chain antibodies, disulfide-linked Fvs (sdFv), fragments containing either the VL or VH domain, fragments produced by a Fab expression library), and anti-idiotypic (anti-Id) antibodies. Fab and F(ab')2 fragments, for example, lack the Fc fragment of an intact antibody. The antibody molecules of the conjugate may be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecule.

[0010] In some embodiments, the antibody is a monoclonal antibody (mAb) or an antigen-binding fragment thereof. In some embodiments, the antibody is an anti-cancer antibody or an antigen-binding fragment thereof. In some embodiments, the antibody or antigen-binding fragment thereof is directed against a target antigen expressed on cancer cells (e.g., specifically expressed on cancer cells). In some embodiments, the antibody is a homolog of the antibody or antigen-binding fragment thereof described herein.

[0011] In some embodiments, the antibody is an antibody-drug conjugate (ADC) or an antigen-binding fragment thereof. In such embodiments, the SPAC comprises a dual payload: (i) a stapled peptide or a pharma- ceutically acceptable salt thereof; and (ii) an antibody or an antigen-binding fragment thereof conjugated to a second agent (i.e., the "drug" component of the antibody-drug conjugate).

[0012] The stapled peptide component of a SPAC may be any stapled peptide (e.g., any single-stapled, doubly-stapled, multiply-stapled, or stitched peptide). In some embodiments, the stapled peptide is a stapled anti-cancer peptide. In some embodiments, the stapled peptide is a stapled antimicrobial peptide (StAMP). In some embodiments, the stapled peptide is a stapled Magainin peptide (e.g., stapled Magainin II peptide). In some embodiments, the stapled peptide is a stapled Esculentin peptide (e.g., stapled Esculentin-1A peptide).

[0013] In some embodiments, the stapled peptide is an inhibitor of a protein-protein interaction (PPI). In some embodiments, the stapled peptide is an inhibitor of a BCL-2 family member protein (e.g., BCL-x LIn some embodiments, the stapled peptide is an inhibitor of BCL-2 family member protein effectors (e.g., BAX, BAK, or BOK). In some embodiments, the stapled peptide is a stapled BCL-2 interacting mediator of cell death (BIM) peptide. In some embodiments, the stapled peptide is a β-catenin inhibitor (e.g., an inhibitor of Wnt / β-catenin signaling). In some embodiments, the stapled peptide is an inhibitor of MDM2 and / or MDMX (e.g., inhibits binding of MDM2 and / or MDMX to p53). Other examples of stapled peptides are described herein.

[0014] In some embodiments, the antibody or antigen-binding fragment thereof is conjugated directly (e.g., via a bond) to the stapled peptide. In some embodiments, the antibody or antigen-binding fragment thereof is conjugated to the stapled peptide via a linker. In some embodiments, the linker is a cleavable linker (e.g., a linker cleavable by pH, or a linker cleavable by proteases, esterases, or intracellular disulfide reduction). In some embodiments, the linker is a peptide linker (e.g., a cleavable peptide linker).

[0015] Also provided herein are pharmaceutical compositions comprising a SPAC provided herein and a pharma- ceutically acceptable carrier. In some embodiments, the pharmaceutical compositions include a therapeutically effective amount (e.g., to treat cancer or inhibit tumor growth in a subject) of a SPAC provided herein.

[0016] The stapled peptide antibody conjugates (SPACs) provided herein can deliver biologically active stapled peptides to cells (e.g., cancer cells, bacterial cells) and are therefore useful for the treatment and / or prevention of various diseases (e.g., proliferative diseases such as cancer, infectious diseases). Methods provided herein include: (i) A method of treating and / or preventing a disease in a subject, comprising administering to the subject a therapeutically and / or prophylactically effective amount of a SPAC provided herein, or a pharmaceutical composition thereof. In some embodiments, the disease is a proliferative disease (e.g., cancer); (ii) a method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a SPAC provided herein, or a pharmaceutical composition thereof; (iii) a method for inhibiting tumor growth in a subject, comprising administering to the subject an effective amount of a SPAC provided herein, or a pharmaceutical composition thereof; (iv) A method of delivering a stapled peptide into a cell, comprising contacting the cell with a SPAC or pharmaceutical composition thereof provided herein. In some embodiments, the cell is a cancer cell. In some embodiments, the stapled peptide is delivered to the cell in vitro. In some embodiments, the stapled peptide is delivered to the cell in vivo (i.e., in a subject); and (v) A method of inducing cancer cell death, comprising contacting a cancer cell with an effective amount of a SPAC provided herein or a pharmaceutical composition thereof. In some embodiments, the stapled peptide is delivered to the cell in vitro. In some embodiments, the stapled peptide is delivered to the cell in vivo (i.e., in a subject). (vi) a method for treating and / or preventing an infectious disease (e.g., a bacterial infection) in a subject, comprising administering to the subject an effective amount of a SPAC provided herein or a pharmaceutical composition thereof; (vii) a method for killing and / or inhibiting the growth of bacteria, comprising contacting the bacteria with an effective amount of a SPAC provided herein or a pharmaceutical composition thereof;

[0017] Also provided herein are SPACs described herein and pharmaceutical compositions thereof for use in any of the methods described herein. In another aspect, provided herein is the use of a SPAC described herein and pharmaceutical compositions thereof for the manufacture of a medicament.

[0018] In another aspect, provided herein is a kit comprising the SPAC or pharmaceutical composition thereof provided herein. The kit described herein may comprise a single dose or multiple doses of the SPAC or pharmaceutical composition thereof. The kit described herein is useful for any of the methods or uses provided herein, and optionally further comprises instructions for using the kit (e.g., instructions for using the SPAC or composition included in the kit).

[0019] Also provided herein are methods for preparing the SPACs described herein.

[0020] The details of certain aspects of the invention are set forth in the detailed description of certain aspects, as set forth below. Other features, objects, and advantages of the invention will be apparent from the definition, examples, figures, and claims.

[0021] definition General definition The following definitions are of general terms used throughout this application.

[0022] The terms "peptide" and "polypeptide" are used interchangeably and refer to a polymer of amino acid residues linked together by peptide bonds. The terms also include proteins and refer to peptides, polypeptides, and proteins of any size, structure, or function. Typically, a peptide will be at least three amino acids long, or at least as long as required by the amino acid sequences provided herein. A peptide may refer to an individual peptide, or a group of peptides. The peptides provided herein may include natural amino acids and / or non-natural amino acids (i.e., compounds that do not occur in nature but can be incorporated into a peptide chain) in any combination. One or more of the amino acids in a peptide may be modified, for example, by the addition of a chemical entity (such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation or functionalization, etc.), or other modification. A peptide may be a fragment or a modified version of a naturally occurring peptide or protein. A peptide may be naturally occurring, recombinant, synthetic, or any combination thereof.

[0023] The term "amino acid" refers to a molecule that contains both an amino group and a carboxyl group. Amino acids include alpha-amino acids, the comprehensive structure of which is depicted below. Each amino acid referred to herein may be represented by a one- to four-letter code (for example, R and Arg represent L-arginine, and hArg represents L-homoarginine). [ka]

[0024] Suitable amino acids include, without limitation, natural alpha-amino acids, such as the D- and L-isomers of the 20 common naturally occurring alpha-amino acids found in peptides (e.g., A, R, N, C, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, V, as provided below), and non-naturally occurring alpha-amino acids.

[0025] Exemplary natural alpha-amino acids (one letter abbreviations are provided in parentheses) include L-alanine (A), L-arginine (R), L-asparagine (N), L-aspartic acid (D), L-cysteine ​​(C), L-glutamic acid (E), L-glutamine (Q), glycine (G), L-histidine (H), L-isoleucine (I), L-leucine (L), L-lysine (K), L-methionine (M), L-phenylalanine (F), L-proline (P), L-serine (S), L-threonine (T), L-tryptophan (W), L-tyrosine (Y), and L-valine (V).

[0026] Exemplary unnatural alpha-amino acids include D-arginine, D-asparagine, D-aspartic acid, D-cysteine, D-glutamic acid, D-glutamine, D-histidine, D-isoleucine, D-leucine, D-lysine, D-methionine, D-phenylalanine, D-proline, D-serine, D-threonine, D-tryptophan, D-tyrosine, D-valine, di-vinyl, α-methyl-alanine (Aib), α-methyl-arginine, α-methyl-asparagine, α-methyl-amino acids. Non-natural amino acids include alpha-amino acids such as spartic acid, alpha-methyl-cysteine, alpha-methyl-glutamic acid, alpha-methyl-glutamine, alpha-methyl-histidine, alpha-methyl-isoleucine, alpha-methyl-leucine, alpha-methyl-lysine, alpha-methyl-methionine, alpha-methyl-phenylalanine, alpha-methyl-proline, alpha-methyl-serine, alpha-methyl-threonine, alpha-methyl-tryptophan, alpha-methyl-tyrosine, alpha-methyl-valine, norleucine, and terminally unsaturated alpha-amino acids. Many non-natural amino acids are known, any of which may be included in the peptides of the present disclosure. See, for example, S. Hunt, The Non-Protein Amino Acids: In Chemistry and Biochemistry of the Amino Acids, edited by GC Barrett, Chapman and Hall, 1985. Non-natural amino acids also include amino acids that contain nitrogenous substituents.

[0027] Certain amino acids referred to herein are provided below in Table 1 (represented by name, structure, and one- to four-letter code). Table 1. Certain amino acids [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4]

[0028] The term "amino acid substitution", when used in reference to an amino acid sequence, refers to an amino acid of an amino acid sequence being replaced by a different amino acid (e.g., replaced by a natural or non-natural amino acid). The amino acid sequences provided herein may contain or include one or more amino acid substitutions. A particular amino acid substitution is indicated by a colloquial nomenclature commonly used in the art of peptide sequencing to indicate variations in amino acid sequences. For example, with reference to SEQ ID NO:2 (below), "amino acid substitution at H7" refers to a histidine (H) at position 7 of the amino acid sequence being replaced by a different amino acid (e.g., a natural or non-natural amino acid other than histidine). Also with reference to SEQ ID NO:2, the amino acid substitution "H7K" refers to the replacement of the histidine (H) at position 7 of the amino acid sequence represented by SEQ ID NO:2 with a lysine (K), resulting in the amino acid sequence represented by SEQ ID NO:3 (below). [Table A]

[0029] The term "amino acid addition", when used in reference to an amino acid sequence, refers to an amino acid (e.g., a natural or unnatural amino acid) being inserted between two amino acids of an amino acid sequence or added at either end of the sequence. Standard colloquial nomenclature is used to represent the specific amino acid addition (e.g., with reference to SEQ ID NO:2, "G3_K4insX" indicates that a hypothetical amino acid X is inserted between amino acids G3 and K4 of the amino acid sequence). In some embodiments, the amino acid sequences herein may include 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid additions.

[0030] The term "amino acid deletion", when used in reference to an amino acid sequence, refers to an amino acid of the amino acid sequence being deleted from the amino acid sequence. Standard colloquial nomenclature is used to indicate the specific amino acid deletion (for example, with reference to SEQ ID NO:2, "G1del" indicates that the amino acid G1 is deleted from the sequence). In some embodiments, the amino acid sequence herein can include 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid deletions.

[0031] As used herein, the term "salt" refers to any and all salts and encompasses pharma- ceutically acceptable salts. Salts include ionic compounds resulting from the neutralization reaction of acids and bases. Salts are composed of one or more cations (positively charged ions) and one or more anions (negative ions) such that the salt is electrically neutral (no net charge). Salts of the peptides of the present invention include salts derived from inorganic and organic acids and bases. Examples of acid addition salts are salts of amino groups formed with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid) or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid) or by using other methods known in the art, such as ion exchange. Other salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, dicurconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobiotin, and tetrahydrofuran. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and N-type salts such as phosphate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, hippurate, and the like. + (C 1~4Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further salts include ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates.

[0032] The term "pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with the tissues of humans and lower animals, within the bounds of sound medical wisdom, without excessive toxicity, irritation, allergic responses, etc., and commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19 (incorporated herein by reference). Pharmaceutically acceptable salts of the peptides of the present invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are the salts of amino groups formed with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid), or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid), or by using other methods known in the art (such as ion exchange). Other pharma- ceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and N-type salts. + (C 1~4 Alkyl)4 -Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Further pharma- ceutically acceptable salts include, where appropriate, non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkylsulfonates, and arylsulfonates.

[0033] Throughout this disclosure, references to "stapleted peptides" as provided herein are intended to encompass peptides comprising any of the amino acid sequences provided herein (including any disclosed amino acid substitutions, additions, deletions, and / or modifications), as well as pharma- ceutically acceptable salts, stereoisomers, tautomers, isotopically labeled derivatives, solvates, hydrates, polymorphs, co-crystals, and prodrugs thereof.

[0034] The terms "composition" and "formulation" are used interchangeably.

[0035] The "subject" to which administration is contemplated refers to a human (i.e., a male of any age group or a female of any age group, e.g., a pediatric subject (e.g., an infant, a child, a minor), or an adult subject (e.g., a young adult, a middle-aged adult, or an elderly adult)), or a non-human animal. In some embodiments, the non-human animal is a mammal (e.g., a primate (e.g., a cynomolgus monkey or a rhesus monkey), a commercially relevant mammal (e.g., a cattle, a pig, a horse, a sheep, a goat, a cat, or a dog), or a bird (e.g., a commercially relevant bird, such as a chicken, a duck, a goose, or a turkey)). In some embodiments, the non-human animal is a fish, a reptile, or an amphibian. The non-human animal may be male or female at any stage of development. The non-human animal may be a transgenic or genetically modified animal. The term "patient" refers to a human subject in need of treatment for a disease.

[0036] The term "biological sample" refers to any sample, including tissue samples (such as tissue sections and tissue needle biopsies); cell samples (e.g., cytological smears (such as Pap or blood smears) or samples obtained by microdissection); whole organism samples (such as yeast or bacterial samples); or cell fractions, fragments, or organelles (such as those obtained by lysing cells and centrifuging or otherwise separating their components). Other examples of biological samples include blood, serum, urine, semen, feces, cerebrospinal fluid, interstitial fluid, mucus, tears, sweat, pus, biopsy tissue (e.g., obtained by surgical or needle biopsy), nipple aspirate, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biological molecules derived from an initial biological sample.

[0037] The terms "administer," "administering," or "administration" refer to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a peptide described herein or a composition thereof into or onto a subject.

[0038] The terms "treatment", "treat" and "treating" refer to arresting, alleviating, delaying the onset or inhibiting the progression of a disease as described herein. In some embodiments, treatment may be administered after one or more signs or symptoms of a disease have developed or been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of a disease or illness. For example, treatment may be administered to a susceptible subject prior to the onset of symptoms (e.g., in light of a history of symptoms and / or exposure to a pathogen). Treatment may also be continued after symptoms have resolved, for example, to delay and / or prevent recurrence.

[0039] The terms "disease," "disease," and "disorder" are used interchangeably.

[0040] An "effective amount" of a SPAC described herein refers to an amount sufficient to elicit a desired biological response. An effective amount of a SPAC described herein may vary depending on factors such as the desired biological endpoint, side effects, severity of the disease or disorder, identity of the specific peptide, pharmacokinetics and pharmacodynamics, condition being treated, mode of administration, route of administration, and desired or required frequency of administration, species, age, and health or general condition of the subject. In some embodiments, an effective amount is a therapeutically effective amount. In some embodiments, an effective amount is a prophylactic treatment. In some embodiments, an effective amount is the amount of a SPAC described herein in a single dose. In some embodiments, an effective amount is the combined amount of a SPAC described herein in multiple doses.

[0041] A "therapeutically effective amount" of a SPAC as described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a disease or to delay or minimize one or more symptoms associated with a disease. A therapeutically effective amount of a SPAC refers to an amount of a therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment of a disease. The term "therapeutically effective amount" can encompass an amount that improves overall treatment, an amount that reduces or avoids symptoms, signs, or causes of a disease, and / or an amount that enhances the therapeutic effectiveness of another therapeutic agent.

[0042] A "prophylactically effective amount" of a SPAC as described herein is an amount sufficient to prevent or prevent the recurrence of a disease or one or more symptoms associated with a disease. A prophylactically effective amount of a SPAC refers to the amount of therapeutic agent alone, or in combination with other agents, that provides a prophylactic benefit in terms of preventing a disease. The term "prophylactically effective amount" can encompass an amount that improves overall prophylaxis or an amount that enhances the prophylactic effectiveness of another prophylactic agent.

[0043] The terms "prevent", "preventing", or "prevention" refer to prophylactic treatment of a subject who does not have the disease and has never had the disease but is at risk of developing the disease, or a subject who has had the disease and is now at risk of developing a relapse of the disease but does not have the disease. In some embodiments, the subject is at higher risk of developing the disease or at higher risk of developing a relapse of the disease than the average member of a healthy population.

[0044] Chemical Definition Definitions of specific functional groups and chemical terms are described in more detail below. Elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside cover, and specific functional groups are generally defined as set forth therein. In addition, general principles of organic chemistry and specific functional moieties and reactivity are described in detail in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Michael B. Smith, March's Advanced Organic Chemistry, 7 th Edition, John Wiley & Sons, Inc., New York, 2013; Richard C. Larock, Comprehensive Organic Transformations, John Wiley & Sons, Inc., New York, 2018; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987.

[0045] The peptides described herein may contain one or more asymmetric centers and thus may exist in various stereoisomeric forms, for example enantiomers and / or diastereomers.For example, the peptides described herein may exist in the form of individual enantiomers, diastereomers, or geometric isomers, or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers.Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric synthesis. See, e.g., Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, ELStereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, SH, Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The present invention additionally encompasses peptides as individual isomers substantially free of other isomers, or alternatively as mixtures of various isomers.

[0046] In the formula, the bond [ka] is a single bond, and the dashed line [ka] is a single bond or is absent, [ka] is a single bond or a double bond. [ka] is a double bond or a triple bond.

[0047] Unless otherwise specified, the formulas and structures depicted herein include peptides that do not include isotopically enriched atoms, and also include peptides that include isotopically enriched atoms ("isotopically labeled derivatives"), e.g., hydrogen has been replaced by deuterium or tritium, or 19 F 18 F or carbon is replaced 13 C or 14 Peptides having this structure, except that C is replaced by enriched carbon, are also within the scope of this disclosure. Such peptides are useful, for example, as analytical tools or probes in biological assays. The term "isotopes" refers to variants of a particular chemical element such that all isotopes of a given element share the same number of protons in each atom of the element, but the isotopes differ in the number of neutrons.

[0048] When a range of values ​​("range") is listed, each value and subrange within the range is encompassed. The range also includes the two endpoints of the range unless otherwise specified. For example, "C 1~6 Alkyl" is C1, C2, C3, C4, C5, C6, C 1~6 , C 1~5 , C 1~4 , C 1~3 , C 1~2 , C 2~6 , C 2~5 , C 2~4 , C 2~3 , C 3~6 , C 3~5 , C 3~4 , C 4~6 , C 4~5 , and C 5~6 Covers alkyl.

[0049] Use of the phrase "at least one" refers to 1, 2, 3, 4, or more, but also covers ranges, examples such as from 1 to 4, from 1 to 3, from 1 to 2, from 2 to 4, from 2 to 3, or from 3 to 4 (inclusive).

[0050] A "non-hydrogen group" refers to any group defined for a specific variable that is not hydrogen.

[0051] The term "aliphatic" refers to alkyl, alkenyl, alkynyl, and carbocyclic groups, while the term "heteroaliphatic" refers to heteroalkyl, heteroalkenyl, heteroalkynyl, and heterocyclic groups.

[0052] The term "alkyl" refers to the radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms ("C 1~20 In some embodiments, an alkyl group has 1 to 6 carbon atoms ("C 1~6 "Alkyl"). C 1~6 Examples of alkyl groups include methyl (C1), ethyl (C2), propyl (C3) (e.g., n-propyl, isopropyl), butyl (C4) (e.g., n-butyl, tert-butyl, sec-butyl, isobutyl), pentyl (C5) (e.g., n-pentyl, 3-pentanyl, amyl, neopentyl, 3-methyl-2-butanyl, tert-amyl), and hexyl (C6) (e.g., n-hexyl). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (C8), n-dodecyl (C9), n-hexyl (C10), n-hexyl (C11), n-hexyl (C12), n-hexyl (C13), n-hexyl (C14), n-hexyl (C15), n-hexyl (C16), n-hexyl (C17), n-hexyl (C18), n-hexyl (C19), n-hexyl (C20), n-hexyl (C210), n-hexyl (C220), n-hexyl (C23), n-hexyl (C24), n-hexyl (C25), n-hexyl (C26), n-hexyl (C27), n-hexyl (C28), n-hexyl (C29), n-hexyl (C30), n-hexyl (C31), n-hexyl (C32), n-hexyl (C33), n-hexyl (C34), n-hexyl (C35), n-hexyl (C36), n-hexyl (C37), n-hexyl (C38), n-hexyl (C39), n-hexyl (C31), n-hexyl (C32), n-hexyl (C33), n-hexyl (C34), n-hexyl (C35), n-hexyl (C36), n-hexyl (C37), n-hexyl (C 12 ) etc.

[0053] The term "haloalkyl" refers to a substituted alkyl group in which one or more of the hydrogen atoms are independently replaced by a halogen, such as fluoro, bromo, chloro, or iodo. "Perhaloalkyl" is a subset of haloalkyl and refers to an alkyl group in which all of the hydrogen atoms are independently replaced by a halogen, such as fluoro, bromo, chloro, or iodo. In some embodiments, the haloalkyl moiety has 1 to 20 carbon atoms ("C 1~20 In some embodiments, all of the haloalkyl hydrogen atoms are independently replaced with fluoro to provide a "perfluoroalkyl" group. In some embodiments, all of the haloalkyl hydrogen atoms are independently replaced with chloro to provide a "perchloroalkyl" group. Examples of haloalkyl groups include -CHF2, -CH2F, -CF3, -CH2CF3, -CF2CF3, -CF2CF2CF3, -CCl3, -CFCl2, -CF2Cl, and the like.

[0054] The term "heteroalkyl" refers to an alkyl group that further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur, located within the parent chain (e.g., inserted between adjacent carbon atoms) and / or at one or more terminal position(s). In certain embodiments, a heteroalkyl group refers to a saturated group having from 1 to 20 carbon atoms and one or more heteroatoms in the parent chain ("heteroC 1~20 "alkyl").

[0055] The term "alkenyl" refers to the radical of a straight-chain or branched hydrocarbon group having from 1 to 20 carbon atoms and one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds). In some embodiments, an alkenyl group has 1-20 carbon atoms ("C 1~20The one or more carbon-carbon double bonds can be internal (e.g., in 2-butenyl) or terminal (e.g., in 1-butenyl). In an alkenyl group, a C=C double bond of unspecified stereochemistry (e.g., -CH=CHCH3 or [ka] may be in the (E)- or (Z)-configuration.

[0056] The term "heteroalkenyl" refers to an alkenyl further including at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur, located within the parent chain (e.g., inserted between adjacent carbons) and / or at one or more terminal position(s). In certain embodiments, a heteroalkenyl group refers to a group having from 1 to 20 carbon atoms, at least one double bond, and one or more heteroatoms in the parent chain ("heteroC 1~20 alkenyl).

[0057] The term "alkynyl" refers to a straight-chain or branched hydrocarbon radical having from 1 to 20 carbon atoms and one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds) (see "C 1~20 The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl).

[0058] The term "heteroalkynyl" refers to an alkynyl group further including at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur, located within the parent chain (e.g., inserted between adjacent carbons) and / or at one or more terminal position(s). In certain embodiments, a heteroalkynyl group refers to a group having from 1 to 20 carbon atoms, at least one triple bond, and one or more heteroatoms in the parent chain ("heteroalkynyl" refers to a group having from 1 to 20 carbon atoms, at least one triple bond, and one or more heteroatoms in the parent chain ("heteroalkynyl" refers to a group having from 1 to 20 carbon atoms, at least one triple bond, and one or more heteroatoms in the parent chain ("heteroalkynyl" refers to a group having from 1 to 20 carbon atoms, at least one triple bond, and at least one heteroatom ...). 1~20 alkynyl").

[0059] The term "carbocyclyl" or "carbocyclic" refers to a ring system having from 3 to 14 ring carbon atoms ("C 3~14 In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms ("C 3~6 Carbocyclyl). 3~6 Carbocyclyl groups include cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), etc. As the examples above illustrate, in certain embodiments, carbocyclyl groups are either monocyclic ("monocyclic carbocyclyl") or polycyclic (containing, for example, fused, bridged, or spiro ring systems, such as a bicyclic ("bicyclic carbocyclyl") or tricyclic ("tricyclic carbocyclyl") system), and may be saturated or may contain one or more carbon-carbon double or triple bonds. "Carbocyclyl" also encompasses ring systems in which a carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups and the point of attachment is on the carbocyclyl ring, in which case the number of carbons is designated uninterrupted as the number of carbons in the carbocyclyl ring system.

[0060] The term "heterocyclyl" or "heterocyclic" refers to a radical of a 3- to 14-membered non-aromatic ring system having ring carbon atoms and one to four ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("3- to 14-membered heterocyclyl"). In heterocyclyl groups containing one or more nitrogen atoms, the point of attachment can be at a carbon atom or at a nitrogen atom, where valence permits. In some embodiments, the heterocyclyl is a substituted or unsubstituted 3- to 7-membered monocyclic heterocyclyl, where one, two, or three atoms in the heterocyclic ring system are independently oxygen, nitrogen, or sulfur, where valence permits. Heterocyclyl groups can be either monocyclic ("monocyclic heterocyclyl") or polycyclic (e.g., fused, bridged, or spiro ring systems, such as bicyclic ("bicyclic heterocyclyl") or tricyclic ("tricyclic heterocyclyl") ring systems) and can be saturated or contain one or more carbon-carbon double or triple bonds. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems in which a heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups (where the point of attachment is on either the carbocyclyl ring or the heterocyclyl ring), or a heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups (where the point of attachment is on the heterocyclyl ring), in which case the number of ring members is designated through the number of ring members in the heterocyclyl ring system.

[0061] The term "aryl" refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared among the cyclic array) having 6 to 14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared among the cyclic array). 6~14 In some embodiments, an aryl group has 6 ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C 10Aryl"; e.g. naphthyl, such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms ("C 14 "Aryl"; for example, anthracyl. "Aryl" also includes ring systems in which an aryl ring is fused with one or more carbocyclyl or heterocyclyl groups, as defined above, but where the radical or point of attachment is on the aryl ring. In such instances, the number of carbon atoms is designated through the number of carbon atoms in the aryl ring system.

[0062] The term "heteroaryl" refers to a radical of a 5-14 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared among the cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-14 membered heteroaryl"). In some embodiments, the heteroaryl is a substituted or unsubstituted 5- or 6-membered monocyclic heteroaryl, where one, two, three, or four atoms in the heteroaryl ring system are independently oxygen, nitrogen, or sulfur. In some embodiments, the heteroaryl is a substituted or unsubstituted 9- or 10-membered bicyclic heteroaryl, where one, two, three, or four atoms in the heteroaryl ring system are independently oxygen, nitrogen, or sulfur. In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be at a carbon atom or a nitrogen atom, as valence permits. Heteroaryl polycyclic ring systems may include one or more heteroatoms in one or both rings. "Heteroaryl" encompasses ring systems in which a heteroaryl ring as defined above is fused with one or more carbocyclyl or heterocyclyl groups, and the point of attachment is on the heteroaryl ring, in such cases the number of ring members is designated through the number of ring members in the heteroaryl ring system. "Heteroaryl" also encompasses ring systems in which a heteroaryl ring as defined above is fused with one or more aryl groups, and the point of attachment is on either the aryl ring or the heteroaryl ring, in such cases the number of ring members is designated through the number of ring members in the fused polycyclic (aryl / heteroaryl) ring system. In polycyclic heteroaryl groups in which one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, etc.), the point of attachment can be on either ring, e.g., on either the ring bearing a heteroatom or the ring that does not contain a heteroatom.

[0063] The addition of the suffix "-ene" to a group indicates that the group is a divalent component, by way of example, alkylene is a divalent component of alkyl, alkenylene is a divalent component of alkenyl, alkynylene is a divalent component of alkynyl, heteroalkylene is a divalent component of heteroalkyl, heteroalkenylene is a divalent component of heteroalkenyl, heteroalkynylene is a divalent component of heteroalkynyl, carbocyclylene is a divalent component of carbocyclyl, heterocyclylene is a divalent component of heterocyclyl, arylene is a divalent component of aryl, and heteroarylene is a divalent component of heteroaryl.

[0064] A chemical moiety is optionally substituted unless expressly provided otherwise. The term "optionally substituted" refers to substituted or unsubstituted. In certain embodiments, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, and acyl groups are optionally substituted. In general, the term "substituted" when referring to a chemical group means that at least one hydrogen present on the group is replaced with an acceptable substituent (e.g., a substituent that upon substitution results in a stable compound, e.g., a compound that does not spontaneously undergo transformation, such as by rearrangement, cyclization, elimination, or other reaction). Unless otherwise indicated, a "substituted" group has a substituent at one or more substitutable positions of the group, and when more than one position is substituted in any given structure, the substituent is either the same or different at each position. The present invention is not limited in any way by the exemplary substituents described herein.

[0065] Exemplary substituents include, but are not limited to, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa , -ON(R bb )2, -N(R bb )2, -N(R bb )3 + X- 、-N(OR cc )R bb 、-SH、-SR aa 、-SCN、-SSR cc 、-C(=O)R aa 、-CO2H、-CHO、-C(OR cc )2、-CO2R aa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2、-OC(=O)N(R bb )2、-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa, -OC(=O)SR aa , -SC(=O)OR aa , -SC(=O)R aa , -P(=O)(R aa )2, -P(=O)(OR cc )2, -OP(=O)(R aa )2, -OP(=O)(OR cc )2, -P(=O)(N(R bb )2)2, -OP(=O)(N(R bb )2)2, -NR bb P(=O)(R aa )2, -NR bb P(=O)(OR cc )2, -NR bb P(=O)(N(R bb )2)2, -P(R cc )2, -P(OR cc )2, -P(R cc )3 + X - , -P(OR cc )3 + X - , -P(R cc )4, -P(OR cc ) 4, -OP(R cc )2, -OP(R cc )3 + X - , -OP(OR cc )2, -OP(OR cc )3 + X - , -OP(R cc ) 4, -OP(OR cc )4, -B(R aa )2, -B(OR cc )2, -BR aa (OR cc ), C 1~20 Alkyl, C 1~20 Perhaloalkyl, C 1~20 Alkenyl, C 1~20 Alkynyl, Hetero C 1~20 Alkyl, Hetero C 1~20 Alkenyl, Hetero C 1~20 Alkynyl, C 3~10 Carbocyclyl, 3-14 membered heterocyclyl, C 6~14aryl, and 5- to 14-membered heteroaryl; - is the counterion; Alternatively, the two geminal hydrogens on a carbon atom can be replaced by groups =O, =S, =NN(R bb )2, =NNR bb C(=O)R aa , =NNR bb C(=O)OR aa , =NNR bb S(=O)2R aa , =NR bb , or =NOR cc has been replaced by; where: R aa In each case, independently, C 1~20 Alkyl, C 1~20 Perhaloalkyl, C 1~20 Alkenyl, C 1~20 Alkynyl, Hetero C 1~20 Alkyl, Hetero C 1~20 Alkenyl, Hetero C 1~20 Alkynyl, C 3~10 Carbocyclyl, 3-14 membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl, or two R aa the groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring; R bb Each of the cases is independently hydrogen, -OH, -OR aa , -N(R cc )2, -CN, -C(=O)R aa , -C(=O)N(R cc )2, -CO2R aa , -SO2R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SRcc , -C(=S)SR cc , -P(=O)(R aa )2, -P(=O)(OR cc )2, -P(=O)(N(R cc )2)2, C 1~20 Alkyl, C 1~20 Perhaloalkyl, C 1~20 Alkenyl, C 1~20 Alkynyl, Hetero C 1~20 Alkyl, Hetero C 1~20 Alkenyl, Hetero C 1~20 Alkynyl, C 3~10 Carbocyclyl, 3-14 membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl, or two R bb the groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring; R cc each occurrence independently represents hydrogen, C 1~20 Alkyl, C 1~20 Perhaloalkyl, C 1~20 Alkenyl, C 1~20 Alkynyl, Hetero C 1~20 Alkyl, Hetero C 1~20 Alkenyl, Hetero C 1~20 Alkynyl, C 3~10 Carbocyclyl, 3-14 membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl, or two R cc groups are joined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring; and each X - is the counter ion.

[0066] In certain embodiments, each substituent is independently a halogen, a substituted (e.g., substituted with one or more halogens) or an unsubstituted C 1~6 Alkyl, -OR aa , -SR aa , -N(R bb )2, -CN, -SCN, -NO2, -N3, -C(=O)R aa , -CO2Raa , -C(=O)N(R bb )2, -OC(=O)R aa , -OCO2R aa , -OC(=O)N(R bb )2, -NR bb C(=O)R aa , -NR bb CO2R aa , or -NR bb C(=O)N(R bb )2.

[0067] The term "halo" or "halogen" refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br) or iodine (iodo, -I).

[0068] The term "hydroxyl" or "hydroxy" refers to an -OH group. The term "substituted hydroxyl" or "substituted hydroxy" by extension refers to a hydroxyl group in which the oxygen atom directly attached to the parent molecule has been replaced with a group other than hydrogen, such as -OR aa , -ON(R bb )2, -OC(=O)SR aa , -OC(=O)R aa , -OCO2R aa , -OC(=O)N(R bb )2, -OC(=NR bb )R aa , -OC(=NR bb ) OR aa , -OC(=NR bb )N(R bb )2, -OS(=O)R aa , -OSO2R aa , -OSi(R aa )3, -OP(R cc )2, -OP(R cc )3 + X - , -OP(OR cc )2, -OP(OR cc )3 + X - , -OP(=O)(R aa )2, -OP(=O)(OR cc )2, and -OP(=O)(N(R bb))2, where X - , R aa , R bb , and R cc is as defined herein.

[0069] The term "thiol" or "thio" refers to the group -SH. The term "substituted thiol" or "substituted thio" by extension refers to a group in which the sulfur atom directly attached to the parent molecule is replaced with a group other than hydrogen and is -SR aa , -S-SR cc , -SC(=S)SR aa , -SC(=S)OR aa , -SC(=S)N(R bb )2, -SC(=O)SR aa , -SC(=O)OR aa , -SC(=O)N(R bb )2, and -SC(=O)R aa (where R aa , R bb , and R cc refers to a thiol group, including groups selected from:

[0070] The term "amino" refers to the -NH group. The term "substituted amino" by extension refers to mono-substituted amino, di-substituted amino, or tri-substituted amino. In certain embodiments, a "substituted amino" is a mono-substituted amino group or a di-substituted amino group. The term "mono-substituted amino" refers to an amino group in which the nitrogen atom directly attached to the parent molecule is replaced with one hydrogen and one non-hydrogen group, -NH(R bb ), -NHC(=O)R aa , -NHCO2R aa , -NHC(=O)N(R bb )2, -NHC(=NR bb )N(R bb )2, -NHSO2R aa , -NHP(=O)(OR cc )2, and -NHP(=O)(N(R bb 2)2)2 includes groups selected from, where R aa , R bb, and R cc is as defined herein, and wherein -NH(R bb ) group R bb is not hydrogen. The term "disubstituted amino" refers to an amino group in which the nitrogen atom directly attached to the parent molecule is replaced with two groups other than hydrogen, -N(R bb )2, -NR bb C(=O)R aa , -NR bb CO2R aa , -NR bb C(=O)N(R bb )2, -NR bb C(=NR bb )N(R bb )2, -NR bb SO2R aa , -NR bb P(=O)(OR cc )2, and -NR bb P(=O)(N(R bb 2)2)2 includes groups selected from, where R aa , R bb , and R cc is as defined herein, except that the nitrogen atom directly attached to the parent molecule is not replaced with a hydrogen. The term "trisubstituted amino" refers to an amino group in which the nitrogen atom directly attached to the parent molecule is replaced with three groups, -N(R bb )3 and -N(R bb )3 + X - where R bb and X - is as defined herein.

[0071] The term "acyl" refers to a group having the general formula -C(=O)R aa , -C(=O)OR aa , -C(=O)-OC(=O)R aa , -C(=O)SR aa , -C(=O)N(R bb )2, -C(=S)R aa , -C(=S)N(R bb )2, and -C(=S)S(R aa ), -C(=NRbb )R aa , -C(=NR bb ) OR aa , -C(=NR bb )SR aa , and -C(=NR bb )N(R bb )2(R in the formula aa and R bb refers to a group having a carbon atom (as defined herein). Exemplary acyl groups include aldehydes (-CHO), carboxylic acids (-COH), ketones, acyl halides, esters, amides, imines, carbonates, carbamates, and ureas.

[0072] A "counterion" or "anionic counterion" is a negatively charged group associated with a positively charged group to maintain electronic neutrality. An anionic counterion may be monovalent (e.g., containing one formal negative charge). An anionic counterion may also be multivalent (e.g., containing more than one formal negative charge), such as divalent or trivalent. Exemplary counterions are halide ions (e.g., F - , Cl - , Br - , I - ), NO3 - , ClO4 - , O.H. - , H2PO4 - , HSO4 - , sulfonate ions (e.g., methanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, 10-camphorsulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1-sulfonic acid-5-sulfonic acid, ethane-1-sulfonic acid-2-sulfonic acid, etc.), carboxylate ions (e.g., acetic acid, propanoic acid, benzoic acid, glyceric acid, lactic acid, tartaric acid, glycolic acid, gluconic acid, etc.), BF4 - , PF4 - , PF6 - , AsF6 - , SbF6 - , B[3,5-(CF3)2C6H3]4] - , B(C6F5)4 - , BPh4- , Al(OC(CF3)3)4 - , and carborane anions (e.g., CB 11 H 12 - or (HCB 11 Me5Br6) - Exemplary counterions, which may be multivalent, include CO3 2- , HPO4 2- , PO4 3- , B4O7 2- , SO4 2- , S2O3 2- , carboxylate anions (e.g., tartaric acid, citric acid, fumaric acid, maleic acid, malic acid, malonic acid, gluconic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, salicylic acid, phthalic acid, aspartic acid, glutamic acid, etc.), and carboranes.

[0073] These and other exemplary substituents are described in more detail in the detailed description, examples, figures, and claims. The present invention is not in any way limited by the above exemplary list of substituents. [Brief description of the drawings]

[0074] BRIEF DESCRIPTION OF THE DRAWINGS The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several aspects of the invention and, together with the description, provide non-limiting examples of the invention.

[0075] [Figure 1] Figures 1A-1B show the cytotoxicity of anti-HER2 SPACs in breast cancer cell lines. Figure 1A shows the cytotoxicity of anti-HER2 SPACs (SPAC1 and SPAC2) in the BT-474 cell line, which has high HER2 expression (HER2+++). Figure 1B shows the cytotoxicity of anti-HER2 SPACs (SPAC1 and SPAC2) in the MCF7 cell line, which has low HER2 expression (HER2+).

[0076] [Diagram 2] FIG. 2 shows the cytotoxicity of anti-CD38 SPAC (SPAC3) in the CD38+ multiple myeloma cell line RPMI 8226.

[0077] [Diagram 3] FIG. 3 shows inhibition of cell proliferation with an anti-CD38 SPAC (SPAC11) containing a stapled MCL-1 inhibitor peptide in two CD38+ multiple myeloma cell lines (NCI-H929 and RPMI 8226).

[0078] [Figure 4] FIG. 4 shows inhibition of cell proliferation with anti-CD38 SPAC containing stapled MDM2 inhibitor peptide (SPAC 8) in a CD38+ multiple myeloma cell line (RPMI 8226).

[0079] [Diagram 5] FIG. 5 shows inhibition of cell proliferation with an anti-CD38 SPAC containing a β-catenin inhibitor peptide (SPAC16) in a CD38+ multiple myeloma cell line (RPMI 8226).

[0080] [Figure 6] Figures 6A-6B show the activity of an anti-HER2 SPAC containing a stapled MDM2 inhibitor peptide (SPAC7) compared to a traditional ADC (trastuzumab emtansine) in a HER2-low p53 WT breast cancer cell line (MCF7) (Figure 6A) and a HER2+++ p53 mut breast cancer cell line (SK-BR-3) (Figure 6B).

[0081] [Figure 7] Figure 7A shows the cytotoxic activity of a stapled peptide comprising SEQ ID NO: 73 in breast cancer cell lines. Figure 7B shows the cytotoxic activity of a stapled peptide comprising SEQ ID NO: 24 in breast cancer cell lines. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0082] DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS Provided herein are stapled peptide-antibody conjugates (SPACs) comprising a stapled peptide conjugated to an antibody or antigen-binding fragment thereof. In some embodiments, the stapled peptide is conjugated to the antibody or antigen-binding fragment thereof via a linker. Also provided herein are pharmaceutical compositions and kits comprising the SPACs provided herein, methods of preparing the SPACs provided herein, and methods of using the SPACs provided herein (e.g., for treating a disease in a subject (e.g., cancer), for delivering the stapled peptide to cells of a subject (e.g., cancer cells), etc.).

[0083] Stapled peptide-antibody conjugates (SPACs) The present disclosure provides stapled peptide-antibody conjugates (SPACs), comprising a stapled peptide conjugated to an antibody or antigen-binding fragment thereof. In some embodiments, the stapled peptide is conjugated to the antibody or antigen-binding fragment thereof via a linker (e.g., a cleavable linker). In some embodiments, the antibody or antigen-binding fragment is an anti-cancer antibody or antigen-binding fragment thereof; and the stapled peptide is a stapled anti-cancer peptide.

[0084] Antibodies and antigen-binding fragments The stapled peptide-antibody conjugates (SPACs) provided herein include antibodies or antigen-binding fragments. As used herein, the term "antibody" refers to a molecule that specifically binds to or is immunologically reactive with a specific antigen and includes at least the variable domain of a heavy chain, and typically includes at least the variable domains of an immunoglobulin heavy and light chains. Unless otherwise indicated, the term "antibody" (Ab) is intended to include both intact (whole) molecules and antibody fragments (e.g., Fab and F(ab')2 fragments) that are capable of specifically binding to a target antigen. Antibodies (including intact antibodies and antigen-binding fragments), variants, and derivatives thereof include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized, primatized, or chimeric antibodies, heteroconjugate antibodies (e.g., bi-, tri-, and tetra-specific antibodies, diabodies, triabodies, and tetrabodies), single domain antibodies (sdAbs), epitope-binding fragments (e.g., Fab, Fab', and F(ab')2, Fd, Fvs, single chain Fvs (scFv), rIgG, single chain antibodies, disulfide-linked Fvs (sdFv), VFv, ... L Domain or V H The antibody molecules of the conjugates may be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecule.

[0085] The term "antigen-binding fragment" as used herein refers to one or more fragments of an immunoglobulin that retain the ability to specifically bind to a target antigen. The antigen-binding function of an immunoglobulin may be performed by a fragment of a full-length antibody. An antibody fragment may be, by way of example, a Fab, F(ab')2, scFv, SMIP, diabody, triabody, affibody, nanobody, aptamer, or domain antibody. Examples of binding fragments encompassed by the term "antigen-binding fragment" of an antibody include, but are not limited to, the following: (i) V L , V H , C L , and C H (ii) a F(ab')2 fragment, which is a bivalent fragment containing two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a V H and C H (iv) a single-arm V fragment of an antibody; L and V H (v) an Fv fragment consisting of the domains V L and V H (vi) V H (vii) a dAb fragment consisting of the V domain; H or V L (viii) an isolated complementarity determining region (CDR); and (ix) a combination of two or more isolated CDRs, optionally linked together by a linker (e.g., a synthetic linker). L and V H Although the V and VL genes are encoded by separate genes, they can be joined together using recombinant methods by a linker that allows them to be integrated into the V L Area and V HThis allows the antibody fragments to be produced as a single protein chain (known as single-chain Fv (scFv)) in which the antibody domain pairs with the antibody to form a monovalent molecule. These antibody fragments (i.e., "antigen-binding fragments") can be obtained using conventional techniques known to those of skill in the art, and the fragments can be screened for utility in the same manner as intact antibodies. Antigen-binding fragments can be produced by recombinant DNA techniques, enzymatic or chemical cleavage of intact immunoglobulins, or in some cases by chemical peptide synthesis procedures known in the art.

[0086] The antibodies described herein may be of murine, rat, human, or any other origin (including chimeric or humanized antibodies and fragments thereof). Any of the antibodies described herein may be either monoclonal or polyclonal. A "monoclonal antibody" refers to a homogeneous antibody population, whereas a "polyclonal antibody" refers to a heterogeneous antibody population. These two terms are not limited by the source of the antibody or the manner in which it is made.

[0087] In some embodiments, the antibody is a monoclonal antibody (mAb) or an antigen-binding fragment thereof. In some embodiments, the antibody is an intact (i.e., whole) mAb. In some embodiments, the antibody is an antigen-binding fragment of a mAb. Examples of monoclonal antibodies (mAbs), including generic names, trade name(s), known target antigen(s), and exemplary use(s), are provided in Table 2 below. Therapeutic applications of the mAbs listed below are not limited to the specific known target antigens and exemplary uses provided. Table 2. Examples of monoclonal antibodies (mAbs) [Table 2-1] [Table 2-2] [Table 2-3]

Table 2-4

Table 2-5

Table 2-6

Table 2-7

Table 2-8

Table 2-9

Table 2-10

Table 2-11

Table 2-12

Table 2-13

Table 2-14

Table 2-15

Table 2-16

Table 2-17

Table 2-18

Table 2-19

[0088] In some embodiments, the antibody is an anti-cancer antibody or an antigen-binding fragment thereof. As used herein, "anti-cancer antibody" refers to an antibody that targets an antigen expressed on a cancer cell (e.g., a cancer-associated antigen or a cancer-specific antigen) and can inhibit cancer or tumor growth and / or induce cancer cell death. In some embodiments, the antibody is an anti-cancer mAb or an antigen-binding fragment thereof. Table 3 below provides examples of anti-cancer mAbs, including common names, known target antigen(s), and exemplary use(s). Other non-limiting examples of anti-cancer mAbs are provided in Table 2 above. The therapeutic applications of the anti-cancer mAbs listed below are not limited to the specific known target antigen(s) and exemplary use(s) provided. Table 3. Examples of anti-cancer monoclonal antibodies (mAbs) [Table 3-1] [Table 3-2]

[0089] In some embodiments, the antibody is a homolog of the antibody described herein, or an antigen-binding fragment thereof. As used herein, the term "homolog" refers to an antibody of similar amino acid composition or sequence as the disclosed antibody, allowing for variations that are not detrimental to the antibody's ability to perform its normal function (e.g., binding to a target antigen). Homologs may be the same length as the disclosed antibodies, or may be shorter or longer. A homologue may have at least about 60% sequence identity (i.e., homology) to the amino acid sequence of a disclosed antibody (e.g., at least about 60%, at least about 62%, at least about 64%, at least about 66%, at least about 68%, at least about 70%, at least about 72%, at least about 74%, at least about 76%, at least about 78%, at least about 80%, at least about 82%, at least about 84%, at least about 86%, at least about 88%, at least about 90%, at least about 92%, at least about 94%, at least about 96%, at least about 98%, or at least about 99%). A homologue may be an antibody sequence that has been modified, for example, by deletion, addition, mutation, or substitution of one or more amino acid residues.

[0090] In some embodiments, the antibody is a homolog of trastuzumab, or an antigen-binding fragment thereof. In some embodiments, the antibody is a homolog of daratumumab, or an antigen-binding fragment thereof.

[0091] Antibodies not disclosed herein and / or not yet known in the art may also be used in the SPACs provided herein.

[0092] In some embodiments, the antibody is an antibody-drug conjugate (ADC) or an antigen-binding fragment thereof. In such embodiments, the SPAC comprises an antibody or an antigen-binding fragment thereof conjugated to (i) a stapled peptide or a pharma- ceutically acceptable salt thereof; and (ii) a second agent (i.e., the "drug" component of the ADC). In other words, the SPAC provided herein may comprise two or more separate payloads that may be selected from various classes of agents (e.g., agents with different mechanisms of action). For example, the SPAC provided herein may comprise an anti-cancer stapled peptide or a pharma- ceutically acceptable salt thereof conjugated to trastuzumab emtansine (i.e., (i) an anti-cancer stapled peptide or a pharma- ceutically acceptable salt thereof; and (ii) trastuzumab conjugated to emtansine). Table 8 below provides examples of antibody-drug conjugates (ADCs) (including generic names, trade names, and exemplary use(s)). Any of these ADCs may be conjugated to a stapled peptide, or a pharma- ceutically acceptable salt thereof, to form a SPAC as provided herein. The therapeutic applications of the ADCs listed below are not limited to the specific known target antigen(s) and exemplary use(s) provided. Table 8. Examples of antibody-drug conjugates (ADCs) [Table 8]

[0093] As used herein, "antigen" refers to an agent that is targeted by and binds to an antibody. In some cases, an antigen triggers the immune system to produce antibodies against the antigen, known as an immune response. In some embodiments, an antigen is expressed in a cell or on the surface of a cell (e.g., a cancer cell). In some embodiments, the antibodies described herein target cluster of differentiation (CD) antigens (e.g., CD2, CD3, CD4, CD5, CD6, CD8, CD11, CD11a (LFA-1), CD15, CD18 (ITGB2), CD19, CD20 (MS4A1), CD22, CD23, CD25, CD27, CD28, CD30, CD33, CD37, CD38, CD40, CD41, CD44, CD49b (ITGA1), CD49c, CD49d, CD49e, CD49f, CD49g, CD49h, CD49i, CD49m ... 2) Antibodies directed against CD51, CD52, CD54 (ICAM-1), CD56, CD62L, CD70, CD74, CD79B, CD80, CD125, CD140a, CD142, CD147, CD152 (CTLA4), CD154, CD200, CD221, CD240D, CD248, CD257 (BAFF), CD274 (PD-L1), CD276, and CD279 (PD-1). Other examples of antigens (i.e., antigens to which the antibodies described herein can be directed) include, but are not limited to, glycoproteins (e.g., TROP2, TPBG, EpCAM, CEA, gpA33, mucins, TAG-72, CA-IX, CA-125 (MUC16), PSMA, endoglin, fibronectin, MUC1, mucin CanAg, rabies virus glycoprotein), glycolipids (e.g., gangliosides (e.g., GD2, GD3, GM2), myelin associated glycoprotein, TAG-72, TN-C, TYRP1), carbohydrates (e.g., Lewis-Y 2), folate binding proteins (e.g., folate receptor 1, folate receptor alpha), vascular targets (e.g., VEGF, VEGFR, αVβ3, α5β1, VAP-1, VEGF-A, VEGFR-1, VEGFR-2), growth factors (e.g., HGF, IGF-1, NGF, HNGF, TGF-β, TGF-β1, TGF-β2, EGFL7, GDF-8), growth factor receptors (e.g., EGFR / ERBB1 / HER1, ERBB2 / HER2, ERBB3 / HER3, HGFR / c-Met, HGFR, HHGFR, IGF- 1 receptor, PDGF-Rα, PDGF-Rβ, EphA3, TRAIL-R1, TRAIL-R2 (DR5), RANKL), stromal and extracellular matrix antigens (e.g., FAP, tensasin), activin receptors (e.g., ACVR2B), activin receptor-like kinases (e.g., activin receptor-like kinase 2), angiopoietins (e.g., angiopoietin-2, angiopoietin-3), interferons (e.g., INF-α, INF-β, INF-γ), interleukins (e.g., IL 17A, IL 17F, IL20, IL-12, IL-23, IL-13, IL-17, IL-1β, IL-22, IL-4, IL-5, IL-6, IL-6 receptor, IL-2, IL-23A, IL-31RA, IL-4, IL-6, IL-9, ILGF2), integrins (for example, α4β7, α5β1, α7β7, α IIb β3, α vβ3), complement components (e.g., C5, CFD), chemokines (e.g., CCL11, CCL2(MCP-1)), chemokine receptors (e.g., CCR2, CCR4, CCR5), Notch receptors (e.g., Notch 1, NRP1), virulence factors (e.g., ClfA), colony-stimulating factors (e.g., CSF2), colony-stimulating factor receptors (e.g., CSF1R), delta-like ligands (e.g., DLL3, DLL4), lipopolysaccharides (e.g., endotoxin), human leukocyte antigens (e.g., HLA-DR), heat shock proteins (e.g., Hsp90), SLAM proteins (e.g., SLAMF7), tissue factor pathway inhibitor, tumor necrosis factor (e.g., TNF-α), tumor necrosis factor receptor (TNFR superfamily member 4), microphage migration inhibitory factor, rhesus factor, neurite outgrowth inhibitor, alpha-fetoprotein, amyloid beta, carcinoembryonic antigen (CEA), neuroapoptosis-regulating protease 1, Ch4D5, CLDN18.2, LOXL2, MSLN, NCA-90, PCSK9, sclerostin, syndecan 1, STEAP1, TSLP, TWEAK receptor, tumor antigen CTAA16.88, nectin-4, and TM4SF1. Other examples of known antigens can be found, by way of example, in Tables 2 and 3 above.

[0094] In some embodiments, the antibodies are directed against antigens expressed on cancer cells. The various classes of antigens expressed on cancer cells include: (i) "cancer associated antigens" (CAAs), which refer to antigens expressed on cancer cells that may also be present on normal cells; (ii) "cancer specific antigens" (CSAs), which refer to antigens expressed on cancer cells that are not found on normal cells; (iii) "tumor associated antigens" (TAAs), which refer to antigens expressed on solid tumor cells that may also be present on normal cells; and (iv) "tumor specific antigens" (TSAs), which refer to antigens expressed on solid tumor cells that are not found on normal cells. In some embodiments, the antibodies are directed against cancer associated antigens. In some embodiments, the antibodies are directed against cancer specific antigens. In some embodiments, the antibodies are directed against tumor associated antigens. In some embodiments, the antibodies are directed against tumor specific antigens.

[0095] In some embodiments, the antibody is directed against a growth factor receptor (e.g., EGFR / ERBB1 / HER1, ERBB2 / HER2, ERBB3 / HER3, HGFR / c-Met, HGFR, HHGFR, IGF-1 receptor, PDGF-Rα, PDGF-Rβ, EphA3, TRAIL-R1, TRAIL-R2(DR5), RANKL). In some embodiments, the antibody is an antibody, or an antigen-binding fragment thereof, directed against human epidermal growth factor receptor 2 (HER2). In some embodiments, the antibody is a mAb, or an antigen-binding fragment thereof, directed against HER2. In some embodiments, the antibody is trastuzumab. In some embodiments, the antibody is pertuzumab. In some embodiments, the antibody is margetuximab.

[0096] In some embodiments, the antibody is an antibody directed against CD38, CD33, CD22, TROP2, CD30, CD79b, or Nectin-4, or an antigen-binding fragment thereof. In some embodiments, the antibody is a mAb directed against CD38, CD33, CD22, TROP2, CD30, CD79b, or Nectin-4, or an antigen-binding fragment thereof.

[0097] In some embodiments, the antibody is an antibody directed against CD38, or an antigen-binding fragment thereof. In some embodiments, the antibody is a mAb directed against CD38, or an antigen-binding fragment thereof. In some embodiments, the antibody is daratumumab. In some embodiments, the antibody is isatuximab.

[0098] TM4SF1-targeting antibody TM4SF1 (transmembrane-4 L6 family member 1) is a membrane glycoprotein originally found on many human epithelial tumor cells. In cancer cells, TM4SF1 is known to support growth, invasion, and metastasis, and is therefore a therapeutic target for cancer. See, for example, Hellstrom et al., Proc. Natl. Acad. Sci. USA, 1986, 83(18), 7059-7063; Kao et al., Clin. Cancer Res., 2003, 9(7), 2807-2816; Gao et al., Cell, 2016, 166(1), 47-62; Shih et al., Cancer Res., 2009, 69(8), 3272-3277; Lin et al., Angiogenesis, 2014, 17(4), 897-907; and Zukauskas et al., Angiogenesis, 2011, 14(3), 345-354, the entire contents of each of which are incorporated herein by reference.

[0099] In some embodiments, the SPAC provided herein comprises an antibody, or an antigen-binding fragment thereof, directed against TM4SF1. In some embodiments, the antibody is a mAb, or an antigen-binding fragment thereof, directed against TM4SF1. In some embodiments, the antibody, or an antigen-binding fragment thereof, targets the nucleus of a cancer cell (e.g., targets an antigen in the nucleus of a cancer cell). In some embodiments, the antibody is capable of being internalized into the nucleus of a cancer cell.

[0100] Antibodies directed against TM4SF1 are described, for example, in Sciuto et al., Biochem Biophys Res. Commun., 2015, 465(3), 338-43; and Visintin et al., Mol. Cancer. Ther., 2015, 14(8), 1868-1876. In certain embodiments, the antibody is an antibody disclosed in WO 2020 / 176794, published September 3, 2020; WO 2021 / 222783, published November 4, 2021; WO 2021 / 195598, published September 30, 2021; WO 2019 / 046338, published March 7, 2019; or WO 2019 / 241430, published December 19, 2019 (the entire contents of each of which are incorporated by reference herein).

[0101] Stapled Peptides Stapled peptide-antibody conjugates (SPACs) as described herein comprise a stapled peptide conjugated to an antibody. The terms "stapled" and "bridged" are used interchangeably and refer to a peptide in which two amino acids (i.e., the bridged amino acids) are connected (i.e., stapled) via an internal bridge to form a macrocycle. The terms "bridge" and "staple" are used interchangeably and refer to a covalent linking moiety, other than the peptide backbone, that connects the bridged amino acid pair to form the macrocycle.

[0102] Stapled peptide technology is described, by way of example, in U.S. Patent Nos. 7,192,713; 7,786,072; 8,895,699; 9,505,801; 9,951,099; and 10,487,110, the entire contents of each of which are incorporated herein by reference. Other examples of stapled peptide technology are described, for example, in International PCT Publication No. WO 2017 / 004591, published January 5, 2017; WO 2019 / 018499, published January 24, 2019; WO 2021 / 126827, published June 24, 2021; WO 2021 / 126827, published June 24, 2021; WO 2014 / 052647, published April 3, 2014; WO 2014 / 159969, published October 2, 2014; WO 2011 / 008260, published January 20, 2011; WO 2011 / 008260, published October 15, 2009; No. 2009 / 126292; No. 2013 / 123266, published Aug. 22, 2013; and No. 2021 / 188659, published Sep. 23, 2021, the entire contents of each of which are incorporated herein by reference. See also, for example, Mourtada et al., Nature Biotechnology, 2019, vol. 37, 1186-1197.

[0103] Stapled peptides of the present disclosure include (i) "single-stapled" peptides, meaning peptides that include one internal bridge connecting two cross-linked amino acids; (ii) "double-stapled" peptides, meaning peptides that include two internal bridges, each connecting a different pair of cross-linked amino acids; and (iii) "stitched" peptides, meaning peptides that include at least two tandem staples, i.e., staples attached to the same cross-linked amino acid. Stapled peptides can include more than two bridges (i.e., multiple staples), where the number of staples in the stitched configuration is any number.

[0104] In some embodiments, the bridge is attached to the α-position of the bridged amino acid. In some embodiments, the bridged amino acids have 3 amino acids between them in the amino acid sequence, forming an "i+4 bridge". In some embodiments, the bridged amino acids have 4 amino acids between them in the amino acid sequence, forming an "i+5 bridge". In some embodiments, the bridged amino acids have 6 amino acids between them in the amino acid sequence, forming an "i+7 bridge". In some embodiments, the bridged amino acids have 7 amino acids between them in the amino acid sequence, forming an "i+8 bridge".

[0105] Stapling (e.g., cross-linking) a peptide can stabilize the secondary structure (e.g., the secondary structure of an α-helix) of the peptide. In some embodiments, one or more cross-links of a stapled peptide provided herein stabilize the α-helix of the peptide. In some embodiments, the peptide has increased α-helicity compared to the corresponding unstapled (e.g., non-cross-linked) peptide.

[0106] The stapled peptides may exhibit α-helical stability by maintaining the structure of the α-helical structure as measured by circular dichroism or NMR, for example, in some embodiments, the stapled peptides exhibit at least a 1.1, 1.2, 1.25, 1.3, 1.4, 1.5, 1.6, 1.7, 1.75, 1.8, 1.9, or 2-fold increase in α-helicity (e.g., as measured by circular dichroism or NMR) compared to the corresponding unstapled peptide. In certain embodiments, the stapled peptides provided herein may exhibit about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% α-helicity compared to the corresponding unstapled peptide (e.g., as measured by circular dichroism or NMR).

[0107] The stapled peptide can be of any length. In some embodiments, the stapled peptide is 100 amino acids or less in length. In some embodiments, the stapled peptide is 90 amino acids or less in length. In some embodiments, the stapled peptide is 80 amino acids or less in length. In some embodiments, the stapled peptide is 70 amino acids or less in length. In some embodiments, the stapled peptide is 60 amino acids or less in length. In some embodiments, the stapled peptide is 50 amino acids or less in length. In some embodiments, the stapled peptide is 45 amino acids or less in length. In some embodiments, the stapled peptide is 40 amino acids or less in length. In some embodiments, the stapled peptide is 35 amino acids or less in length. In some embodiments, the stapled peptide is 30 amino acids or less in length. In some embodiments, the stapled peptide is 25 amino acids or less in length. In some embodiments, the stapled peptide is 20 amino acids or less in length. In some embodiments, the stapled peptide is no more than 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 amino acids in length. In some embodiments, the stapled peptide is at least the length of the amino acid sequence provided herein. In some embodiments, the stapled peptide is the length of any of the amino acid sequences provided herein.

[0108] In some embodiments, the stapled peptide is conjugated (e.g., via a linker, such as a cleavable linker) to one or more stapled peptides. In some embodiments, the stapled peptide is part of a string of two or more stapled peptides linked together (e.g., via a linker, such as a cleavable linker) in a linear or non-linear configuration.

[0109] In some embodiments, the stapled peptide is a stapled anti-cancer peptide. "Stappled anti-cancer peptide" (also referred to as "stappled oncolytic peptide"), as used herein, refers to a stapled variant of a peptide having anti-cancer activity (i.e., a peptide capable of inducing cancer cell death and / or inhibiting cancer or tumor growth). In some embodiments, the stapled peptide induces cancer cell death. Examples of stapled anti-cancer peptides (i.e., stapled oncolytic peptides), any of which may be used as the stapled peptide component of the SPACs provided herein, can be found in International PCT Publication No. WO 2021 / 126827, published June 24, 2021, the entire contents of which are incorporated herein by reference.

[0110] In some embodiments, the stapled peptide is a stapled antimicrobial peptide (StAMP). "Stapled antimicrobial peptide" as used herein refers to a stapled variant of a peptide having antimicrobial (e.g., antibacterial) activity. Examples of StAMPs can be found in International PCT Application Publication Nos. WO 2017 / 004591, published January 5, 2017; and WO 2019 / 018499, published January 24, 2019, the entire contents of each of which are incorporated herein by reference. Stapled peptides may have both anticancer and antibacterial activity.

[0111] Stapled peptide inhibitors of protein-protein interactions (PPIs) In some embodiments, the stapled peptide is an inhibitor of protein-protein interaction (PPI). In some embodiments, the PPI is associated with the formation and / or growth of cancer. See, for example, Wang et al. Chem. Sci., 2021, 12, 5977; Ali et al., Computational and Structural Biotechnology, Journal, 2019, vol. 17, 263-281; ​​Iyer, Current Medicinal Chemistry, 2016, vol. 23, no. 27, pp. 3025-3043; and Jamieson et al., Reports in Organic Chemistry, 2015, 5, 65-74 (the entire contents of each of which are incorporated herein by reference).

[0112] Stapled BCL-2 Family Member Protein Inhibitors For example, in some embodiments, the stapled peptide is an inhibitor of a BCL-2 family member protein (e.g., BCL-xL, BCL-2, BCL-W, or MCL1). In some embodiments, the stapled peptide is an inhibitor of an MCL-1 inhibitor (e.g., MCL-1 SAHB A , MCL-1 SAHB B , MCL-1 SAHB C , MCL-1 SAHB D , MCL-1 SAHB E In some embodiments, the stapled peptide is a BFL-1 inhibitor. See, e.g., Huhn et al., Cell Chem. Biol., 2016, 23(9):1123-1134, the entire contents of which are incorporated herein by reference.

[0113] In one embodiment, the stapled peptide is MCL-1 SAHB, as described, for example, in Stewart et al., Nat. Chem. Biol., 2010, 6(8):595-601, the entire contents of which are incorporated herein by reference. D MCL-1 SAHBD has the following amino acid sequence: [ka] (SEQ ID NO:148), where both X are connected via a bridge alk.

[0114] In some embodiments, the stapled peptide is an activator of a BCL-2 family member protein effector (e.g., BAX, BAK, or BOK). In some embodiments, the stapled peptide is a stapled BH3 peptide. In some embodiments, the stapled peptide is a stapled BCL-2 interacting mediator of cell death (BIM) peptide. In some embodiments, the stapled peptide is a BIM SAHB A1 or BIM SAHB A2 See, e.g., Walensky et al., Science, 2004, 305(5689):1466-1470; Walensky et al., Mol. Cell., 2006, 24(2):199-210; Gavathiotis et al., Nature, 2008, 455(7216):1076-1081; Araghi et al., PNAS, 2018, 115(5), E886-E895, the entire contents of each of which are incorporated herein by reference. See also, by way of example, International PCT Publication Nos. WO 2010 / 068684, published June 17, 2010; WO 2016 / 149613, published September 22, 2016; and WO 2017 / 075349, published May 4, 2017, the entire contents of each of which are incorporated herein by reference. In one embodiment, the stapled peptide is BID SAHB A See, e.g., Walensky et al., Molecular Cell, 2006, vol. 24, 199-210. In some embodiments, the stapled peptide is a stapled PUMA peptide. See, e.g., Edwards et al., Chemistry & Biology, 2013, vol. 20, 888-902.

[0115] Stapled β-catenin inhibitors In some embodiments, the stapled peptide is a β-catenin inhibitor. In some embodiments, the stapled peptide is an inhibitor of Wnt / β-catenin signaling. In some embodiments, the stapled peptide is a stapled BCL9 peptide. See, for example, Takada et al., Sci.Transl.Med. 2012, 4(148):148ra117, pp.1-19; Grossman et al., PNAS, 2012, 109(44), 17942-17947; and Liao et al., Cell Discovery, 2020, 6, No. 35 (the entire contents of each of which are incorporated herein by reference). See also, by way of example, International PCT Application Publication No. WO 2012 / 040459, published March 29, 2012; WO 2012 / 142604, published October 18, 2012; WO 2019 / 051327, published March 14, 2019; and WO 2020 / 041270, published February 7, 2020 (the entire contents of each of which are incorporated herein by reference).

[0116] For example, in one embodiment, the stapled peptide is xStAx-34, as described, for example, in Grossman et al., PNAS, 2012, 109(44), 17942-17947, the entire contents of which are incorporated herein by reference. xStAx-34 comprises the following amino acid sequence: RWPQXILDXHVRRVWR (SEQ ID NO: 149), where both Xs are connected via a bridge alk.

[0117] For example, in one embodiment, the stapled peptide can be, for example, SAH-BCL9 as described in Takada et al., Sci. Transl. Med. 2012, 4(148):148ral17, pp. 1-19, the entire contents of which are incorporated herein by reference. B SAH-BCL9 Bcomprises the following amino acid sequence: LSQEQLEHRERSLXTLRXIQRBLF (SEQ ID NO: 150), where both X's are connected via a bridge alk.

[0118] Stapled MDM2 / MDMX Inhibitors In some embodiments, the stapled peptide is an inhibitor of MDM2 and / or MDMX. In some embodiments, the stapled peptide is an MDM2 inhibitor. In some embodiments, the stapled peptide is an MDMX inhibitor. In some embodiments, the stapled peptide inhibits the binding of MDM2 to p53. In some embodiments, the stapled peptide inhibits the binding of MDMX to p53. In some embodiments, the stapled peptide is a stapled p53 peptide. See, for example, Verdine et al., J. Am. Chem. Soc. 2007, 129, 2456-2457; Bernal et al., Cancer Cell, 2010, 18(5):411-422; Chang et al., PNAS, 2013, 110(36), E3445-E3454. See, for example, International PCT Application Publication No. WO 2021 / 222243, published November 4, 2021; WO 2017 / 165617, published September 28, 2017; WO 2008 / 095063, published August 7, 2008; WO 2009 / 126292, published October 15, 2009; and WO 2013 / 123266, published August 22, 2013 (the entire contents of each of which are incorporated by reference herein). See, for example, U.S. Patent Nos. 7,192,713; 7,786,072; 8,895,699; 9,505,801; 9,951,099; and 10,487,110, the entire contents of each of which are incorporated herein by reference. In some embodiments, the stapled peptide is ALRN-6924 or ATSP-7041. See, for example, Ye Che, Methods Mol. Biol., 2019, 2001, 97-106; and Chang et al., PNAS, 2013, 110(36), E3445-E3454, the entire contents of each of which are incorporated herein by reference.

[0119] The structures of ALRN-6924 and ATSP-7041 are shown below: [ka] (ALRN-6924; SEQ ID NO: 151) [ka] (ATSP-7041; sequence number 152).

[0120] In some embodiments, the stapled peptide is ATSP-7041, in which the cyclobutylalanine amino acid (Cba) is replaced by leucine (L) (i.e., SEQ ID NO: 152 with a Cba10L amino acid substitution) (referred to herein as "ATSP-7041 Cba10L"). In some embodiments, the stapled peptide has the following amino acid sequence (where both X are amino acids connected via a bridge): [ka] or a pharma- ceutically acceptable salt thereof.

[0121] In one embodiment, the stapled peptide is 8 and S 5 are linked together to form the bridge alk2): [ka] or a pharma- ceutically acceptable salt thereof.

[0122] Stapled Magainin Peptides In some embodiments, the stapled peptides are based on the amino acid sequence of a magainin peptide (e.g., magainin II). Magainin is a class of antimicrobial peptides (AMPs) that were first discovered in Xenopus laevis. The peptides are cationic and generally lack a stable conformation in water, but form amphipathic α-helices in membranes. They are generally known to disrupt cell membranes of a wide range of cells, including bacteria, protozoa, and fungi. They have also been reported to have anti-cancer activity. The amino acid sequences of the peptides known as "magainin I" and "magainin II" are provided below. [Table B]

[0123] Examples of stapled magainin peptides, any of which may be used as stapled peptide components of the SPACs provided herein, can be found in International PCT Publication Nos. WO 2017 / 004591, published January 5, 2017; WO 2019 / 018499, published January 24, 2019; and WO 2021 / 126827, published June 24, 2021, the entire contents of each of which are incorporated herein by reference. See also, for example, U.S. Provisional Application No. (USSN) 63 / 160,245, filed March 12, 2021, the entire contents of which are incorporated herein by reference. See also, for example, Mourtada et al., Nature Biotechnology, 2019, vol. 37, 1186-1197, the entire contents of which are incorporated herein by reference.

[0124] In some embodiments, the stapled peptide is a stapled magainin peptide. In some embodiments, the stapled peptide is a stapled magainin II peptide.

[0125] In one embodiment, the stapled peptide has the amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof, X 1 , X 2 , X 3 , and X 4 is an amino acid (i.e., a bridged amino acid); X 1 and X 2 and are connected via bridges, and X 3 and X 4 are connected via bridges; and The amino acid sequence is expressed as 0 to 9 amino acid substitutions (inclusive), X 1 , X 2 , X 3 , and X 4 In some embodiments, the amino acid sequence includes 0 amino acid substitutions. In some embodiments, the amino acid sequence includes 1 amino acid substitution. In some embodiments, the amino acid sequence includes 2 amino acid substitutions. In some embodiments, the amino acid sequence includes 3 amino acid substitutions. In some embodiments, the amino acid sequence includes 4 amino acid substitutions. In some embodiments, the amino acid sequence includes 5 amino acid substitutions. In some embodiments, the amino acid sequence includes 6 amino acid substitutions. In some embodiments, the amino acid sequence includes 7 amino acid substitutions. In some embodiments, the amino acid sequence includes 8 amino acid substitutions. In some embodiments, the amino acid sequence includes 9 amino acid substitutions.

[0126] In one embodiment, the stapled peptide has the amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof, X 1 , X 2 , X 3 , and X 4 is an amino acid (i.e., a bridged amino acid); X 1 and X 2and are connected via bridges, and X 3 and X 4 and are connected via bridges; the amino acid sequence is a sequence of 0 to 11 amino acid substitutions (inclusive) X 1 , X 2 , X 3 , and X 4 In some embodiments, the amino acid sequence includes 0 amino acid substitutions. In some embodiments, the amino acid sequence includes 1 amino acid substitution. In some embodiments, the amino acid sequence includes 2 amino acid substitutions. In some embodiments, the amino acid sequence includes 3 amino acid substitutions. In some embodiments, the amino acid sequence includes 4 amino acid substitutions. In some embodiments, the amino acid sequence includes 5 amino acid substitutions. In some embodiments, the amino acid sequence includes 6 amino acid substitutions. In some embodiments, the amino acid sequence includes 7 amino acid substitutions. In some embodiments, the amino acid sequence includes 8 amino acid substitutions. In some embodiments, the amino acid sequence includes 9 amino acid substitutions.

[0127] In certain embodiments, the stapled peptide, or a pharma- ceutically acceptable salt thereof, comprises one of the following amino acid sequences: [ka] [ka] [ka]

[0128] In one embodiment, the stapled peptide is represented by one of SEQ ID NOs: 1-57 and 167-186, or a pharma- ceutically acceptable salt thereof. In one embodiment, the stapled peptide is represented by one of SEQ ID NOs: 1-57 and 167-186, or a pharma- ceutically acceptable salt thereof, wherein the C-terminus of the peptide is amidated with -NH2. In one embodiment, the stapled peptide is represented by one of SEQ ID NOs: 1-57 and 167-186, or a pharma- ceutically acceptable salt thereof, wherein the C-terminus of the peptide is amidated with -NH2; and 1 and X 2 and X 3 and X 4 are connected to each other via bridges (alks).

[0129] In one embodiment, the stapled peptide has the amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof. In one embodiment, the stapled peptide or a pharma- ceutically acceptable salt thereof is represented by SEQ ID NO: 48, wherein X 1 and X 2 and X 3 and X 4 and wherein the C-terminus of the stapled peptide is amidated with -NH2.

[0130] In one embodiment, the stapled peptide has the amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof. In one embodiment, the stapled peptide or a pharma- ceutically acceptable salt thereof is represented by SEQ ID NO:26, wherein X 1 and X 2 and X 3 and X 4and wherein the C-terminus of the stapled peptide is amidated with -NH2.

[0131] In one embodiment, the stapled peptide has the amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof. In one embodiment, the stapled peptide or a pharma- ceutically acceptable salt thereof is represented by SEQ ID NO:5, wherein X 1 and X 2 and X 3 and X 4 and wherein the C-terminus of the stapled peptide is amidated with -NH2.

[0132] In one embodiment, the stapled peptide has the amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof. In one embodiment, the stapled peptide or a pharma- ceutically acceptable salt thereof is represented by SEQ ID NO:23, wherein X 1 and X 2 and X 3 and X 4 and wherein the C-terminus of the stapled peptide is amidated with -NH2.

[0133] In one embodiment, the stapled peptide has the amino acid sequence: [ka] Includes.

[0134] or a pharma- ceutically acceptable salt thereof. In one embodiment, the stapled peptide or a pharma- ceutically acceptable salt thereof is represented by SEQ ID NO:24, wherein X 1 and X2 and X 3 and X 4 and is connected via a bridge represented by the formula (alk); and wherein the C-terminus of the stapled peptide is amidated with -NH2. In some embodiments, the stapled peptide provided herein, or a pharma- ceutically acceptable salt thereof, has the following amino acid sequence: [ka] Includes one of the following.

[0135] In some embodiments, the stapled peptide is represented by one of SEQ ID NOs: 58-71, or a pharma- ceutically acceptable salt thereof. In some embodiments, the stapled peptide is represented by one of SEQ ID NOs: 58-71, or a pharma- ceutically acceptable salt thereof, wherein the C-terminus is amidated with -NH2. In some embodiments, the stapled peptide is represented by one of SEQ ID NOs: 58-71, or a pharma- ceutically acceptable salt thereof, wherein the C-terminus of the peptide is amidated with -NH2; and 1 and X 2 and X 3 and X 4 are connected to each other via bridges (alks).

[0136] In one embodiment, the stapled peptide has the following amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof, X 1 , X 2 , X 3 , and X 4 is an amino acid (i.e., a bridged amino acid); X 1 and X 2 and are connected via bridges, and X 3 and X 4 are connected via bridges; and The amino acid sequence may be arbitrarily substituted with 0 to 5 amino acids (inclusive), 1 , X 2 , X 3 , and X 4 In some embodiments, the amino acid sequence includes 0 amino acid substitutions. In some embodiments, the amino acid sequence includes 1 amino acid substitution. In some embodiments, the amino acid sequence includes 2 amino acid substitutions. In some embodiments, the amino acid sequence includes 3 amino acid substitutions. In some embodiments, the amino acid sequence includes 4 amino acid substitutions. In some embodiments, the amino acid sequence includes 5 amino acid substitutions.

[0137] In some embodiments, the stapled peptide comprises SEQ ID NO: 72. In some embodiments, the stapled peptide is represented by SEQ ID NO: 72 or a pharma- ceutically acceptable salt thereof. In some embodiments, the stapled peptide is represented by SEQ ID NO: 72 or a pharma- ceutically acceptable salt thereof, wherein the C-terminus is amidated with -NH2. In some embodiments, the stapled peptide is represented by SEQ ID NO: 72 or a pharma- ceutically acceptable salt thereof, wherein the C-terminus is amidated with -NH2; and wherein X is a nucleotide sequence selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 1 and X 2 and X 3 and X 4 are connected to each other via bridges (alks).

[0138] Stapled Esculentin Peptide In some embodiments, the stapled peptide is based on the amino acid sequence of an esculentin peptide (e.g., esculentin-1A). Esculentins are a class of cytotoxic peptides with antibacterial and antifungal activity that were first found in the skin secretions of many species of frogs and toads. Esculentin-1A is a specific antimicrobial peptide (AMP) that was first isolated from frog skin. Esculentin peptides may also have anticancer activity. The amino acid sequence of the peptide known as "esculentin-1A" is provided below. In some embodiments, the stapled peptide is based on amino acids 1-21 represented by SEQ ID NO:155. [Table C]

[0139] In some embodiments, the stapled peptide is a stapled esculentin peptide. In some embodiments, the stapled peptide is a stapled esculentin-1A peptide. Examples of stapled esculentin peptides, any of which may be used as the stapled peptide component of the SPACs provided herein, can be found, for example, in U.S. Provisional Application Nos. (USSN) 63 / 185,641, filed May 7, 2021; and 63 / 185,673, filed May 7, 2021, the entire contents of each of which are incorporated herein by reference. See also, for example, Mourtada, et al., Nature Biotechnology, 2019, vol. 37, 1186-1197, the entire contents of which are incorporated herein by reference.

[0140] In one embodiment, the stapled peptide has the amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof, X 1 , X 2 , X 3 , and X4 is an amino acid (i.e., a bridged amino acid); X 1 and X 2 and are connected via bridges, and X 3 and X 4 are connected via bridges; and The amino acid sequence is expressed as 0 to 9 amino acid substitutions (inclusive), X 1 , X 2 , X 3 , and X 4 In some embodiments, the amino acid sequence includes 0 amino acid substitutions. In some embodiments, the amino acid sequence includes 1 amino acid substitution. In some embodiments, the amino acid sequence includes 2 amino acid substitutions. In some embodiments, the amino acid sequence includes 3 amino acid substitutions. In some embodiments, the amino acid sequence includes 4 amino acid substitutions. In some embodiments, the amino acid sequence includes 5 amino acid substitutions. In some embodiments, the amino acid sequence includes 6 amino acid substitutions. In some embodiments, the amino acid sequence includes 7 amino acid substitutions. In some embodiments, the amino acid sequence includes 8 amino acid substitutions. In some embodiments, the amino acid sequence includes 9 amino acid substitutions. In one embodiment, the stapled peptide, or a pharma- ceutically acceptable salt thereof, has the following amino acid sequence: [ka] Includes one of the following.

[0141] In some embodiments, the stapled peptide is represented by one of SEQ ID NOs: 73-96, or a pharma- ceutically acceptable salt thereof. In some embodiments, the stapled peptide is represented by one of SEQ ID NOs: 73-96, or a pharma- ceutically acceptable salt thereof, wherein the C-terminus of the peptide is amidated with -NH2. In some embodiments, the stapled peptide is represented by one of SEQ ID NOs: 73-96, or a pharma- ceutically acceptable salt thereof, wherein the C-terminus of the peptide is amidated with -NH2; and wherein X 1 and X 2and X 3 and X 4 are connected to each other via bridges (alks).

[0142] In some embodiments, the stapled peptide or a pharma- ceutically acceptable salt thereof comprises SEQ ID NO: 73. In some embodiments, the stapled peptide is represented by SEQ ID NO: 73 or a pharma- ceutically acceptable salt thereof. In some embodiments, the stapled peptide is represented by SEQ ID NO: 73 or a pharma- ceutically acceptable salt thereof, wherein the C-terminus is amidated with -NH2. In some embodiments, the stapled peptide is represented by SEQ ID NO: 73 or a pharma- ceutically acceptable salt thereof, wherein the C-terminus is amidated with -NH2; and wherein X is a pharma- ceutically acceptable salt thereof. 1 and X 2 and X 3 and X 4 are connected to each other via bridges (alks).

[0143] In some embodiments, the stapled peptide provided herein has the following amino acid sequence: [ka] [ka] Includes one of the following.

[0144] In some embodiments, the stapled peptide is represented by one of SEQ ID NOs: 97-104, or a pharma- ceutically acceptable salt thereof. In some embodiments, the stapled peptide is represented by one of SEQ ID NOs: 97-104, or a pharma- ceutically acceptable salt thereof, wherein the C-terminus is amidated with -NH2. In some embodiments, the stapled peptide is represented by one of SEQ ID NOs: 97-104, or a pharma- ceutically acceptable salt thereof, wherein the C-terminus is amidated with -NH2; and 1 and X 2 and X 3 and X 4are connected to each other via bridges (alks).

[0145] In one embodiment, the stapled peptide has the amino acid sequence: [ka] and pharma- ceutically acceptable salts thereof, wherein: X 1 , X 2 , X 3 , and X 4 is an amino acid (i.e., a bridged amino acid); X 1 and X 2 and are connected via bridges, and X 3 and X 4 are connected via bridges; and The amino acid sequence can be arbitrarily selected from 0 to 8 amino acid substitutions (inclusive), X 1 , X 2 , X 3 , and X 4 In some embodiments, the amino acid sequence includes 0 amino acid substitutions. In some embodiments, the amino acid sequence includes 1 amino acid substitution. In some embodiments, the amino acid sequence includes 2 amino acid substitutions. In some embodiments, the amino acid sequence includes 3 amino acid substitutions. In some embodiments, the amino acid sequence includes 4 amino acid substitutions. In some embodiments, the amino acid sequence includes 5 amino acid substitutions. In some embodiments, the amino acid sequence includes 6 amino acid substitutions. In some embodiments, the amino acid sequence includes 7 amino acid substitutions. In some embodiments, the amino acid sequence includes 8 amino acid substitutions.

[0146] In one embodiment, the stapled peptide has the following amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof, wherein: X 1 , X 2 , X 3 , and X4 is an amino acid (i.e., a bridged amino acid); X 1 and X 2 and are connected via bridges, and X 3 and X 4 are connected via bridges; and The amino acid sequence can be arbitrarily selected from 0 to 8 amino acid substitutions (inclusive), X 1 , X 2 , X 3 , and X 4 In some embodiments, the amino acid sequence includes 0 amino acid substitutions. In some embodiments, the amino acid sequence includes 1 amino acid substitution. In some embodiments, the amino acid sequence includes 2 amino acid substitutions. In some embodiments, the amino acid sequence includes 3 amino acid substitutions. In some embodiments, the amino acid sequence includes 4 amino acid substitutions. In some embodiments, the amino acid sequence includes 5 amino acid substitutions. In some embodiments, the amino acid sequence includes 6 amino acid substitutions. In some embodiments, the amino acid sequence includes 7 amino acid substitutions. In some embodiments, the amino acid sequence includes 8 amino acid substitutions.

[0147] In some embodiments, the stapled peptide, or a pharma- ceutically acceptable salt thereof, has the following amino acid sequence: [ka] Includes one of the following.

[0148] In some embodiments, the stapled peptide, or a pharma- ceutically acceptable salt thereof, is represented by one of SEQ ID NOs: 105-114. In some embodiments, the stapled peptide, or a pharma- ceutically acceptable salt thereof, is represented by one of SEQ ID NOs: 105-114, wherein the C-terminus is amidated with -NH2. In some embodiments, the stapled peptide, or a pharma- ceutically acceptable salt thereof, is represented by one of SEQ ID NOs: 105-114, wherein the C-terminus is amidated with -NH2; and wherein X 1 and X 2 and X 3 and X4 are connected to each other via bridges (alks).

[0149] In some embodiments, the stapled peptide or a pharma- ceutically acceptable salt thereof comprises SEQ ID NO: 105. In some embodiments, the stapled peptide is represented by SEQ ID NO: 105, or a pharma- ceutically acceptable salt thereof. In some embodiments, the stapled peptide is represented by SEQ ID NO: 105, or a pharma- ceutically acceptable salt thereof, wherein the C-terminus is amidated with -NH2. In some embodiments, the stapled peptide is represented by SEQ ID NO: 105, or a pharma- ceutically acceptable salt thereof, wherein the C-terminus is amidated with -NH2; and wherein X is an amino acid sequence selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 1 and X 2 and X 3 and X 4 are connected to each other via bridges (alks).

[0150] In one embodiment, the stapled peptide has the amino acid sequence: [ka] or a pharmaceutically acceptable salt thereof. In some embodiments, the stapled peptide is represented by SEQ ID NO: 113, or a pharmaceutically acceptable salt thereof. In some embodiments, the stapled peptide is represented by SEQ ID NO: 113, or a pharmaceutically acceptable salt thereof, wherein the C-terminus is amidated with -NH2. In some embodiments, the stapled peptide is represented by SEQ ID NO: 113, or a pharmaceutically acceptable salt thereof, wherein the C-terminus is amidated with -NH2; and wherein X 1 and X 2 and X 3 and X 4 are connected to each other via bridges (alks).

[0151] In some embodiments, the stapled peptide has the following amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof, wherein: X 1 and X 2 is an amino acid (i.e., a bridged amino acid); Here, the amino acid sequence is represented by X, which is a substitution of 0 to 6 amino acids (including both ends). 1 and X 2 In some embodiments, the amino acid sequence includes 0 amino acid substitutions. In some embodiments, the amino acid sequence includes 1 amino acid substitution. In some embodiments, the amino acid sequence includes 2 amino acid substitutions. In some embodiments, the amino acid sequence includes 3 amino acid substitutions. In some embodiments, the amino acid sequence includes 4 amino acid substitutions. In some embodiments, the amino acid sequence includes 5 amino acid substitutions. In some embodiments, the amino acid sequence includes 6 amino acid substitutions. In some embodiments, the amino acid sequence includes X 1 and X 2 are connected via dithio bridges (e.g., (mxy), (pxy), (but), (bbn), (bbf), (bbp), (pfb), (hfb)).

[0152] In certain embodiments, the stapled peptide is one of the following, or a pharma- ceutically acceptable salt thereof: [Table D]

[0153] In certain embodiments, the stapled peptide is one of the following, or a pharma- ceutically acceptable salt thereof: [Table E-1] [Table E-2]

[0154] In certain embodiments, the stapled peptide is one of the following, or a pharma- ceutically acceptable salt thereof: [Table F-1] [Table F-2]

[0155] In some embodiments, the stapled peptide is the following, or a pharma- ceutically acceptable salt thereof: [Table G]

[0156] Stapled peptide crosslinking As described herein, a stapled peptide includes bridges (e.g., staples) where each bridge connects two amino acids (i.e., the amino acids being bridged) to form a macrocycle. In some embodiments, the amino acid sequence (e.g., SEQ ID NOs: 1-147 provided herein) is X, 1 and X 2 When contains X 1 and X 2 are bridged amino acids connected via a bridge. Also, in some embodiments, the amino acid sequences (e.g., SEQ ID NOs: 1-147 provided herein) are 3 and X 4 When contains X 3 and X 4 are bridged amino acids connected via a bridge. Certain embodiments below describing stapled peptide bridges apply to all stapled peptides described herein, including all amino acid sequences described herein (e.g., SEQ ID NOs: 1-147) and variants thereof.

[0157] In some embodiments, the bridges are independently at the α-position of the bridged amino acid (e.g., X 1 , X 2 , X 3 , and X 4 In some embodiments, the bridges are attached to the α-position of the bridged amino acid (e.g., X 1 , X2 , X 3 , and X 4 ) and the bridged amino acids are independently α,α-disubstituted amino acids.

[0158] In certain embodiments, each bridge is independently from about 5 Å to about 35 Å in length, inclusive. In certain embodiments, each bridge is independently from about 5 Å to about 25 Å in length, inclusive (e.g., in the case of the i+4 bridge). In certain embodiments, each bridge is independently from about 6 Å to about 22 Å in length, inclusive. In certain embodiments, each bridge is independently from about 7 Å to about 20 Å in length, inclusive. In certain embodiments, each bridge is independently from about 8 Å to about 18 Å in length, inclusive. In certain embodiments, each bridge is independently from about 9 Å to about 17 Å in length, inclusive. In certain embodiments, each bridge is independently from about 10 Å to about 16 Å in length, inclusive. In certain embodiments, each bridge is independently from about 11 Å to about 15 Å in length, inclusive. In some embodiments, each bridge is independently about 12 Å to about 14 Å in length (inclusive). In some embodiments, each bridge is independently about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 Å in length.

[0159] In certain embodiments, each bridge is independently from about 15 Å to about 35 Å in length, inclusive (e.g., in the case of the i+7 bridge). In certain embodiments, each bridge is independently from about 17 Å to about 33 Å in length, inclusive. In certain embodiments, each bridge is independently from about 19 Å to about 31 Å in length, inclusive. In certain embodiments, each bridge is independently from about 20 Å to about 30 Å in length, inclusive. In certain embodiments, each bridge is independently from about 22 Å to about 29 Å in length, inclusive. In certain embodiments, each bridge is independently from about 24 Å to about 28 Å in length, inclusive. In certain embodiments, each bridge is independently from about 25 Å to about 27 Å in length, inclusive. In certain embodiments, each bridge is independently about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 Å in length.

[0160] In some embodiments, the length of each bridge is approximately equal to the length of 5-25 (inclusive) carbon-carbon and / or carbon-sulfur bonds, hi some embodiments, the length of each bridge is approximately equal to the length of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 (inclusive) carbon-carbon and / or carbon-sulfur bonds.

[0161] In some embodiments, the length of each bridge is approximately equal to the length of 5-20 (inclusive) carbon-carbon and / or carbon-sulfur bonds. In some embodiments, the length of each bridge is approximately equal to the length of 5-15 (inclusive) carbon-carbon and / or carbon-sulfur bonds. In some embodiments, the length of each bridge is approximately equal to the length of 5-13 (inclusive) carbon-carbon and / or carbon-sulfur bonds. In some embodiments, the length of each bridge is approximately equal to the length of 6-12 (inclusive) carbon-carbon and / or carbon-sulfur bonds. In some embodiments, the length of each bridge is approximately equal to the length of 7-11 (inclusive) carbon-carbon and / or carbon-sulfur bonds. In some embodiments, the length of each bridge is approximately equal to the length of 8-10 (inclusive) carbon-carbon and / or carbon-sulfur bonds.

[0162] In some embodiments, the length of each bridge is approximately equal to the length of 10-20 (inclusive) carbon-carbon and / or carbon-sulfur bonds. In some embodiments, the length of each bridge is approximately equal to the length of 11-19 (inclusive) carbon-carbon and / or carbon-sulfur bonds. In some embodiments, the length of each bridge is approximately equal to the length of 12-18 (inclusive) carbon-carbon and / or carbon-sulfur bonds. In some embodiments, the length of each bridge is approximately equal to the length of 13-17 (inclusive) carbon-carbon and / or carbon-sulfur bonds. In some embodiments, the length of each bridge is approximately equal to the length of 14-16 (inclusive) carbon-carbon and / or carbon-sulfur bonds.

[0163] In some embodiments, at least one bridge spans at least one turn of the α-helix of the peptide. In some embodiments, each bridge spans at least one turn of the α-helix of the peptide. In some embodiments, at least one bridge spans at least one turn of the α-helix of the peptide. In some embodiments, each bridge spans at least one turn of the α-helix of the peptide.

[0164] In some embodiments, each pair of cross-linked amino acids (e.g., X 1 and X 2 and X 3 and X 4 and ) are independently connected by a bridge to form a compound having the following formula: [ka] where α represents the α-carbon of the bridged amino acid; 1 is a bridge; and R 1 each instance independently represents hydrogen or an optionally substituted C 1~6 It is an alkyl.

[0165] In some embodiments, each bridge (e.g., L 1 ) are independently optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted acylene, or any combination thereof.

[0166] In some embodiments, each bridge (e.g., L 1 ) is independently a hydrocarbon bridge. For purposes of this disclosure, a "hydrocarbon bridge" is a bridge consisting of optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, and combinations thereof.

[0167] In some embodiments, each bridge (e.g., L 1 ) is independently an optionally substituted alkenylene (e.g., unsubstituted alkenylene). In certain embodiments, each bridge independently has the formula: [ka] where each n is independently an integer from 1 to 10, inclusive. In certain embodiments, the sum of the two n's on the same bridge is 6.

[0168] In some embodiments, the cross-linked amino acids (e.g., X 1 , X 2 , X 3 , and X 4 ) are independently α,α-disubstituted amino acids. Illustratively, in some embodiments, each pair of bridged amino acids (e.g., X 1 and X 2 and X 3 and X 4 and ) are independently connected by a bridge to form a compound having the following formula: [ka] where α represents the α-carbon of the bridged amino acid; and 1 Each instance of is independently an optionally substituted C 1~6 In certain embodiments, the sum of two n's on the same bridge is 6.

[0169] For example, in some embodiments, crosslinking (e.g., L 1 ) are independently expressed in the formula: [ka] Represented.

[0170] For example, in one embodiment, a pair of cross-linked amino acids (e.g., X 1 and X 2 and X 3 and X 4 and ) are independently connected via a bridge to form a compound having the following formula: [ka] where α represents the α-carbon of the bridged amino acid.

[0171] In one embodiment, X1 and X 2 are connected to form an expression (alk).

[0172] In one embodiment, X 3 and X 4 are connected to form an expression (alk).

[0173] In some embodiments, crosslinking (e.g., L 1 ) is independently an optionally substituted alkylene (e.g., unsubstituted alkylene). In certain embodiments, each bridge independently has the formula: [ka] wherein m is an integer from 1 to 20, inclusive. In some embodiments, m is 6.

[0174] In some embodiments, a pair of cross-linked amino acids (e.g., X 1 and X 2 and X 3 and X 4 and) are independently linked by bridges to form a compound of the formula: [ka] where α represents the α-carbon of the bridged amino acid; and 1 Each instance of is independently an optionally substituted C 1~6 In some embodiments, m is 6.

[0175] For example, in some embodiments, crosslinking (e.g., L 1 ) are independently selected from the formula: [ka] It is expressed as:

[0176] For example, in one embodiment, a pair of cross-linked amino acids (e.g., X 1 and X 2 and X3 and X 4 and ) are connected via a bridge to form the following formula: [ka] where α represents the α-carbon of the bridged amino acid.

[0177] In some embodiments, crosslinking (e.g., L 1 ) are independently selected from the formula: [ka] It is expressed as:

[0178] For example, in one embodiment, a pair of cross-linked amino acids (e.g., X 1 and X 2 and X 3 and X 4 and ) are independently connected via a bridge to form a compound having the following formula: [ka] where α represents the α-carbon of the bridged amino acid.

[0179] In some embodiments, crosslinking (e.g., L 1 ) are independently selected from the formula: [ka] It is expressed as:

[0180] For example, in one embodiment, a pair of cross-linked amino acids (e.g., X 1 and X 2 and X 3 and X 4 and ) are independently connected via a bridge to form a compound having the following formula: [ka] where α represents the α-carbon of the bridged amino acid.

[0181] In some embodiments, crosslinking (e.g., L 1 ) is independently an optionally substituted alkynylene (eg, unsubstituted alkynylene).

[0182] In some embodiments, crosslinking (e.g., L 1 ) are independently a dithio bridge. For purposes of this disclosure, a "dithio bridge" (i.e., a "dithio staple") is a bridge that contains two thioethers (i.e., two -S- groups). In certain embodiments, the bridges are independently represented by the following formula: [ka] wherein each n is independently an integer from 1 to 10, inclusive; and L is independently an optionally substituted alkylene, an optionally substituted alkenylene, an optionally substituted alkynylene, an optionally substituted heteroalkylene, an optionally substituted heteroalkenylene, an optionally substituted heteroalkynylene, an optionally substituted carbocyclylene, an optionally substituted heterocyclylene, an optionally substituted arylene, an optionally substituted heteroarylene, an optionally substituted acylene, or any combination thereof. In some embodiments, each instance of n is 1. In some embodiments, each instance of n is 2.

[0183] In certain embodiments, the bridges independently have the formula: [ka] wherein each n is independently an integer from 1 to 10, inclusive; and L 2 is optionally substituted alkylene, [ka] , optionally substituted arylene, optionally substituted heteroarylene, or -A 1 -A 1-; 1 Each of is independently an optionally substituted arylene or an optionally substituted heteroarylene. In some embodiments, each instance of n is 1. In some embodiments, each instance of n is 2.

[0184] In certain embodiments, the bridges independently have the formula: [ka] In some embodiments, each instance of n is 1. In some embodiments, each instance of n is 2.

[0185] For example, in certain embodiments, the bridges independently have the formula: [ka] It is a dithio bridge represented by one of the following formulas:

[0186] In other embodiments, the bridges independently have the formula: [ka] wherein each n is independently an integer from 1 to 10, inclusive; L 2 is an optionally substituted aromatic ring (e.g., a polyhalogenated aryl or heteroaryl ring) or -A 1 -A 1 - is; where A 1 Each of is independently an optionally substituted aromatic ring (e.g., a polyhalogenated aryl or heteroaryl ring). In some embodiments, each instance of n is 1. In some embodiments, each instance of n is 2.

[0187] In certain embodiments, the bridges independently have the formula: [ka] where each n is independently an integer from 1 to 10, inclusive. In certain embodiments, each instance of n is 1. In certain embodiments, each instance of n is 2.

[0188] For example, in certain embodiments, the bridges independently have the formula: [ka] It is expressed as one of the following.

[0189] For purposes of this disclosure, the specific bridges (mxy), (pxy), (but), (bbn), (bbf), (bbp), (pfb), and (hfb) referred to herein are formed by bridging two cysteine ​​(C) residues of the peptide. In other words, the peptides provided herein, or pharma- ceutically acceptable salts thereof, comprising a (mxy), (pxy), (but), (bbn), (bbf), (bbp), (pfb), and / or (hfb) bridge, each pair of bridged amino acids (e.g., X) connected via a dithio bridge forming the following formula: 1 and X 2 , X 3 and X 4 ) includes: [ka] where each α is the α-position of a dithio-bridged amino acid (e.g., X 1 , X 2 , X 3 , X 4 ), and L 2 as indicated in Table 4 below. Table 4. Some dithio bridges [Table 4-1] [Table 4-2]

[0190] In some embodiments, crosslinking (e.g., L1 ) is independently a triazolylene bridge. For purposes of this disclosure, a "triazolylene bridge" refers to at least one triazolylene moiety (e.g., [ka] It is a bridge interrupted by.

[0191] In certain embodiments, the bridges independently have the formula: [ka] where each n is independently an integer from 1 to 10, inclusive. In certain embodiments, the sum of the two n's on the same bridge is 5.

[0192] For example, in certain embodiments, the bridges independently have the formula: [ka] It is a triazolylene bridge represented by one of the following formulas:

[0193] n and R 1 The following aspects apply to all general formulas and subgenera provided herein, and to all stapled and unstapled peptides provided herein.

[0194] In some embodiments, the sum of the two n's on the same bridge is an integer from 3 to 9 (inclusive). In some embodiments, the sum of the two n's on the same bridge is an integer from 4 to 8 (inclusive). In some embodiments, the sum of the two n's on the same bridge is an integer from 5 to 7 (inclusive). In some embodiments, the sum of the two n's on the same bridge is 5. In some embodiments, the sum of the two n's on the same bridge is 6. In some embodiments, the sum of the two n's on the same bridge is 7.

[0195] In some embodiments, at least one of n is 1. In some embodiments, at least one of n is 2. In some embodiments, at least one of n is 3. In some embodiments, at least one of n is 4. In some embodiments, at least one of n is 5. In some embodiments, at least one of n is 6. In some embodiments, at least one of n is 7. In some embodiments, at least one of n is 8. In some embodiments, at least one of n is 9. In some embodiments, at least one of n is 10.

[0196] In some embodiments, m is an integer from 3 to 9, inclusive. In some embodiments, m is an integer from 4 to 8, inclusive. In some embodiments, m is an integer from 5 to 7, inclusive. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7.

[0197] In one embodiment, R 1 is hydrogen. 1 is hydrogen. 1 In at least one case, non-substituted C 1~6 In some embodiments, R 1 In at least one case, non-substituted C 1~3 In some embodiments, R 1 is methyl. 1 is methyl.

[0198] Herein, the recitation of a list of chemical groups in any definition of a variable includes that definition of the variable as any single group or combination of groups in the list. Herein, the recitation of an embodiment of a variable includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof. Herein, the recitation of an embodiment includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.

[0199] Peptide C-terminal modification Stapled peptides may include one or more additional modifications anywhere on the peptide (e.g., on the side chain of an amino acid, on the α-carbon of an amino acid, on the peptidic nitrogen, at the C-terminus, the N-terminus, etc.). Stapled peptides may include modifications to the C-terminus and / or N-terminus of a polypeptide. In some embodiments, the stapled peptide includes a modified C-terminus. Examples of C-terminal modifications are described herein.

[0200] In some embodiments, the stapled peptide comprises an amidated C-terminus. Traditionally, peptides comprise a carboxyl group (-C(=O)OH) at the C-terminus. The stapled peptide may also comprise an amide at the C-terminus (e.g., -C(=O)NR2, where the group NR2 is NH2, mono-substituted amino, di-substituted amino, or tri-substituted amino) and is referred to as an "amidated C-terminus." For example, a peptide with an "-NH2-amidated C-terminus" comprises the group -C(=O)NH2 at the C-terminus in place of a carboxyl (-C(=O)OH). The amidated C-terminus may also be represented by the inclusion of -NR2 (e.g., -NH2) at the end of the amino acid sequence.

[0201] The stapled peptide may also be amidated at the C-terminus with an amino acid, peptide, or protein. The amino acid, peptide, or protein may be natural or non-natural. In some embodiments, the stapled peptide comprises a peptide conjugated to the C-terminus. In some embodiments, the peptide is 2 to 6 amino acids in length (inclusive) and comprises amino acids selected from G, E, S, A, and K.

[0202] In some embodiments, the peptide is from 2 to 6 amino acids in length (inclusive) and comprises amino acids selected from G, E, and S. In some embodiments, the peptide is from 2 to 6 amino acids in length (inclusive) and comprises amino acids selected from G and E. In some embodiments, the peptide is 2 amino acids in length and comprises amino acids selected from G and E. In some embodiments, the peptide is 3 amino acids in length and comprises amino acids selected from G and E. In some embodiments, the peptide is 4 amino acids in length and comprises amino acids selected from G and E. Non-limiting examples of peptides that can be conjugated to the C-terminus of the stapled peptide are as follows: [Table H]

[0203] The stapled peptide may also include a small molecule, a lipophilic group, or a polymer conjugated to the C-terminus of the peptide.

[0204] In some embodiments, the stapled peptide comprises a lipophilic group conjugated to the C-terminus of the peptide. In some embodiments, the lipophilic group is a lipid or a fatty acid. In some embodiments, the lipophilic group is a hydrocarbon chain.

[0205] In some embodiments, the stapled peptide comprises a polymer conjugated to the C-terminus of the peptide. In some embodiments, the polymer is a polyether, such as polyethylene glycol (PEG). In some embodiments, the polymer is PEG. In some embodiments, the polymer is PEG3. As described herein, PEG3 has the formula: [ka] It is expressed as:

[0206] In some embodiments, the stapled peptide is amidated at the C-terminus with a group of the formula: -NH-(PEG)-CONH2, where PEG is polyethylene glycol. In some embodiments, the stapled peptide is amidated at the C-terminus with a group of the formula: -NH(CH2CH2O) 1~20 In some embodiments, the stapled peptide is amidated at the C-terminus with a group represented by one of the following formulas: -NHCH2CH2OCH2CH2CONH2, -NH(CH2CH2O)2-CH2CH2CONH2, -NH(CH2CH2O)3-CH2CH2CONH2, -NH(CH2CH2O)4-CH2CH2CONH2, or -NH(CH2CH2O)5-CH2CH2CONH2.

[0207] In some embodiments, the stapled peptide comprises a small molecule conjugated to the C-terminus of the peptide. In some embodiments, the small molecule is an anti-cancer drug.

[0208] Linkers and Conjugation As described herein, the SPACs provided herein comprise a stapled peptide conjugated to an antibody or antigen-binding fragment thereof. In some embodiments, the antibody or antigen-binding fragment thereof is conjugated to the N-terminus of the stapled peptide. In some embodiments, the antibody or antigen-binding fragment thereof is conjugated to the C-terminus of the stapled peptide. In some embodiments, the antibody or antigen-binding fragment thereof is conjugated to an internal position on the stapled peptide (e.g., to an amino acid residue or to a bridge of the stapled peptide).

[0209] In some embodiments, the stapled peptide is conjugated through a thiol of the antibody or antigen-binding fragment thereof. In some embodiments, the stapled peptide is conjugated through a cysteine ​​residue of the antibody or antigen-binding fragment thereof. In some embodiments, the stapled peptide is conjugated through an amine of the antibody or antigen-binding fragment thereof. In some embodiments, the stapled peptide is conjugated through a lysine residue of the antibody or antigen-binding fragment thereof.

[0210] In some embodiments, the antibody or antigen-binding fragment thereof is conjugated directly (e.g., via a bond) to the stapled peptide. In some embodiments, the antibody or antigen-binding fragment thereof is conjugated to the stapled peptide via a linker. "Linker," as used herein, refers to a moiety that links the antibody or antigen-binding fragment thereof to the stapled peptide and should not be confused with one or more "bridges" that connect the amino acids of the stapled peptide.

[0211] In certain embodiments, the linker comprises an optionally substituted alkylene, an optionally substituted alkenylene, an optionally substituted alkynylene, an optionally substituted heteroalkylene, an optionally substituted heteroalkenylene, an optionally substituted heteroalkynylene, an optionally substituted carbocyclylene, an optionally substituted heterocyclylene, an optionally substituted arylene, an optionally substituted heteroarylene, an optionally substituted acylene, or any combination thereof.

[0212] In some embodiments, the linker comprises an optionally substituted alkylene. In some embodiments, the linker comprises an optionally substituted alkenylene. In some embodiments, the linker comprises an optionally substituted alkynylene. In some embodiments, the linker comprises an optionally substituted heteroalkylene. In some embodiments, the linker comprises an optionally substituted heteroalkenylene. In some embodiments, the linker comprises an optionally substituted heteroalkynylene. In some embodiments, the linker comprises an optionally substituted carbocyclylene. In some embodiments, the linker comprises an optionally substituted heterocyclylene. In some embodiments, the linker comprises an optionally substituted arylene. In some embodiments, the linker comprises an optionally substituted heteroarylene. In some embodiments, the linker comprises an optionally substituted acylene.

[0213] In some embodiments, the linker is a cleavable linker. "Cleavable linker" as used herein refers to a linker that can be cleaved under physiological conditions. In some embodiments, the linker is cleavable by pH or by proteases, esterases, or intracellular disulfide reduction. In some embodiments, the linker is cleavable by proteases. See, for example, Bargh et al., Chem. Soc. Rev. 2019, 48(16), 4361-4374; Zheng Su et al., "Antibody-drug conjugates: Recent advances in linker chemistry", Acta Pharmaceutica Sinica B, 2021; and Leriche et al., Bioorganic & Medicinal Chemistry, 2012, vol. 20, 571-582 (the entire contents of each of which are incorporated herein by reference).

[0214] In some embodiments, the linker is a peptide linker. In some embodiments, the linker is a cleavable peptide linker. "Peptide linker" as used herein refers to a linker that includes two or more amino acids linked via a peptide bond. In some embodiments, the peptide linker is -Y A Y B Y C Y D (SEQ ID NO: 159), wherein: Y A is glycine, glutamic acid, or absent; Y B is valine, phenylalanine, alanine, tyrosine, or glycine; Y C is citrulline, arginine, lysine, alanine, or glycine; and Y D is glycine or absent.

[0215] In some embodiments, the peptide linker comprises -GGFG- (SEQ ID NO: 160). In some embodiments, the peptide linker comprises -GGG-. In some embodiments, the peptide linker comprises -EVC-. See, for example, Anami et al., Nature Communications, 2018, 9, 2512, the entire contents of which are incorporated herein by reference.

[0216] In some embodiments, the peptide linker comprises -valine-citrulline- (i.e., -VC-). Table 5 below provides non-limiting examples of such linkers, represented by linking reagents and the corresponding resulting linker structures. Table 5. Examples of linkers and coupling reagents [Table 5-1] [Table 5-2] [Table 5-3] *S in the structures denotes the point of attachment to the antibody or antigen-binding fragment thereof; N denotes the point of attachment to the N-terminus of the stapled peptide.

[0217] In some embodiments, the linker comprises a triazolylene moiety. As described herein, the linker comprising the triazolylene moiety may be formed by an azide-alkyne cycloaddition reaction. Non-limiting examples of triazole-containing linkers are shown in Table 9 below. Table 9. Examples of trazolylene-containing linkers [Table 9-1] [Table 9-2] [Table 9-3] [Table 9-4] [Table 9-5] *A in the structures denotes the point of attachment to the antibody or antigen-binding fragment; N denotes the point of attachment to the N-terminus of the stapled peptide.

[0218] In some embodiments, the SPACs provided herein include one stapled peptide conjugated to an antibody or antigen-binding fragment thereof (i.e., a 1:1 stapled peptide:antibody ratio). In some embodiments, two or more stapled peptides are conjugated to an antibody or antigen-binding fragment thereof (i.e., a 2:1 stapled peptide:antibody ratio or greater). In some embodiments, 1-20 stapled peptides are conjugated to an antibody or antigen-binding fragment thereof (i.e., a 1:1 to 20:1 stapled peptide to antibody ratio, inclusive). In some embodiments, 2-20 stapled peptides are conjugated to an antibody or antigen-binding fragment thereof (i.e., a 2:1 to 20:1 stapled peptide to antibody ratio, inclusive). In some embodiments, 1-10 stapled peptides are conjugated to an antibody or antigen-binding fragment thereof (i.e., a 1:1 to 10:1 stapled peptide to antibody ratio, inclusive). In some embodiments, between 2 and 10 stapled peptides are conjugated to the antibody or antigen-binding fragment thereof (i.e., a stapled peptide to antibody ratio of 2:1 to 10:1, inclusive). In some embodiments, between 5 and 10 stapled peptides are conjugated to the antibody or antigen-binding fragment thereof (i.e., a stapled peptide to antibody ratio of 1:1 to 10:1, inclusive). In some embodiments, the antibody or antigen-binding fragment thereof is conjugated to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 stapled peptides. In some embodiments, about 8 stapled peptides are conjugated to the antibody or antigen-binding fragment thereof (i.e., a stapled peptide to antibody ratio of 8:1). In some embodiments, the stapled peptides are the same or different in any combination.

[0219] Additional Aspects Additional embodiments and examples of SPACs are provided below, including in Table 6.

[0220] In some embodiments, the stapled peptide is a stapled anti-cancer peptide; and the antibody is a mAb antibody directed against HER2, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide is a stapled anti-cancer peptide; and the antibody is a mAb antibody directed against CD38, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide is a stapled anti-cancer peptide; and the antibody is trastuzumab. In some embodiments, the stapled peptide is a stapled anti-cancer peptide; and the antibody is trastuzumab emtansine. In some embodiments, the stapled peptide is a stapled anti-cancer peptide; and the antibody is daratumumab.

[0221] In some embodiments, the stapled peptide is represented by SEQ ID NO: 48 or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against HER2, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide is represented by SEQ ID NO: 26 or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against HER2, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide is represented by SEQ ID NO: 5 or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against HER2, or an antigen-binding fragment thereof.

[0222] In some embodiments, the stapled peptide is represented by SEQ ID NO: 48, or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against CD38, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide is represented by SEQ ID NO: 26, or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against CD38, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide is represented by SEQ ID NO: 5, or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against CD38, or an antigen-binding fragment thereof.

[0223] In some embodiments, the stapled peptide is represented by SEQ ID NO:26 or a pharmaceutically acceptable salt thereof; and the antibody is trastuzumab (e.g., SPAC1 in Table 6 below). In some embodiments, the stapled peptide is represented by SEQ ID NO:26 or a pharmaceutically acceptable salt thereof; and the antibody is trastuzumab emtansine (e.g., SPAC17 and SPAC18 in Table 6 below). In some embodiments, the stapled peptide is represented by SEQ ID NO:48 or a pharmaceutically acceptable salt thereof; and the antibody is trastuzumab (e.g., SPAC2 in Table 6 below). In some embodiments, the stapled peptide is represented by SEQ ID NO:26 or a pharmaceutically acceptable salt thereof; and the antibody is daratumumab (e.g., SPAC3 in Table 6 below). In some embodiments, the stapled peptide is represented by SEQ ID NO:48 or a pharmaceutically acceptable salt thereof; and the antibody is daratumumab (e.g., SPAC4 in Table 6 below). In one embodiment, the stapled peptide is represented by SEQ ID NO:5, or a pharma- ceutically acceptable salt thereof; and the antibody is trastuzumab (e.g., SPAC5 in Table 6 below). In one embodiment, the stapled peptide is represented by SEQ ID NO:5, or a pharma- ceutically acceptable salt thereof; and the antibody is daratumumab (e.g., SPAC6 in Table 6 below). Table 6. Examples of SPACs [Table 6]

[0224] Additional embodiments and examples of SPACs are provided below, including in Table 7.

[0225] In some embodiments, the stapled peptide is an MDM2 inhibitor, or its pharmaceutically acceptable salt; and the antibody is a mAb antibody directed against HER2, or its antigen-binding fragment.In some embodiments, the stapled peptide is ATSP-7041, or its pharmaceutically acceptable salt; and the antibody is a mAb antibody directed against HER2, or its antigen-binding fragment.In some embodiments, the stapled peptide is ATSP-7041, or its pharmaceutically acceptable salt; and the antibody is trastuzumab.In some embodiments, the stapled peptide is ATSP-7041, or its pharmaceutically acceptable salt; and the antibody is trastuzumab emtansine.

[0226] In some embodiments, the stapled peptide comprises any one of SEQ ID NOs: 161-166, or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against HER2, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide comprises any one of SEQ ID NOs: 161-166, or a pharmaceutically acceptable salt thereof; and the antibody is trastuzumab. In some embodiments, the stapled peptide comprises any one of SEQ ID NOs: 161-166, or a pharmaceutically acceptable salt thereof; and the antibody is trastuzumab emtansine. In some embodiments, the stapled peptide is ATSP-7041 Cba10L, or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against HER2, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide is ATSP-7041 Cba10L, or a pharmaceutically acceptable salt thereof; and the antibody is trastuzumab (e.g., SPAC7 in Table 7 below). In some embodiments, the stapled peptide is ATSP-7041 Cba10L, or a pharma- ceutically acceptable salt thereof; and the antibody is trastuzumab emtansine (eg, SPAC9 in Table 7 below).

[0227] In some embodiments, the stapled peptide is an MDM2 inhibitor, or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against CD38, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide is ATSP-7041, or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against CD38, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide is ATSP-7041, or a pharmaceutically acceptable salt thereof; and the antibody is daratumumab.

[0228] In some embodiments, the stapled peptide comprises any one of SEQ ID NOs: 161-166, or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against CD38, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide comprises any one of SEQ ID NOs: 161-166, or a pharmaceutically acceptable salt thereof; and the antibody is daratumumab. In some embodiments, the stapled peptide is ATSP-7041 Cba10L, or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against CD38, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide is ATSP-7041 Cba10L, or a pharmaceutically acceptable salt thereof; and the antibody is daratumumab (e.g., SPAC8 in Table 7 below).

[0229] In some embodiments, the stapled peptide is an MCL-1 inhibitor; and the antibody is a mAb antibody, or an antigen-binding fragment thereof, directed against HER2. In some embodiments, the stapled peptide is an MCL-1 SAHB D or a pharma- ceutically acceptable salt thereof; and the antibody is a mAb antibody, or an antigen-binding fragment thereof, directed against HER2. In one embodiment, the stapled peptide is MCL-1 SAHB D or a pharma- ceutically acceptable salt thereof; and the antibody is trastuzumab (e.g., SPAC10 in Table 7 below). In some embodiments, the stapled peptide is MCL-1 SAHB D or a pharma- ceutically acceptable salt thereof; and the antibody is trastuzumab emtansine (eg, SPAC12 in Table 7 below).

[0230] In one embodiment, the stapled peptide is an MCL-1 inhibitor; and the antibody is a mAb antibody directed against CD38, or an antigen-binding fragment thereof. In one embodiment, the stapled peptide is an MCL-1 SAHB Dor a pharma- ceutically acceptable salt thereof; and the antibody is a mAb antibody directed against CD38, or an antigen-binding fragment thereof. In one embodiment, the stapled peptide is D or a pharmaceutically acceptable salt thereof; and the antibody is daratumumab (eg, SPAC11 in Table 7 below).

[0231] In some embodiments, the stapled peptide is a β-catenin inhibitor; and the antibody is a mAb antibody, or an antigen-binding fragment thereof, directed against HER2. In some embodiments, the stapled peptide is SAH-BCL9 B or a pharma- ceutically acceptable salt thereof; and the antibody is a mAb antibody, or an antigen-binding fragment thereof, directed against HER2. In one embodiment, the stapled peptide is SAH-BCL9 B or a pharma- ceutically acceptable salt thereof; and the antibody is trastuzumab (eg, SPAC13 in Table 7 below).

[0232] In one embodiment, the stapled peptide is a β-catenin inhibitor; and the antibody is a mAb antibody, or an antigen-binding fragment thereof, directed against CD38. In one embodiment, the stapled peptide is SAH-BCL9 B or a pharma- ceutically acceptable salt thereof; and the antibody is a mAb antibody directed against CD38, or an antigen-binding fragment thereof. In one embodiment, the stapled peptide is SAH-BCL9 B or a pharma- ceutically acceptable salt thereof; and the antibody is daratumumab (e.g., SPAC14 in Table 7 below).

[0233] In some embodiments, the stapled peptide is xStAx-34, or a pharmaceutically acceptable salt thereof; and the antibody is a mAb antibody directed against HER2, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide is xStAx-34, or a pharmaceutically acceptable salt thereof; and the antibody is trastuzumab (e.g., SPAC15 in Table 7 below).

[0234] In some embodiments, the stapled peptide is xStAx-34, or a pharma- ceutically acceptable salt thereof; and the antibody is a mAb antibody directed against CD38, or an antigen-binding fragment thereof. In some embodiments, the stapled peptide is xStAx-34, or a pharma- ceutically acceptable salt thereof; and the antibody is daratumumab (e.g., SPAC16 in Table 7 below). Table 7. Additional examples of SPACs [Table 7]

[0235] In one embodiment, the stapled peptide is an MDM2 inhibitor; and the antibody is an antibody directed against TM4SF1, or an antigen-binding fragment thereof. In one embodiment, the stapled peptide comprises any one of SEQ ID NOs: 161-166, or a pharmaceutically acceptable salt thereof; and the antibody is an antibody directed against TM4SF1, or an antigen-binding fragment thereof. In one embodiment, the stapled peptide is represented by any one of SEQ ID NOs: 164-166, or a pharmaceutically acceptable salt thereof; and the antibody is an antibody directed against TM4SF1, or an antigen-binding fragment thereof. In one embodiment, the stapled peptide is represented by any one of SEQ ID NOs: 164-166, or a pharmaceutically acceptable salt thereof; the antibody is an antibody directed against TM4SF1, or an antigen-binding fragment thereof; and the linker comprises any one of A1-A20.

[0236] Methods for preparing stapled peptide-antibody conjugates (SPACs) Also provided herein are methods of preparing the stapled peptide-antibody conjugates (SPACs) described herein. In some embodiments, the stapled peptide is conjugated to an antibody or antigen-binding fragment thereof using a linking reagent. "Linking reagent," as used herein, refers to a molecule that includes two reactive moieties, one of which is capable of reacting with a reactive moiety on an antibody to form at least one covalent bond, and the other of which is capable of reacting with a reactive moiety on the stapled peptide to form at least one covalent bond.

[0237] For example, the linking reagent may include (i) a moiety capable of reacting with a thiol (e.g., a cysteine ​​residue) or amine (e.g., a lysine residue) of an antibody; and (ii) a moiety capable of reacting with the N-terminal amine of the stapled peptide. For example, the linking reagent may include (i) a maleimide or iodoacetamide (e.g., capable of reacting with a thiol (e.g., a cysteine ​​residue) or amine (e.g., a lysine residue) of an antibody; and (ii) a carboxylic acid or carboxylic acid ester (e.g., capable of reacting with the N-terminal amine of the stapled peptide). Non-limiting examples of linking reagents are provided in Table 5.

[0238] In one embodiment, a method for preparing a stapled peptide-antibody conjugate (SPAC) as described herein comprises the steps of: (a) contacting the stapled peptide with a linking reagent under conditions sufficient to conjugate the linking reagent to the stapled peptide, thereby forming a stapled peptide-linking reagent intermediate; and (b) contacting the stapled peptide-linked reagent intermediate with an antibody or antigen-binding fragment thereof under conditions sufficient to conjugate the stapled peptide-linked reagent intermediate to the antibody or antigen-binding fragment thereof, thereby forming a stapled peptide-antibody conjugate (SPAC).

[0239] In one embodiment, a method for preparing a stapled peptide-antibody conjugate (SPAC) as described herein comprises the steps of: (a) contacting an antibody or antigen-binding fragment thereof with a linking reagent under conditions sufficient to conjugate the linking reagent to the antibody or antigen-binding fragment thereof, thereby forming an antibody-linking reagent intermediate; and (b) contacting the antibody-linking reagent intermediate with the stapled peptide under conditions sufficient to conjugate the antibody-linking reagent intermediate to the stapled peptide, thereby forming a stapled peptide-antibody conjugate (SPAC).

[0240] In other embodiments, a method for preparing a stapled peptide-antibody conjugate (SPAC) described herein comprises contacting a stapled peptide comprising a first reactive moiety with an antibody or antigen-binding fragment thereof comprising a second reactive moiety under conditions sufficient to form at least one covalent bond between the first reactive moiety and the second reactive moiety, thereby forming a SPAC. In certain embodiments, the first reactive moiety and the second reactive moiety are "click chemistry" handles capable of reacting with each other to form one or more covalent bonds therebetween.

[0241] "Click chemistry" is a chemical approach introduced by Sharpless in 2001 that describes tailored chemistry to rapidly and reliably generate substances by linking small units together. See, for example, Kolb, Finn and Sharpless Angewandte Chemie International Edition (2001) 40:2004-2021; Evans, Australian Journal of Chemistry (2007) 60:384-395. Exemplary coupling reactions (some of which may be classified as "click chemistry") include, but are not limited to, the formation of esters, thioesters, and amides from activated acids or acyl halides (e.g., peptide coupling); nucleophilic substitution reactions (e.g., nucleophilic substitution of halides or ring opening of strained ring systems); azide-alkyne Huisgen cycloaddition; thiol-yne addition; imine formation; Michael addition (e.g., maleimide addition); and Diels-Alder reactions (e.g., tetrazine [4+2] cycloaddition). Examples of alkyne-azide reactions can be found, for example, in Kolb, Finn and Sharpless Angewandte Chemie International Edition (2001) 40:2004-2021; Kolb and Sharpless, Drug Discov Today (2003) 24:1128-1137; and Evans, Australian Journal of Chemistry (2007) 60:384-395.

[0242] In some embodiments, the first reactive moiety is an azide; and the second reactive moiety is an alkyne. In some embodiments, the first reactive moiety is an alkyne; and the second reactive moiety is an azide.

[0243] For example, a method for preparing a stapled peptide-antibody conjugate (SPAC) described herein includes contacting an azide-containing stapled peptide with an alkyne-containing antibody or antigen-binding fragment thereof under conditions sufficient to form a triazolylene-containing linker, thereby forming a SPAC.

[0244] In some embodiments, the azide-containing stapled peptide has the following formula: [ka] [ka] [ka] (for example, forming any one of the linkers A1 to A20).

[0245] Provided herein are stapled peptides comprising any one of SEQ ID NOs: 161-166, or a pharma- ceutically acceptable salt thereof; further comprising an azide. For example, provided herein are stapled peptides comprising any one of SEQ ID NOs: 161-166, or a pharma- ceutically acceptable salt thereof; and the following formula: [ka] [ka] [ka] at the N-terminus of the amino acid sequence.

[0246] In some embodiments, the antibody or antigen-binding fragment thereof comprises a terminal alkyne (e.g., for use in copper-promoted cycloaddition with azides). In some embodiments, the antibody or antigen-binding fragment thereof comprises a cyclic alkyne (e.g., for use in strain-promoted (e.g., copper-free) cycloaddition with azides). Non-limiting examples of cyclic alkyne moieties include DBCO and sulfo-DBCO: [ka] and [ka] Includes:

[0247] Pharmaceutical Compositions, Kits, and Administration The present invention provides a pharmaceutical composition comprising a SPAC disclosed herein. The pharmaceutical composition may include one or more pharma- ceutically acceptable carriers / excipients. In some embodiments, the SPAC described herein is provided in an effective amount in the pharmaceutical composition. In some embodiments, the effective amount is an amount that is therapeutically effective (e.g., for treating cancer in a subject and / or for inhibiting tumor growth in a subject). In some embodiments, the effective amount is an amount that is prophylactically effective.

[0248] The pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology.In general, such preparation methods include bringing into association the SPACs described herein (i.e., "active ingredient") with a carrier or excipient, and / or one or more other accessory ingredients, and then, if necessary and / or desired, shaping and / or packaging the product into a desired single-dose or multi-dose unit.

[0249] Pharmaceutical compositions can be prepared, packaged, and / or sold in bulk, as single unit doses, and / or as a plurality of single unit doses. A "unit dose" is a discrete amount of pharmaceutical composition that contains a predetermined amount of active ingredient. The amount of active ingredient is generally equal to the dosage of the active ingredient that would be administered to a subject, and / or a convenient fraction of such a dosage, such as one-half or one-third of such a dosage.

[0250] The relative amount of active ingredient, pharma- ceutical acceptable excipient, and / or any additional ingredient in the pharmaceutical compositions described herein may vary depending on the identity, size, and / or condition of the subject to be treated, and also depending on the route by which the composition should be administered.The composition may contain between 0.1% and 100% (w / w) active ingredient.The composition may contain between 0.1% and 50% (w / w) active ingredient.

[0251] Pharmaceutically acceptable excipients used in the manufacture of the provided pharmaceutical compositions include inert diluents, dispersing and / or granulating agents, surfactants and / or emulsifying agents, disintegrating agents, binders, preservatives, buffering agents, lubricating agents, and / or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening agents, flavoring agents, and perfuming agents may also be present in the composition.

[0252] Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and mixtures thereof.

[0253] Exemplary granulating and / or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clay, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose, and wood products, natural sponge, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethylcellulose, cross-linked sodium carboxymethylcellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethylcellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof.

[0254] Exemplary surfactants and / or emulsifiers include natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate)), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxypolymethylene, polyacrylic acid, acrylic acid polymers, and carboxyvinyl polymers), carrageenan, cellulose derivatives (e.g., sodium carboxymethylcellulose, powdered cellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, ... ), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate (Tween® 20), polyoxyethylene sorbitan (Tween® 60), polyoxyethylene sorbitan monooleate (Tween® 80), sorbitan monopalmitate (Span® 40), sorbitan monostearate (Span® 60), sorbitan tristearate (Span® 65), glyceryl monooleate, sorbitan monooleate (Span® 80)) , polyoxyethylene esters (e.g., polyoxyethylene monostearate (Myrj® 45), polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol®), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., Cremophor®), polyoxyethylene ethers (e.g., polyoxyethylene lauryl ether (Brij® 30)), poly(vinylpyrrolidone), diethylene glycol monolaurate,Triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic® F-68, Poloxamer® P-188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, and / or mixtures thereof.

[0255] Exemplary binders include starches (e.g., corn starch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, and the like), natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husk, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinylpyrrolidone), magnesium aluminum silicate (Veegum®), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, and / or mixtures thereof.

[0256] Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoan preservatives, alcohol preservatives, acidic preservatives, and other preservatives. In some embodiments, the preservative is an antioxidant. In other embodiments, the preservative is a chelating agent.

[0257] Exemplary antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.

[0258] Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and its salts and hydrates (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, etc.), citric acid and its salts and hydrates (e.g., citric acid monohydrate), fumaric acid and its salts and hydrates, malate and its salts and hydrates, phosphoric acid and its salts and hydrates, and tartaric acid and its salts and hydrates. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.

[0259] Exemplary antifungal preservatives include butylparaben, methylparaben, ethylparaben, propylparaben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.

[0260] Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.

[0261] Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.

[0262] Other preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant® Plus, Phenonip®, methylparaben, Germall® 115, Germaben® II, Neolone®, Kathon®, and Euxyl®.

[0263] Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and mixtures thereof.

[0264] Exemplary lubricants include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.

[0265] Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, chamomile, canola, caraway, carnauba, castor oil, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cottonseed, emu, eucalyptus, evening primrose, fish, linseed, geraniol, loofah, grape seed, hazelnut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon. , ritsea cuba, macadamia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, camellia, savory, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, camellia, vetiver, walnut, and wheat germ. Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixtures thereof.

[0266] In some embodiments, the formulation comprises a polymeric excipient. In some embodiments, the formulation comprises a polyether. In some embodiments, the formulation comprises a polyethylene glycol (PEG) (e.g., PEG200, PEG300, PEG400, etc.).

[0267] Liquid dosage forms for parenteral administration include pharma- ceutically acceptable emulsions, microemulsions, solutions, and suspensions.In addition to the active ingredient, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, and mixtures thereof.In some embodiments for parenteral administration, the conjugates described herein are mixed with solubilizers, such as Cremophor®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof.

[0268] In the preparation for injection, for example, sterile injectable aqueous or oily suspension can be formulated according to known technology using suitable dispersing or wetting agent and suspending agent. Sterile injectable preparation can be sterile injectable solution, suspension or emulsion in non-toxic parenterally acceptable diluent or solvent, for example, solution in 1,3-butanediol. Among acceptable vehicles and solvents that can be used are water, Ringer's solution (USP) and isotonic sodium chloride solution. In addition, sterile fixed oil is conventionally used as a solvent or suspending medium. For this purpose, any non-irritating fixed oil, including synthetic mono- or di-glycerides, can be used. In addition, fatty acids such as oleic acid are used in the preparation for injection. In some embodiments, the carrier is a buffered aqueous solution.

[0269] Injectable preparations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0270] Although the description of pharmaceutical compositions provided herein is primarily directed to pharmaceutical compositions suitable for administration to humans, it will be understood by those skilled in the art that such compositions are generally suitable for administration to any and all animals. Modifications of pharmaceutical compositions suitable for administration to humans to make compositions suitable for administration to a variety of animals are well understood, and the ordinarily skilled veterinary pharmacologist may design and / or perform such modifications using routine experimentation.

[0271] The SPACs provided herein are typically formulated in dosage unit form for ease of administration and uniformity of dosage.However, it will be understood that the total daily usage of the compositions described herein will be determined by a physician within the scope of sound medical judgment.The specific therapeutically effective dose level for any particular subject or organism will depend on a variety of factors, including the severity of the disease and disorder being treated; the activity of the specific active ingredient being employed; the specific composition being employed; the subject's age, weight, general health, sex, and dietary habits; the time of administration, route of administration, and excretion rate of the specific active ingredient being employed; the duration of treatment; the drugs used in combination with or simultaneously with the specific active ingredient being employed; and the like factors well known in the medical field.

[0272] The SPACs and compositions provided herein may be administered by any route, including parenterally, enterally (e.g., orally), intravenously, intramuscularly, intraarterially, intramedullary, intrathecally, subcutaneously, intracerebroventricularly, transdermally, intradermally, rectally, intravaginally, intraperitoneally, topically (as by powders, ointments, creams, and / or drops), mucosally, nasally, bucally, sublingually; by intratracheal instillation, bronchial instillation, and / or inhalation; and / or as an oral spray, nasal spray, and / or aerosol. Specifically contemplated routes are intravenous administration (e.g., systemic intravenous injection), local administration via the blood and / or lymphatic supply, and / or direct administration to the affected area. In general, the most appropriate route of administration will depend on a variety of factors, including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract) and / or the condition of the subject (e.g., whether the subject can tolerate a certain route of administration).

[0273] The exact amount of SPAC required to achieve an effective amount will vary from subject to subject, depending, for example, on the species, age, and general condition of the subject, the severity of the side effects or disorder, the identity of the specific SPAC, the mode of administration, etc. An effective amount may be included in a single dose (e.g., a single oral dose) or multiple doses (e.g., multiple oral doses). In some embodiments, when multiple doses are administered to a subject or applied to a tissue or cell, any two doses of the multiple doses include different or substantially the same amount of the SPAC described herein. In some embodiments, when multiple doses are administered to a subject or applied to a tissue or cell, the frequency of administering the multiple doses to a subject or applying the multiple doses to a tissue or cell is 3 doses per day, 2 doses per day, 1 dose per day, 1 dose every other day, 1 dose every 2 days, 1 dose every week, 1 dose every other week, 1 dose every 3 weeks, or 1 dose every 4 weeks. In some embodiments, when multiple doses are administered to a subject or applied to tissue or cell, the period between the first and last doses of the multiple doses is 1 day, 2 days, 4 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years, 5 years, 7 years, 10 years, 15 years, 20 years, or the lifespan of the subject, tissue, or cell.In some embodiments, the period between the first and last doses of the multiple doses is 3 months, 6 months, or 1 year.In some embodiments, the period between the first and last doses of the multiple doses is the lifespan of the subject, tissue, or cell.

[0274] The dosage ranges as described herein provide guidance for administration of the provided pharmaceutical compositions to adults. For example, the amount to be administered to a child or adolescent can be determined by a physician or person skilled in the art and can be less than or the same as that administered to an adult.

[0275] The SPAC or composition, as described herein, may be administered in combination with one or more additional pharmaceutical agents (e.g., therapeutically and / or prophylactically active agents). The SPAC or composition may be administered in combination with an additional pharmaceutical agent that improves their activity (e.g., activity (e.g., efficacy and / or effectiveness) in treating a disease in a subject in need thereof, preventing a disease in a subject in need thereof, reducing the risk of developing a disease in a subject in need thereof), improves bioavailability, improves safety, reduces drug resistance, reduces and / or modifies metabolism, inhibits excretion, and / or modifies distribution in a subject or cell. It will also be understood that the treatments employed may achieve a desired effect for the same disorder and / or may achieve a different effect. In some embodiments, the pharmaceutical composition described herein that includes a SPAC as described herein and an additional pharmaceutical agent exhibits a synergistic effect that is not present in a pharmaceutical composition that includes one of the SPAC and the additional pharmaceutical agent, but not both. In some embodiments, the additional pharmaceutical agent achieves a desired effect for the same disorder. In some embodiments, the additional pharmaceutical agent achieves a different effect.

[0276] The SPAC or composition may be administered simultaneously with, prior to, or subsequent to one or more additional pharmaceutical agents that may be useful, for example, as a combination therapy. Pharmaceutical agents include therapeutically active agents. Pharmaceutical agents also include prophylactically active agents. Pharmaceutical agents include drug compounds (e.g., compounds approved for human or veterinary use by the U.S. Food and Drug Administration, as provided in the U.S. Code of Federal Regulations (CFR)), SPACs, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic SPACs or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNA, RNA, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and small organic molecules such as cells.

[0277] Additional pharmaceutical agents include, but are not limited to, anti-proliferative agents, anti-cancer agents, anti-angiogenic agents, steroidal or non-steroidal anti-inflammatory agents (NSAIDs), immunosuppressants, antibacterial agents, antiviral agents, cardiovascular agents, cholesterol lowering agents, antidiabetic agents, anti-allergy agents, contraceptives, pain-relieving agents, anesthetics, anticoagulants, enzyme inhibitors, steroidal agents, steroidal or antihistamines, antigens, vaccines, antibodies, decongestants, sedatives, opioids, analgesics, antipyretics, hormones, and prostaglandins.

[0278] In some embodiments, the additional pharmaceutical agent is an anti-cancer agent. "Anti-cancer agent" encompasses biological anti-cancer agents as well as chemotherapeutic agents.

[0279] Exemplary biologic anti-cancer agents include, but are not limited to, interferons, cytokines (e.g., tumor necrosis factor, interferon alpha, interferon gamma), vaccines, hematopoietic growth factors, monoclonal serum therapy, immunostimulatory and / or immunomodulatory agents (e.g., IL-1, 2, 4, 6, or 12), immune cell growth factors (e.g., GM-CSF), and antibodies (e.g., Herceptin (trastuzumab), T-DM1, AVASTIN (bevacizumab), ERBITUX (cetuximab), Vectibix (panitumumab), Rituxan (rituximab), Bexxar (tositumomab), and those listed in Table 2).

[0280] Exemplary chemotherapeutic agents include, but are not limited to, antiestrogens (e.g., tamoxifen, raloxifene, and megestrol), LHRH agonists (e.g., goserelin and leuprolide), antiandrogens (e.g., flutamide and bicalutamide), photodynamic therapy (e.g., verteporfin (BPD-MA), phthalocyanines, photosensitizer Pc4, and demethoxy-hypocrelin A (2BA-2-DMHA)), nitrogen mustards (e.g., cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, estramustine, and melphalan), nitrosoureas (e.g., carmustine (BCNU) and lomustine (CCNU)), arsenic sulfonates, and the like. kiru (e.g., busulfan and treosulfan), triazenes (e.g., dacarbazine, temozolomide), platinum-containing compounds (e.g., cisplatin, carboplatin, oxaliplatin), vinca alkaloids (e.g., vincristine, vinblastine, vindesine, and vinorelbine), taxoids (e.g., paclitaxel or paclitaxel equivalents, e.g., nanoparticle albumin-bound paclitaxel (Abraxane), docosaxaenoic acid-bound paclitaxel (DHA-paclitaxel, Taxoplexin), glutamic acid-bound paclitaxel (PG-paclitaxel, paclitaxel poliglumex, CT-2103, XYOTAX), tumor-activated prodrugs (TAPs)ANG1005 (Angiopep-2 conjugated to three molecules of paclitaxel), paclitaxel-EC-1 (paclitaxel conjugated to the erbB2 recognition peptide EC-1), and glucose-conjugated paclitaxel (e.g., 2'-paclitaxel methyl 2-glucopyranosyl succinate; docetaxel, taxol), epipodophyllin (e.g., etoposide, etoposide phosphate, teniposide, topotecan, 9-aminocamptothecin, camptoirinotecan, irinotecan, crisnatol, mitomycin C), antimetabolites, DHFR inhibitors bitters (e.g., methotrexate, dichloromethotrexate, trimetrexate, edatrexate), isoform dehydrogenase inhibitors (e.g., mycophenolic acid, tiazofurin, ribavirin, and EICAR), ribonucleotide reductase inhibitors (e.g., hydroxyurea and deferoxamine), uracil analogues (e.g., 5-fluorouracil (5-FU), floxuridine, doxifluridine, raltitrexed, tegafur-uracil, capecitabine), cytosine analogues (e.g., cytarabine (arabinose)), C), cytosine arabinoside, and fludarabine), purine analogs (e.g., mercaptopurine and thioguanine), vitamin D3 analogs (e.g., EB 1089, CB 1093, and KH 1060), isoprenylation inhibitors (e.g., lovastatin), dopaminergic neurotoxins (e.g., 1-methyl-4-phenylpyridinium ion), cell cycle inhibitors (e.g., staurosporine), actinomycins (e.g., actinomycin D, dactinomycin), bleomycins (e.g., bleomycin A2, bleomycin B2, peplomycin), anthracyclines (e.g., daunorubicin, doxorubicin, pegylated liposomal doxorubicin, idarubicin, epirubicin, pirarubicin, zorubicin, mitoxantrone), MDR inhibitors (e.g., verapamil), Ca2+ATPase inhibitors (e.g., thapsigargin), imatinib, thalidomide, lenalidomide, tyrosine kinase inhibitors (e.g., axitinib (AG013736), bosutinib (SKI-606), cediranib (RECENTIN™, AZD2171), dasatinib (SPRYCEL®, BMS-354825), erlotinib (TARCEVA®), gefitinib (IRESSA®), (Toxico®), imatinib (Gleevec®, CGP57148B, STI-571), lapatinib (TYKERB®, TYVERB®), lestaurtinib (CEP-701), neratinib (HKI-272), nilotinib (TASIGNA®), semaxanib (semaxinib, SU5416), sunitinib (SUTENT®, SU11248), toceranib (PALLADIA®), (R), vandetanib (ZACTIMA®, ZD6474), vatalanib (PTK787, PTK / ZK), trastuzumab (HERCEPTIN®), bevacizumab (AVASTIN®), rituximab (RITUXAN®), cetuximab (ERBITUX®), panitumumab (VECTIBIX®), ranibizumab (Lucentis®), nivolumab (Nelson ... Lotinib (TASIGNA®), sorafenib (NEXAVAR®), everolimus (AFINITOR®), alemtuzumab (CAMPATH®), gemtuzumab ozogamicin (MYLOTARG®), temsirolimus (TORISEL®), ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992 (TOVOK™), SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF1120 (VARGATEF®), AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, and / or XL228), proteasome inhibitors (e.g., bortezomib (Velcade)), mTOR inhibitors (e.g., rapamycin, temsirolimus (CCI-779), everolimus (RAD-001), ridaforolimus, AP23573 (Ariad), AZD8055 (AstraZeneca), BEZ235 (Novartis), BGT226 (Norvartis), XL765 (Sanofi Aventis), PF-4691502 (Pfizer), GDC0980 (Genetech), SF1126 (Semafoe) and OSI-027 (OSI)), oblimersen, gemcitabine, carminomycin, leucovorin, pemetrexed, cyclophosphamide, dacarbazine, procarbazine, prednisolone, dexamethasone, camptothecin, plicamycin, asparaginase, aminopterin, methopterin, porfiromycin, melphalan, leurocidin, leurosine, chlorambucil, trabectedin, procarbazine, discodermolide, carminomycin, aminopterin, and hexamethylmelamine.

[0281] Each additional pharmaceutical agent may be administered at a dose and / or schedule determined for that pharmaceutical. The additional pharmaceutical agents may also be administered together with each other and / or with the SPAC or compositions described herein in a single dose or composition, or may be administered separately in different doses or compositions. The particular combination employed in the regimen will take into consideration the compatibility of the SPAC described herein with the additional pharmaceutical agent(s) and / or the desired therapeutic and / or prophylactic effect to be achieved. In general, it is expected that the additional pharmaceutical agent(s) in the combination will be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in the combination will be lower than the levels utilized individually.

[0282] In some embodiments, SPAC is used in combination with one or more different treatment modalities, such as radiation therapy or surgery.

[0283] Also covered by the present disclosure are kits (e.g., pharmaceutical packs). The kits provided may include a pharmaceutical composition or SPAC described herein and a container (e.g., a vial, an ampoule, a bottle, a syringe, and / or a dispenser package, or other suitable container). In some embodiments, the kits provided may optionally further include a second container that includes a pharmaceutical excipient for diluting or suspending the pharmaceutical composition or SPAC described herein. In some embodiments, the pharmaceutical composition or SPAC provided in the first container and the second container described herein are combined to form one unit dosage form. Thus, in one aspect, provided is a kit that includes a first container that includes a SPAC or pharmaceutical composition described herein. In some embodiments, the kit is useful for treating a disease (e.g., cancer) in a subject in need thereof. In some embodiments, the kit is useful for preventing a disease in a subject in need thereof.

[0284] In some embodiments, the kit described herein further comprises instructions for using the kit. The kit described herein may also comprise information as required by regulatory authorities, such as the U.S. Food and Drug Administration (FDA). In some embodiments, the information contained in the kit is prescription information. In some embodiments, the kit provides instructions for treating a disease (e.g., cancer) in a subject in need thereof. In some embodiments, the kit provides instructions for preventing a disease (e.g., cancer) in a subject in need thereof. The kit described herein may comprise one or more additional pharmaceutical agents as separate compositions as described herein.

[0285] Treatment Methods and Uses The stapled peptide antibody conjugates (SPACs) provided herein are capable of delivering biologically active stapled peptides to cells and are therefore useful for the treatment and / or prevention of disease (e.g., proliferative diseases (e.g., cancer), infectious diseases).

[0286] Provided herein are methods of treating and / or preventing a disease in a subject, comprising administering to the subject a therapeutically and / or prophylactically effective amount of a SPAC provided herein, or a pharmaceutical composition thereof. Also provided herein are SPACs and pharmaceutical compositions thereof for use in treating and / or preventing a disease in a subject. Also provided herein are uses of SPACs and pharmaceutical compositions thereof for the manufacture of a medicament. In some embodiments, the disease is a proliferative disease (e.g., cancer), an infectious disease (e.g., a bacterial infection), an inflammatory disease, or an autoimmune disease.

[0287] In some embodiments, the disease is a proliferative disease (e.g., cancer). Provided herein is a method of treating a proliferative disease (e.g., cancer) in a subject, comprising administering to the subject a therapeutically effective amount of a SPAC provided herein, or a pharmaceutical composition thereof. Also provided herein are SPACs and pharmaceutical compositions thereof for use in treating a proliferative disease (e.g., cancer) in a subject. Also provided herein is the use of SPACs and pharmaceutical compositions thereof for the manufacture of a medicament for treating a proliferative disease (e.g., cancer). In some embodiments, the proliferative disease is cancer.

[0288] "Proliferative disease" refers to a disease resulting from abnormal growth or expansion by multiplication of cells (see, e.g., Walker, Cambridge Dictionary of Biology; Cambridge University Press: Cambridge, UK, 1990). Proliferative diseases may involve: (1) pathological proliferation of cells that are normally quiescent; (2) pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); (3) pathological expression of proteolytic enzymes such as matrix metalloproteinases (e.g., collagenase, gelatinase, and elastase); or (4) pathological angiogenesis, such as that seen in proliferative retinopathies and tumor metastasis. Exemplary proliferative diseases include cancer (i.e., "malignant neoplasms"), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.

[0289] The term "angiogenesis" refers to the physiological process by which new blood vessels are formed from pre-existing vessels. Angiogenesis is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesodermal cell precursors. The first blood vessels in the developing embryo are formed through vasculogenesis, and angiogenesis is responsible for most blood vessel growth during normal and abnormal development. Angiogenesis is an essential process in growth and development, as well as in wound healing and in the formation of granulation tissue. However, angiogenesis is also a fundamental step in the transition of tumors from benign to malignant states, leading to the use of angiogenesis inhibitors in the treatment of cancer. Angiogenesis may be chemically stimulated by angiogenic proteins such as growth factors (e.g., VEGF). "Pathological angiogenesis" refers to abnormal (e.g., excessive or insufficient) angiogenesis that amounts to and / or is associated with disease.

[0290] The terms "neoplasm" and "tumor" are used interchangeably herein and refer to a mass of abnormal tissue, where the growth of the mass exceeds and is out of step with the growth of normal tissue. A neoplasm or tumor may be "benign" or "malignant" depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis. "Benign tumors" are generally well differentiated, have characteristically slower growth than malignant tumors, and remain localized to the site of appearance. In addition, benign tumors do not have the ability to invade, invade, or metastasize to distant sites. Exemplary benign neoplasms include, but are not limited to, lipomas, chondromas, adenomas, acrochordons, senile hemangiomas, seborrheic keratosis, lentigines, and sebaceous hyperplasia. In some cases, a "benign" tumor may later give rise to a malignant neoplasm, which may result from additional genetic changes in a subpopulation of neoplastic cells of the tumor; these tumors are referred to as "premalignant neoplasms." An exemplary premalignant neoplasm is a teratoma. In contrast, a "malignant neoplasm" is generally poorly differentiated (anaplasia) and has characteristically rapid growth accompanied by progressive infiltration, invasion, and destruction of surrounding tissue. Furthermore, a malignant neoplasm generally has the ability to metastasize to distant sites. The terms "metastasis," "metastatic," or "metastasize" refer to the spread or migration of cancerous cells from a primary or original tumor to another organ or tissue, typically identifiable by the presence of a "secondary tumor" or "secondary cell mass" of the tissue type of the primary or original tumor, rather than the tissue type of the organ or tissue in which the secondary (metastatic) tumor is located.

[0291] The term "cancer" refers to a class of diseases characterized by the development of abnormal cells that proliferate uncontrollably and have the ability to invade and destroy normal body tissues. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is a hematopoietic cancer (i.e., blood cancer).

[0292] In some embodiments, the cancer is a hematopoietic cancer (e.g., leukemia (e.g., acute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL)); lymphoma (e.g., Hodgkin's lymphoma (HL) (e.g., B-cell HL, T-cell HL)), non-Hodgkin's lymphoma (NHL) (e.g., B-cell NHL, e.g., diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma)), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (e.g., mucosal intralymphoid tissue (MALT) lymphoma, muscular marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt's lymphoma, lymphoplasmacytic lymphoma (i.e., Waldenstrom lymphoma), lymphoplasmocytic lymphoma (i.e., Waldenstrom lymphoma), lymphoplasmocytic lymphoma (i.e., Waldenstrom lymphoma), lymphomas of the esophagus, ... Strohm's macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma, T-cell NH, e.g., precursor T lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sézary syndrome)), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous lipitis-like T-cell lymphoma , anaplastic large cell lymphoma); heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease); myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), primary myelofibrosis (AMM), also known as myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); multiple myeloma (MM); plasma cell neoplasia; familial hypereosinophilia; inflammatory myofibroblastic tumor; immunocytic amyloidosis). In some embodiments, the cancer is leukemia. In some embodiments, the cancer is acute lymphocytic leukemia (ALL).In some embodiments, the cancer is early T-cell precursor (ETP)-acute lymphoblastic leukemia (ALL).

[0293] In some embodiments, the cancer is a musculoskeletal cancer (e.g., bone cancer (e.g., osteosarcoma, osteoid osteoma, malignant fibrous histiocytoma, Ewing's sarcoma, chordoma, malignant giant cell chordoma, chondrosarcoma, osteochondroma, benign chondroma, chondroblastoma, chondromyxoid fibroma, myelodysplastic syndrome (MDS)), muscle cancer (e.g., rhabdomyosarcoma, rhabdomyoma), connective tissue cancer, synovium).

[0294] In some embodiments, the cancer is a cancer of the nervous system (e.g., brain cancer (e.g., astrocytoma, medulloblastoma, glioma (e.g., astrocytoma, oligodendroglioma), glioblastoma, glioblastoma multiforme, medulloblastoma, ependymoma, germinoma (i.e., pinealoma), oligodendroglioma, schwannoma, retinoblastoma, congenital tumor, craniopharyngioma), spinal cancer, neurofibroma (e.g., neurofibromatosis (NF) type 1 or 2, schwannomatosis), neuroblastoma, primitive neuroectodermal tumor (PNT), meningeal carcinomatosis (e.g., meningioma, meningeal sarcoma, gliomatosis), cancer of the skull, acoustic neuroma, ependymoma, hemangioblastoma, eye cancer (e.g., intraocular melanoma, retinoblastoma)). In some embodiments, the disease to be treated is a brain tumor. In some embodiments, the disease is polymorphous xanthoastrocytoma (PXA). In some embodiments, the disease is childhood pleomorphic xanthoastrocytoma (PXA).

[0295] In some embodiments, the cancer is selected from endocrine / exocrine cancers (e.g., thyroid cancer (e.g., papillary thyroid carcinoma, follicular thyroid carcinoma; medullary thyroid carcinoma, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid carcinoma, pheochromocytoma, paraganglioma), pancreatic cancer (e.g., pancreatic adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), islet cell tumor, ductal adenocarcinoma, insulinoma, glucagonoma, vipoma), adrenal cancer, neuroendocrine cancer (e.g., gastroenteropancreatic neuroendocrine tumor (GEP-NET), carcinoid tumor), sebaceous gland carcinoma, sweat gland carcinoma). In some embodiments, the cancer is sweat gland carcinoma (e.g., sweat gland carcinoma).

[0296] In some embodiments, the cancer is liver cancer (e.g., hepatocellular carcinoma (HCC) (e.g., hepatocellular carcinoma, hepatoblastoma, hepatocellular adenoma), malignant liver cancer, hemangioma, biliary tract cancer (e.g., cholangiocarcinoma)).

[0297] In some embodiments, the cancer is head and neck cancer (e.g., squamous cell carcinoma of the head and neck (SCCHN), adenoid cystic carcinoma). In some embodiments, the cancer is oral cancer (e.g., buccal cavity cancer, lip cancer, tongue cancer, mouth cancer, pharynx cancer, hypopharyngeal cancer (e.g., hypopharyngeal cancer), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer), salivary gland cancer). In some embodiments, the cancer is esophageal cancer (e.g., esophageal squamous cell carcinoma, esophageal adenocarcinoma, Barrett's adenocarcinoma, esophageal leiomyosarcoma).

[0298] In some embodiments, the cancer is a gastrointestinal cancer (e.g., anal cancer, colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma), gallbladder cancer, stomach cancer (e.g., gastric cancer (e.g., gastric adenocarcinoma)), gastrointestinal stromal tumor (GIST), small bowel cancer (e.g., appendix cancer, small bowel cancer, e.g., small bowel adenocarcinoma), small intestine cancer, large bowel cancer, large intestine cancer).

[0299] In some embodiments, the cancer is a cardiovascular cancer (e.g., primary cardiac tumors, angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma), endotheliosarcoma (e.g., Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma), cardiac myxoma, cardiac rhabdomyoma).

[0300] In some embodiments, the cancer is lung cancer (e.g., bronchial cancer (e.g., bronchial carcinoma, bronchial adenoma), alveolar carcinoma, mesothelioma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung adenocarcinoma, chondrotic hamartoma, papillary adenocarcinoma).

[0301] In some embodiments, the cancer is a genitourinary cancer (e.g., bladder cancer (e.g., urothelial carcinoma), urethral cancer, kidney cancer (e.g., nephroblastoma, also known as Wilms' tumor, renal cell carcinoma), testicular cancer (e.g., seminoma, embryonal carcinoma testis), germ cell carcinoma, prostate cancer (e.g., prostate adenocarcinoma), penile cancer (e.g., Paget's disease of the penis and scrotum).

[0302] In some embodiments, the cancer is a gynecological cancer (e.g., endometrial cancer (e.g., uterine cancer (e.g., uterine sarcoma, choriocarcinoma), endometrial carcinoma), cervical cancer (e.g., cervical adenocarcinoma), ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma), germ cell cancer, vulvar cancer (e.g., Paget's disease of the vulva), vaginal cancer, fallopian tube cancer).

[0303] In some embodiments, the cancer is breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast, triple negative breast cancer, HER-2 positive breast cancer, HER2 negative breast cancer).

[0304] In some embodiments, the cancer is a skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC), dermatofibroma).

[0305] In some embodiments, the cancer is a soft tissue cancer (e.g., intraepithelial neoplasia, epithelial carcinoma, epithelial sarcoma, adenocarcinoma, adenoma, fibrosarcoma, fibroma, liposarcoma, lipoma, myxoma, teratoma).

[0306] In some embodiments, the cancer is a rare cancer. The term "rare cancer" refers to cancer that occurs in a relatively small number of patients. Rare cancers include, but are not limited to, sarcoma (e.g., soft tissue sarcoma, liposarcoma, uterine sarcoma, leiomyosarcoma, myxofibrosarcoma, osteosarcoma, angiosarcoma, Ewing's sarcoma, synovial sarcoma, rhabdomyosarcoma, intimal sarcoma), malignant lymphoma, thymic carcinoma (e.g., thymoma), mesothelioma, gastrointestinal stromal tumor (GIST), neuroendocrine cancer, eye cancer, brain tumor, bone and soft tissue tumor, skin cancer, and germ cell tumor.

[0307] In some embodiments, the cancer is breast cancer, gastric cancer, ovarian cancer, or esophageal cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is gastric cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is esophageal cancer. In some embodiments, the cancer is multiple myeloma, leukemia, lymphoma, or colon cancer. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is leukemia. In some embodiments, the cancer is lymphoma. In some embodiments, the cancer is colon cancer.

[0308] In some embodiments, the cancer is a HER2 positive cancer. In some embodiments, the cancer is a HER2 positive cancer and the antibody component of the SPAC is an antibody or an antigen-binding fragment thereof directed against HER2. In some embodiments, the cancer is a HER2 positive cancer; the antibody component of the SPAC is an antibody or an antigen-binding fragment thereof directed against HER2; and the stapled peptide is a stapled anti-cancer peptide. In some embodiments, the HER2 positive cancer is breast cancer, gastric cancer, ovarian cancer, or esophageal cancer. In some embodiments, the HER2 positive cancer is HER2 positive breast cancer. In some embodiments, the antibody directed against HER2 is trastuzumab or pertuzumab. Other examples of antibodies directed against HER2 are also provided herein.

[0309] In some embodiments, the cancer expresses an antigen selected from CD38, CD33, CD22, TROP2, CD30, CD79b, and Nectin-4. In some embodiments, the cancer expresses the antigen, and the antibody component of the SPAC is an antibody or antigen-binding fragment thereof directed against the antigen. In some embodiments, the cancer expresses the antigen; the antibody component of the SPAC is an antibody or antigen-binding fragment thereof directed against the antigen; and the stapled peptide is a stapled anti-cancer peptide.

[0310] In some embodiments, the cancer expresses CD38. In some embodiments, the cancer expresses CD38, and the antibody component of the SPAC is an antibody directed against CD38, or an antigen-binding fragment thereof. In some embodiments, the cancer expresses CD38; the antibody component of the SPAC is an antibody directed against CD38, or an antigen-binding fragment thereof; and the stapled peptide is a stapled anti-cancer peptide. In some embodiments, the cancer expressing CD38 is multiple myeloma, leukemia, lymphoma, or colorectal cancer. In some embodiments, the antibody directed against HER2 is daratumumab. Other examples of antibodies directed against CD38 are also provided herein.

[0311] Additionally, provided herein is a method of inhibiting tumor growth in a subject comprising administering to the subject an effective amount of a SPAC provided herein, or a pharmaceutical composition thereof. Also provided herein are SPACs and pharmaceutical compositions thereof for use in inhibiting tumor growth in a subject. Also provided herein is the use of SPACs and pharmaceutical compositions thereof provided herein for the manufacture of a medicament for inhibiting tumor growth. The tumor may express any of the antigens described herein (e.g., HER2, CD38, CD33, CD22, TROP2, CD30, CD79b, Nectin-4).

[0312] As used herein, the term "inhibit" or "inhibition" in the context of tumor growth refers to, for example, a reduction in the growth rate of a tumor (i.e., a reduction in the proliferation rate of cells of a tumor). In some embodiments, the term refers to a reduction in the growth rate of a tumor to a level that is statistically significantly slower than the initial rate (e.g., the growth rate of the tumor before administration or application of a SPAC provided herein). In some embodiments, the term refers to a reduction in the growth rate of a tumor to a rate that is less than 75%, less than 50%, less than 40%, less than 30%, less than 25%, less than 20%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%, less than 0.01%, less than 0.001%, or less than 0.0001% of the initial rate (e.g., the growth rate of the tumor before administration or application of a SPAC provided herein).

[0313] In some embodiments, treating cancer and / or inhibiting tumor growth can result in a reduction in tumor size or volume. For example, after treatment, tumor size is reduced by 5% or more (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more) compared to its size before treatment. Tumor size can be measured by any reproducible measurement means. Tumor size can be measured as tumor diameter or by any reproducible measurement means. In some embodiments, tumor size is reduced by at least 25% compared to its size before treatment.

[0314] In some embodiments, treating cancer and / or inhibiting tumor growth may also result in a reduction in the number of tumors. For example, after treatment, the number of tumors is reduced by 5% or more (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more) compared to the number before treatment. The number of tumors may be measured by any reproducible measurement means. The number of tumors may be measured by counting the tumors visible to the naked eye or at a specified magnification (e.g., 2x, 3x, 4x, 5x, 10x, or 50x).

[0315] In some embodiments, treating cancer can result in a reduction in the number of metastatic nodes in other tissues or organs distant from the primary tumor site.For example, after treatment, the number of metastatic nodes is reduced by 5% or more (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more) compared to the number before treatment.The number of metastatic nodes can be measured by any reproducible measuring means.The number of metastatic nodes can be measured by counting the number of visible metastatic nodes with the naked eye or at a specified magnification (e.g., 2x, 10x, or 50x).

[0316] In some embodiments, treating cancer can result in an increase in the average survival time of a population of subjects treated according to the present disclosure compared to a population of untreated subjects.For example, the average survival time is increased by more than 30 days (more than 60 days, 90 days, or 120 days).The increase in the average survival time of a population can be measured by any reproducible means.The increase in the average survival time of a population can be measured, for example, by calculating the average length of survival for a population after the start of treatment with a compound of the present disclosure.The increase in the average survival time of a population can also be measured, for example, by calculating the average length of survival for a population after the completion of the first round of treatment with a compound of the present disclosure.

[0317] In some embodiments, treating cancer may also result in a reduction in the mortality rate of the treated population compared to the untreated population.For example, the mortality rate is reduced by more than 2% (for example, more than 5%, 10%, or 25%).The reduction in the mortality rate of the treated population may be measured by any reproducible means, for example, by calculating the average number of disease-related deaths per unit time for the population after the start of treatment with the compound of the present disclosure.The reduction in the mortality rate of the population may also be measured by, for example, calculating the average number of disease-related deaths per unit time for the population after the completion of the first round of treatment with the compound of the present disclosure.

[0318] In some embodiments, treating cancer may also result in an increased mean progression-free survival time of a population of treated subjects compared to an untreated population. For example, the mean progression-free survival time is increased by more than 30 days (more than 60 days, 90 days, or 120 days). The increase in the mean progression-free survival time of a population may be measured by any reproducible means. The increase in the mean progression-free survival time of a population may be measured, for example, by calculating the mean length of progression-free survival for a population after the start of treatment with a compound of the present disclosure. The increase in the mean progression-free survival time of a population may also be measured, for example, by calculating the mean length of progression-free survival for a population after the completion of a first round of treatment with a compound of the present disclosure. "Progression-free survival" as used herein refers to the length of time during and after administration or treatment during which the disease (e.g., cancer) being treated does not worsen.

[0319] Also provided herein is a method of delivering a stapled peptide into a cell, comprising contacting the cell with a SPAC or pharmaceutical composition thereof provided herein. In some embodiments, the cell is a cancer cell. In some embodiments, the stapled peptide has improved cellular uptake compared to the corresponding unconjugated stapled peptide. In some embodiments, the stapled peptide is delivered to a cell in vitro. In some embodiments, the stapled peptide is delivered to a cell in vivo (i.e., in a subject). In some embodiments, the stapled peptide is delivered to a cell of a biological sample.

[0320] Also provided herein is a method of inducing cancer cell death comprising contacting a cancer cell with an effective amount of a SPAC provided herein or a pharmaceutical composition thereof. In some embodiments, the method is for selectively inducing cancer cell death (i.e., selectively killing cancer cells). In some embodiments, the SPAC provided herein is selectively cytotoxic to cancer cells. In some embodiments, the cells are contacted in vitro. In some embodiments, the cells are contacted in vivo (i.e., in a subject). In some embodiments, the cells are contacted in a biological sample.

[0321] A SPAC described herein "selectively" induces cell death of one type of cell over another if it induces cell death of one type of cell to a greater extent than the other type (e.g., selectively induces cancer cell death over non-cancer cell death). A SPAC described herein "selectively" induces cancer cell death if it induces cancer cell death to a greater extent than non-cancer cell death. A peptide described herein is "selectively" cytotoxic to cancer cells over non-cancer cells if it is more toxic to cancer cells than non-cancer cells (e.g., by lysing, killing, promoting their apoptosis, or otherwise damaging them). In some embodiments, the selectivity in any of the above embodiments is at least 1.1-fold, at least 1.5-fold, 2-fold, at least 3-fold, at least 5-fold, at least 10-fold, at least 30-fold, at least 50-fold, at least 100-fold, at least 300-fold, at least 500-fold, at least 1,000-fold, at least 3,000-fold, at least 5,000-fold, at least 10,000-fold, at least 30,000-fold, at least 50,000-fold, or at least 100,000-fold. In some embodiments, the selectivity is 100,000-fold or less, 10,000-fold or less, 100-fold or less, 10-fold or less, or 2-fold or less. Combinations of the above ranges (e.g., at least 2-fold and 10,000-fold or less) are also within the scope of the present disclosure.

[0322] As described herein, the cell may be a cancer cell. In some embodiments, the cell is a breast cancer (e.g., BT-474, SK-BR-3, MCF-7), ovarian cancer (e.g., SK-OV-3), esophageal cancer (e.g., OE19, KYSE-410), gastric cancer (e.g., NCI-N87), multiple myeloma (e.g., NCIH929, RMPI 8226), colon cancer (e.g., HCT-116, COLO-678), lymphoma: (e.g., DAUDI), or ALL (e.g., DND41).

[0323] Also provided herein is a method of treating and / or preventing an infectious disease (e.g., a bacterial infection) in a subject, comprising administering to the subject an effective amount of a SPAC provided herein or a pharmaceutical composition thereof. Also provided herein are SPACs and pharmaceutical compositions thereof for use in treating and / or preventing an infectious disease (e.g., a bacterial infection) in a subject. Also provided herein is the use of SPACs and pharmaceutical compositions thereof for the manufacture of a medicament for treating an infectious disease (e.g., a bacterial infection). In some embodiments, the infectious disease is a bacterial infection. In some embodiments, the bacterial infection is an antibiotic-resistant bacterial infection.

[0324] Also provided herein are methods of killing and / or inhibiting the growth of bacteria (e.g., gram-negative and / or gram-positive bacteria), the methods comprising contacting the bacteria (e.g., in vitro or in vivo) with a SPAC provided herein, or a pharmaceutical composition thereof.

[0325] "Infectious disease" refers to any disease caused by a pathogen (i.e., a pathogenic microorganism). An infectious disease may be caused by a bacterium, a virus, a parasite, or a fungus. An infectious disease may be a microbial infection. "Microbial infection" refers to an infection caused by a microorganism, such as a fungus, a bacterium, or a virus. Various bacterial infections include, but are not limited to, skin infections (e.g., bacterial cellulitis, wound infections), gastrointestinal infections, throat infections (e.g., strep throat), urinary tract infections (UTIs), urogenital infections, sexually transmitted diseases (e.g., gonorrhea, chlamydia, syphilis), lung infections (e.g., pneumonia, pneumococcal pneumonia, tuberculosis, whooping cough), food poisoning, sepsis, bacterial meningitis, Lyme disease, cholera, botulism, tetanus, anthrax, blood infections, and systemic infections. In some embodiments, the microbial infection is an infection caused by a bacterium, i.e., a "bacterial infection." In some embodiments, the bacteria is a gram-negative bacteria. In some embodiments, the bacteria is a gram-positive bacteria.

[0326] "Gram-negative bacteria" were originally defined by their ability not to retain the Gram stain; however, since then, Gram-negative bacteria have been further defined as bacteria that generally have a cell wall with a thin peptidoglycan layer and have a lipid outer membrane. "Gram-positive bacteria" are bacteria that take up crystal violet stain in a Gram stain test and generally have a cell wall that contains a thin peptidoglycan layer but no lipid outer membrane.

[0327] As used herein, an "antibiotic-resistant bacterial infection" is a bacterial infection caused by an antibiotic-resistant bacterium. "Antibiotic resistance" occurs when a microorganism evolves a mechanism to protect itself from the effects of antibiotics. A microorganism that is resistant to multiple antimicrobial drugs is called "multidrug-resistant" (MDR). In some embodiments, the methods herein are for treating a multidrug-resistant bacterial infection. In some embodiments, the methods herein are for killing and / or inhibiting the growth of multidrug-resistant bacteria.

[0328] example Common methods Solid-phase peptide synthesis: Antimicrobial peptides and their stapled derivatives were synthesized using Fmoc-based solid-phase peptide synthesis. To achieve i+4 staple length, α-methyl, α-alkenyl amino acids were used for flanking three residues. For the stapling reaction, Grubbs first generation ruthenium catalyst dissolved in dichloroethane was added to the peptide while still on the resin. To ensure maximum conversion, 3-5 rounds of stapling were performed. Once stapled, the appropriate maleimide linker was coupled to the N-terminus and the linker-peptide was cleaved from the resin using trifluoroacetic acid, then precipitated using a hexane:ether (1:1) mixture, and subsequently purified using preparative HPLC. Characterization of the final linker-peptide for purity was assessed using a UHPLC / MS system.

[0329] Cell culture: Cell lines were maintained in appropriate medium supplemented with fetal bovine serum to a final concentration of 10%.

[0330] 72-hour cytotoxicity assay: Cells were seeded in a 96-well format and after 24 hours of incubation, serial dilutions from a 1 mg / mL stock of SPACs or vehicle were then added to the cells in a final volume of 100 μl. After 72 hours of incubation at 37° C., 100 μl of CellTiter-Glo® reagent was added to the cells and the plate was incubated at room temperature for 15 minutes. Luminescence was then measured on a microplate reader.

[0331] Example 1: Preparation of SPACs Peptide conjugation protocol: (1) prepare the stapled peptide using solid phase synthesis; (2) add a coupling reagent to the on-resin, N-terminally deprotected stapled peptide. For example, 6-maleimidohexanoyl-Val-Cit-p-aminobenzoyl carbonate-4-nitrophenyl ester (Mc-Val-Cit-PABC-PNP) can be used; (3) cleave from the resin and purify by HPLC; (4) reduce the antibody in a separate batch using TCEP (see protocol below); (5) conjugate the stapled peptide to the antibody; (6) quench the unreacted peptide using N-acetylcysteine; and (7) purify by salt exchange.

[0332] Antibody conjugation protocol: (1) buffer exchange the antibody into PBS-E, pH 6-8, by the following protocol: (a) dilute the 21 mg / mL solution of antibody provided by the manufacturer to 1 mg / mL in PBS-E (pH 6-8), (b) remove the loading buffer by centrifugation using a spin column; equilibrate by adding more PBS-E and further centrifugation, (c) add antibody solution (1 mg / mL), centrifuge and collect the flow-through, (d) measure the antibody concentration in the eluate, and (e) increase the antibody concentration to 10 mg / mL by using an ultrafiltration device according to the manufacturer's instructions; (2) reduce the antibody with TCEP; (3) conjugate the peptide through co-incubation at room temperature; (4) quench the reaction with n-acetylcysteine; and (5) purify.

[0333] Example 2: Cytotoxicity of anti-HER2 SPACs Anti-HER2 SPAC1 and SPAC2 (see Table 6) are cytotoxic to both low and high HER2 expressing breast cancer cells. See Figures 1A-1B. SPAC1 and SPAC2 were cytotoxic in the HER2 high (HER2+++) BT-474 cell line (Figure 1A). SPAC1 and SPAC2 were also cytotoxic in the HER2 low (HER2+) MCF7 cell line (Figure 1B).

[0334] Example 3: Cytotoxicity of anti-CD38 SPACs Anti-CD38 SPAC3 (see Table 6) is cytotoxic to CD38+ multiple myeloma cells. See Figure 2. SPAC3 shows cytotoxicity in the CD38+ multiple myeloma cell line RPMI 8226.

[0335] Example 4: Antiproliferative activity of anti-CD38 SPACs containing PPI inhibitors Anti-CD38 SPACs were used to inhibit cancer cell proliferation by delivering various stapled peptide protein-protein interaction (PPI) inhibitors (e.g., MCL-1 inhibitor, MDM2 inhibitor, β-catenin inhibitor). As shown in Figures 3-5, SPACs 8, 11, and 16 (see Table 7), each containing the anti-CD38 antibody daratumumab, inhibit the proliferation of multiple myeloma cells.

[0336] Example 5: Selectivity of anti-HER2 SPACs containing PPI inhibitors As shown in Figures 6A-6B, SPACs can be highly selective, which is beneficial when trying to avoid on-target toxicity associated with traditional ADCs. SPACs can also overcome receptor low expression by exploiting oncogene addiction. Figure 6A shows the results of the HER2-low cell line MCF7, which has wild-type (wt) p53 status and is therefore sensitive to MDM2 inhibition. The traditional ADC trastuzumab emtansine does not show any activity in this cell line, while SPAC7 (see Table 7), which includes an MDM2 inhibitor, as provided herein, shows anti-proliferative activity. Figure 6B shows the results of a cell line that highly expresses HER2 but has mutated p53 and is therefore sensitive to MDM2 inhibition. In this setting, the traditional ADC trastuzumab emtansine shows efficacy at relatively low concentrations, while SPAC7 (see Table 7) requires relatively high concentrations. These data demonstrate the selectivity of SPACs. These data also demonstrate that on-target toxicity is unlikely, as toxicity may require high antibody concentrations and higher receptor expression than normal tissues.

[0337] Additional Aspects Additional aspects of the present disclosure are provided by the following numbered paragraphs: 1. Stapled peptide-antibody conjugates (SPACs), which comprise a stapled peptide conjugated to an antibody or antigen-binding fragment thereof. 2. The SPAC of paragraph 1, wherein the antibody is a monoclonal antibody (mAb) or an antigen-binding fragment thereof. 3. The SPAC of paragraphs 1 or 2, wherein the antibody is an anti-cancer antibody or an antigen-binding fragment thereof. 4. The SPAC of any one of paragraphs 1-3, wherein the antibody or antigen-binding fragment thereof is directed to a target antigen expressed on a cancer cell. 5. The SPAC of any one of paragraphs 1-4, wherein the antibody is an antibody, or an antigen-binding fragment thereof, directed against human epidermal growth factor receptor 2 (HER2). 6. The SPAC of paragraph 5, wherein the antibody is trastuzumab. 7. The SPAC of paragraph 5, wherein the antibody is pertuzumab. 8. The SPAC of any one of paragraphs 1-4, wherein the antibody is an antibody directed against CD38, CD33, CD22, TROP2, CD30, CD79b, Nectin-4, or TM4SF1, or an antigen-binding fragment thereof. 9. The SPAC of any one of paragraphs 1-4, wherein the antibody is an antibody, or an antigen-binding fragment thereof, directed against TM4SF1. 10. The SPAC of any one of paragraphs 1-4, wherein the antibody is an antibody, or an antigen-binding fragment thereof, directed against CD38. 11. The SPAC of paragraph 10, wherein the antibody is daratumumab. 12. The SPAC of any one of paragraphs 1-11, wherein the antibody is an antibody-drug conjugate (ADC) or an antigen-binding fragment thereof. 13. The SPAC of paragraph 12, wherein the antibody is trastuzumab emtansine. 14. The SPAC of any one of paragraphs 1-13, wherein the stapled peptide is a stapled anti-cancer peptide. 15. The SPAC of any one of paragraphs 1-14, wherein the stapled peptide is a stapled antimicrobial peptide (StAMP). 16. The SPAC of any one of paragraphs 1-15, wherein the stapled peptide is a single-stapled peptide, a double-stapled peptide, or a stitched peptide. 17. The SPAC of any one of paragraphs 1-16, wherein the stapled peptide is an inhibitor of protein-protein interaction (PPI). 18. The SPAC of any one of paragraphs 1-17, wherein the stapled peptide is an inhibitor of a BCL-2 family member protein. 19. Stapled peptide is BCL-x L , the SPAC of paragraph 18, which is an inhibitor of BCL-2, BCL-W, and / or MCL1. 20. The SPAC of paragraph 19, wherein the stapled peptide is an MCL1 inhibitor. 21. The SPAC of any one of paragraphs 1-20, wherein the stapled peptide is an activator of a BCL-2 family member protein effector. 22. The SPAC of paragraph 21, wherein the stapled peptide is an activator of BAX, BAK, or BOK. 23. The SPAC of any one of paragraphs 1-22, wherein the stapled peptide is a stapled BCL-2 interacting mediator of cell death (BIM) peptide. 24. Stapled peptide is SAHB A1 or BIM SAHB A2 Any one of paragraphs 1 to 23 of a SPAC. 25. The SPAC of any one of paragraphs 1-17, wherein the stapled peptide is a β-catenin inhibitor. 26. The SPAC of paragraph 25, wherein the stapled peptide is an inhibitor of Wnt / β-catenin signaling. 27. The SPAC of any one of paragraphs 1-17, wherein the stapled peptide is an MDM2 inhibitor. 28. A SPAC of paragraph 27, wherein the stapled peptide inhibits binding of MDM2 to p53. 29. The SPAC of paragraph 27 or 28, wherein the stapled peptide is ALRN-6924, ATSP-7041, or ATSP 7041 Cba10L. 30. The SPAC of paragraph 27 or 28, wherein the stapled peptide comprises any one of SEQ ID NOs: 161-166, or a pharma- ceutically acceptable salt thereof. 31. A SPAC of any one of paragraphs 1-30, wherein the stapled peptide induces cancer cell death. 32. The SPAC of any one of paragraphs 1-17, wherein the stapled peptide is a stapled magainin peptide. 33. The SPAC of paragraph 32, wherein the stapled peptide is a stapled magainin II peptide. 34. A stapled peptide has the amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof, X 1 , X 2 , X 3 , and X 4 is an amino acid; X 1 and X 2 and are connected via bridges, and X 3 and X 4 are connected via bridges; and The amino acid sequence is expressed as 0 to 9 amino acid substitutions (inclusive), X 1 , X 2 , X 3 , and X 4 SPAC in paragraph 33, which is included in a position other than the 35. A stapled peptide has the amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof, wherein the amino acid sequence comprises 0 to 11 amino acid substitutions (inclusive) of X, 1 , X 2 , X 3 , and X 4 SPAC in paragraph 34, which is included in a position other than the 36. A stapled peptide has the amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof. 37. A stapled peptide has the amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof. 38. The SPAC of any one of paragraphs 1-17, wherein the stapled peptide is a stapled esculetin peptide. 39. The SPAC of paragraph 38, wherein the stapled peptide is stapled esculentin-1A peptide. 40. A stapled peptide has the amino acid sequence: [ka] and pharma-ceutically acceptable salts thereof, wherein: X 1 , X 2 , X 3 , and X 4 is an amino acid; X 1 and X 2 and are connected via bridges, and X 3 and X 4 are connected via bridges; and The amino acid sequence is expressed as 0 to 9 amino acid substitutions (inclusive), X 1 , X 2 , X 3 , and X 4 SPAC in paragraph 39, which is included in a position other than the 41. A stapled peptide has the amino acid sequence: [ka] and pharma- ceutically acceptable salts thereof, wherein: X 1 , X 2 , X 3 , and X 4 is an amino acid; X 1 and X 2 and are connected via bridges, and X 3 and X 4 are connected via bridges; and The amino acid sequence can be arbitrarily selected from 0 to 8 amino acid substitutions (inclusive), X 1 , X 2 , X 3 , and X 4 SPAC in paragraph 40, which is included in a position other than the 42. The SPAC of paragraph 40, wherein the stapled peptide comprises SEQ ID NO: 73, or a pharma- ceutically acceptable salt thereof. 43. The SPAC of paragraph 41, wherein the stapled peptide comprises SEQ ID NO:105, or a pharma- ceutically acceptable salt thereof. 44. A stapled peptide has the amino acid sequence: [ka] or a pharma- ceutically acceptable salt thereof. 45. The SPAC of any one of paragraphs 1 to 44, wherein the stapled peptide is an α-helical peptide. 46. ​​The SPAC of any one of paragraphs 1-45, wherein the stapled peptide is 100 amino acids or less in length. 47. The SPAC of any one of paragraphs 1-46, wherein the stapled peptide is 30 amino acids or less in length. 48. The SPAC of any one of paragraphs 1-47, wherein the stapled peptide is conjugated to one or more stapled peptides. 49. The stapled peptide is represented by SEQ ID NO: 48, wherein 1 and X 2 and X 3 and X 4 is the formula: [ka] wherein α represents the α-carbon of the bridge amino acid; and wherein the C-terminus of the stapled peptide is amidated with -NH2. 50. The SPAC of paragraph 37, wherein the stapled peptide is represented by SEQ ID NO: 26, wherein X 1 and X 2 and X 3 and X 4 and wherein the C-terminus of the stapled peptide is amidated with -NH2. 51. The SPAC of paragraph 42, wherein the stapled peptide is represented by SEQ ID NO: 73, wherein X 1 and X 2 and X 3 and X 4 and wherein the C-terminus of the stapled peptide is amidated with -NH2. 52. The SPAC of paragraph 43, wherein the stapled peptide is represented by SEQ ID NO: 105, wherein X 1 and X 2 and X 3 and X 4 and wherein the C-terminus of the stapled peptide is amidated with -NH2. 53. The SPAC of paragraph 44, wherein the stapled peptide is represented by SEQ ID NO: 113, wherein X 1 and X 2 and X 3 and X 4 and wherein the C-terminus of the stapled peptide is amidated with -NH2. 54. The SPAC of any one of paragraphs 1 to 53, wherein the antibody or antigen-binding fragment thereof is conjugated to the N-terminus of the stapled peptide. 55. The SPAC of any one of paragraphs 1-53, wherein the antibody or antigen-binding fragment thereof is conjugated to the C-terminus of the stapled peptide via a lysine residue. 56. The SPAC of any one of paragraphs 1-55, wherein the stapled peptide is conjugated to a cysteine ​​residue of the antibody or antigen-binding fragment thereof. 57. The SPAC of any one of paragraphs 1-55, wherein the stapled peptide is conjugated through a lysine residue on the antibody or antigen-binding fragment thereof. 58. The SPAC of any one of paragraphs 1 to 57, wherein the antibody or antigen-binding fragment thereof is conjugated to the stapled peptide via a linker. 59. The conjugate of paragraph 58, wherein the linker comprises an optionally substituted alkylene, an optionally substituted alkenylene, an optionally substituted alkynylene, an optionally substituted heteroalkylene, an optionally substituted heteroalkenylene, an optionally substituted heteroalkynylene, an optionally substituted carbocyclylene, an optionally substituted heterocyclylene, an optionally substituted arylene, an optionally substituted heteroarylene, an optionally substituted acylene, or any combination thereof. 60. The SPAC of paragraph 58 or 59, wherein the linker is a cleavable linker. 61. The SPAC of any one of paragraphs 58-60, wherein the linker is cleavable by pH or by a protease, an esterase, or intracellular disulfide reduction. 62. The SPAC of paragraph 61, wherein the linker is cleavable by a protease. 63. The SPAC of any one of paragraphs 58-62, wherein the linker is a peptide linker. 64. The peptide linker is -Y A Y B Y C Y D - (SEQ ID NO: 159), where Y A is glycine, glutamic acid, or absent; Y B is valine, phenylalanine, alanine, tyrosine, or glycine; Y C is citrulline, arginine, lysine, alanine, or glycine; and Y D is glycine or absent, the SPAC of paragraph 63. 65. The SPAC of paragraph 64, wherein the peptide linker comprises -valine-citrulline-. 66. The linker has the formula: [ka] (Maleimido-caproic acid-valine-citrulline-para-aminobenzyl), [ka] (Maleimido-caproic acid-valine-citrulline-glycine), [ka] (iodoacetamido-(PEG3)-valine-citrulline), [ka] (iodoacetamido-(PEG3)-valine-citrulline-para-aminobenzyl), [ka] (Maleimido-2,3-diaminopropionate-valine-citrulline-para-aminobenzyl), [ka] (Maleimido-caproic acid-valine-citrulline), [ka] (Maleimido-caproic acid-lysine-valine-citrulline), or [ka] (Maleimide-caproic acid-(PEG3)-(PEG3)-valine-citrulline) wherein S represents a point of attachment to an antibody or antigen-binding fragment thereof; and N represents a point of attachment to the N-terminus of a stapled peptide. 67. The linker has the formula: [ka] [ka] [ka] [ka] [ka] wherein A represents a point of attachment to an antibody or antigen-binding fragment thereof; and N represents a point of attachment to the N-terminus of the stapled peptide. 68. The SPAC of any one of paragraphs 1 to 67, wherein the antibody or antigen-binding fragment thereof is conjugated to two or more stapled peptides. 69. The SPAC of any one of paragraphs 1 to 68, wherein the antibody or antigen-binding fragment thereof is conjugated to 2 to 10 stapled peptides, inclusive. 70. The SPAC of any one of paragraphs 1-69, comprising an antibody or antigen-binding fragment thereof:staple peptide ratio of about 1:8. 71. A pharmaceutical composition comprising the SPAC of any one of paragraphs 1 to 70 and a pharma- ceutically acceptable carrier. 72. A method for treating a proliferative disease in a subject, comprising administering to the subject a SPAC or a pharmaceutical composition thereof of any one of paragraphs 1 to 70. 73. The method of paragraph 72, wherein the proliferative disease is cancer. 74. The method of paragraph 73, wherein the cancer is a HER2-positive cancer. 75. The method of paragraph 73 or 74, wherein the cancer is colon cancer, breast cancer, gastric cancer, ovarian cancer, or esophageal cancer. 76. The method of any one of paragraphs 73-75, wherein the cancer is HER2-positive breast cancer. 77. The method of paragraph 73, wherein the cancer expresses CD38. 78. The method of paragraph 73 or 77, wherein the cancer is multiple myeloma, leukemia, or lymphoma. 79. A method for inhibiting tumor growth in a subject, comprising administering to the subject a SPAC or a pharmaceutical composition thereof of any one of paragraphs 1 to 70. 80. A method for delivering a stapled peptide to a cell, comprising contacting the cell with a SPAC of any one of paragraphs 1 to 70, or a pharmaceutical composition thereof. 81. The method of paragraph 80, wherein the cell is a cancer cell. 82. The method of paragraph 80 or 81, wherein the stapled peptide has improved cellular uptake compared to the corresponding unconjugated stapled peptide. 83. A method for inducing cancer cell death, comprising contacting a cancer cell with a SPAC or a pharmaceutical composition thereof of any one of paragraphs 1 to 70. 84. The method of paragraph 83 for selectively killing cancer cells in the presence of non-cancerous cells. 85. The method of any one of paragraphs 80 to 84, wherein the cells are in vitro. 86. The method of any one of paragraphs 80-84, wherein the cell is in vivo in a subject. 87. The method of any one of the preceding paragraphs, wherein the SPAC is administered intravenously. 88. The method of any one of the preceding paragraphs, wherein the subject is a human. 89. A SPAC of any one of paragraphs 1 to 70 for use in the manner of any one of the preceding paragraphs. 90. Use of a SPAC of any one of paragraphs 1 to 70 for the manufacture of a medicine. 91. A kit comprising a SPAC of any one of paragraphs 1 to 70, or a pharmaceutical composition thereof, and optionally instructions for use.

[0338] Equivalents and Scope In the claims, unless indicated to the contrary or otherwise clear from the context, articles such as "a," "an," and "the" can mean one or more than one. Unless indicated to the contrary or otherwise clear from the context, a claim or description including "or" between one or more members of a group is considered to be satisfied if one, more than one, or all of the members of the group are present in, used in, or otherwise involved in a given product or process. The present disclosure includes embodiments in which exactly one member of a group is present in, used in, or otherwise involved in a given product or process. The present disclosure includes embodiments in which more than one or all of the members of a group are present in, used in, or otherwise involved in a given product or process.

[0339] Furthermore, the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the enumerated claims are introduced into another claim. For example, any claim that is dependent on another claim may be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented in the Markush group format as an example list, each subgroup of elements is also disclosed, and any element(s) may be removed from the group. In general, where the disclosure or aspects of the disclosure are said to include certain elements and / or features, it should be understood that certain aspects of the disclosure or aspects of the disclosure consist of or consist essentially of such elements and / or features. For purposes of simplicity, those aspects have not been specifically submitted as such in this application.

[0340] It is also noted that the terms "comprise" and "containing" are intended to be open ended, permitting the inclusion of additional elements or steps. Where ranges are given, the endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and the understanding of one of ordinary skill in the art, values ​​expressed as ranges may, in different aspects of this disclosure, take any particular value or subrange within the claimed range to one tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

[0341] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. In the event of a conflict between any of the incorporated references and this specification, this specification shall control. In addition, any specific aspects of this disclosure that are in the prior art may be expressly excluded from any one or more of the claims. Such aspects may be excluded even if the exclusion is not expressly stated in this application, since they are deemed to be known to those of ordinary skill in the art. Any specific aspects of this disclosure may be excluded from any claim for any reason, whether or not related to the existence of prior art.

[0342] Those skilled in the art will recognize, or be able to ascertain, many equivalents to the specific embodiments described herein, at most using routine experimentation. The scope of the embodiments described herein is not intended to be limited to the above specification, but rather is set forth in the appended claims. Those skilled in the art will appreciate that various changes and modifications of this description can be made without departing from the spirit or scope of the present disclosure, as defined in the following claims.

Claims

1. A stapled peptide-antibody conjugate (SPAC) comprising a stapled peptide conjugated to an antibody or antigen-binding fragment thereof.

2. The SPAC of claim 1, wherein the antibody is a monoclonal antibody (mAb) or an antigen-binding fragment thereof.

3. The SPAC of claim 1 or 2, wherein the antibody is an anti-cancer antibody or an antigen-binding fragment thereof.

4. The SPAC of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment thereof is directed to a target antigen expressed on a cancer cell.

5. The SPAC of any one of claims 1 to 4, wherein the antibody is an antibody directed against human epidermal growth factor receptor 2 (HER2), or an antigen-binding fragment thereof.

6. The SPAC of claim 5, wherein the antibody is trastuzumab.

7. The SPAC of claim 5, wherein the antibody is pertuzumab.

8. The SPAC of any one of claims 1 to 4, wherein the antibody is directed against CD38, CD33, CD22, TROP2, CD30, CD79b, Nectin-4, or TM4SF1, or an antigen-binding fragment thereof.

9. The SPAC of any one of claims 1 to 4, wherein the antibody is an antibody directed against TM4SF1, or an antigen-binding fragment thereof.

10. The SPAC of any one of claims 1 to 4, wherein the antibody is an antibody directed against CD38, or an antigen-binding fragment thereof.

11. The SPAC of claim 10, wherein the antibody is daratumumab.

12. The SPAC of any one of claims 1 to 11, wherein the antibody is an antibody-drug conjugate (ADC) or an antigen-binding fragment thereof.

13. The SPAC of claim 12, wherein the antibody is trastuzumab emtansine.

14. The SPAC of any one of claims 1 to 13, wherein the stapled peptide is a stapled anti-cancer peptide.

15. The SPAC of any one of claims 1 to 14, wherein the stapled peptide is a stapled antimicrobial peptide (StAMP).

16. The SPAC of any one of claims 1 to 15, wherein the stapled peptide is a single-stapled peptide, a double-stapled peptide, or a stitched peptide.

17. The SPAC of any one of claims 1 to 16, wherein the stapled peptide is an inhibitor of a protein-protein interaction (PPI).

18. The SPAC of any one of claims 1 to 17, wherein the stapled peptide is an inhibitor of a BCL-2 family member protein.

19. Stapled peptides are BCL-x L 19. The SPAC of claim 18, which is an inhibitor of BCL-2, BCL-W, and / or MCL1.

20. 20. The SPAC of claim 19, wherein the stapled peptide is an MCL1 inhibitor.

21. The SPAC of any one of claims 1 to 20, wherein the stapled peptide is an activator of a BCL-2 family member protein effector.

22. 22. The SPAC of claim 21, wherein the stapled peptide is an activator of BAX, BAK, or BOK.

23. The SPAC of any one of claims 1 to 22, wherein the stapled peptide is a stapled BCL-2 interacting mediator of cell death (BIM) peptide.

24. Stapled peptide, SAHB A1 or BIM SAHB A2 The SPAC of any one of claims 1 to 23,

25. The SPAC of any one of claims 1 to 17, wherein the stapled peptide is a β-catenin inhibitor.

26. The SPAC of claim 25, wherein the stapled peptide is an inhibitor of Wnt / β-catenin signaling.

27. The SPAC of any one of claims 1 to 17, wherein the stapled peptide is an MDM2 inhibitor.

28. The SPAC of claim 27, wherein the stapled peptide inhibits binding of MDM2 to p53.

29. 29. The SPAC of claim 27 or 28, wherein the stapled peptide is ALRN-6924, ATSP-7041, or ATSP 7041 Cba10L.

30. The SPAC of claim 27 or 28, wherein the stapled peptide comprises any one of SEQ ID NOs: 161-166, or a pharma- ceutically acceptable salt thereof.

31. The SPAC of any one of claims 1 to 30, wherein the stapled peptide induces cancer cell death.

32. The SPAC of any one of claims 1 to 17, wherein the stapled peptide is a stapled magainin peptide.

33. 33. The SPAC of claim 32, wherein the stapled peptide is a stapled magainin II peptide.

34. The stapled peptide has the amino acid sequence: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, X 1 , X 2 , X 3 , and X 4 is an amino acid; X 1 and X 2 and are connected via bridges, and X 3 and X 4 are connected via bridges; and The amino acid sequence is expressed as 0 to 9 amino acid substitutions (inclusive), 1 , X 2 , X 3 , and X 4 The SPAC of claim 33, comprising at a position other than

35. The stapled peptide has the amino acid sequence: 【Chemistry 2】 or a pharma- ceutically acceptable salt thereof, wherein the amino acid sequence comprises 0 to 11 amino acid substitutions (inclusive) of X, 1 , X 2 , X 3 , and X 4 The SPAC of claim 34, comprising at a position other than

36. The stapled peptide has the amino acid sequence: 【Chemistry 3】 or a pharma- ceutically acceptable salt thereof.

37. The stapled peptide has the amino acid sequence: 【Chemistry 4】 or a pharma- ceutically acceptable salt thereof.

38. The SPAC of any one of claims 1 to 17, wherein the stapled peptide is a stapled esculetin peptide.

39. 39. The SPAC of claim 38, wherein the stapled peptide is a stapled esculentin-1A peptide.

40. The stapled peptide has the amino acid sequence: 【Chemistry 5】 and pharma- ceutically acceptable salts thereof, wherein: X 1 , X 2 , X 3 , and X 4 is an amino acid; X 1 and X 2 and are connected via bridges, and X 3 and X 4 are connected via bridges; and The amino acid sequence is expressed as 0 to 9 amino acid substitutions (inclusive), 1 , X 2 , X 3 , and X 4 The SPAC of claim 39, comprising at a position other than

41. The stapled peptide has the amino acid sequence: 【Chemistry 6】 and pharma-ceutically acceptable salts thereof, wherein: X 1 , X 2 , X 3 , and X 4 is an amino acid; X 1 and X 2 and are connected via bridges, and X 3 and X 4 are connected via bridges; and The amino acid sequence can be arbitrarily selected to substitute 0 to 8 amino acids (inclusive), 1 , X 2 , X 3 , and X 4 The SPAC of claim 40, comprising at a position other than

42. 41. The SPAC of claim 40, wherein the stapled peptide comprises SEQ ID NO: 73, or a pharma- ceutically acceptable salt thereof.

43. 42. The SPAC of claim 41, wherein the stapled peptide comprises SEQ ID NO: 105, or a pharma- ceutically acceptable salt thereof.

44. The stapled peptide has the amino acid sequence: 【Chemistry 7】 or a pharma- ceutically acceptable salt thereof.

45. The SPAC of any one of claims 1 to 44, wherein the stapled peptide is an α-helical peptide.

46. 46. ​​The SPAC of any one of claims 1 to 45, wherein the stapled peptide is 100 amino acids or less in length.

47. 47. The SPAC of any one of claims 1 to 46, wherein the stapled peptide is 30 amino acids or less in length.

48. The SPAC of any one of claims 1 to 47, wherein the stapled peptide is conjugated to one or more stapled peptides.

49. The stapled peptide is represented by SEQ ID NO: 48, 1 and X 2 and X 3 and X 4 is the formula: 【Chemistry 8】 where α represents the α-carbon of the bridging amino acid; and where the C-terminus of the stapled peptide is -NH 2 is amidated with The SPAC of claim 36, wherein the SPAC is connected via a bridge represented by the formula:

50. The stapled peptide is represented by SEQ ID NO: 26, 1 and X 2 and X 3 and X 4 and is connected via a bridge represented by the formula (alk): 2 38. The SPAC of claim 37, which is amidated with

51. The stapled peptide is represented by SEQ ID NO: 73, where X 1 and X 2 and X 3 and X 4 and is connected via a bridge represented by the formula (alk): 2 The SPAC of claim 42, which is amidated with

52. The stapled peptide is represented by SEQ ID NO: 105, wherein 1 and X 2 and X 3 and X 4 and is connected via a bridge represented by the formula (alk): 2 44. The SPAC of claim 43, which is amidated with

53. The stapled peptide is represented by SEQ ID NO: 113, where X 1 and X 2 and X 3 and X 4 and is connected via a bridge represented by the formula (alk): 2 The SPAC of claim 44, which is amidated with

54. The SPAC of any one of claims 1 to 53, wherein the antibody or antigen-binding fragment thereof is conjugated to the N-terminus of the stapled peptide.

55. The SPAC of any one of claims 1 to 53, wherein the antibody or antigen-binding fragment thereof is conjugated to the C-terminus of the stapled peptide via a lysine residue.

56. The SPAC of any one of claims 1 to 55, wherein the stapled peptide is conjugated to a cysteine ​​residue of an antibody or antigen-binding fragment thereof.

57. The SPAC of any one of claims 1 to 55, wherein the stapled peptide is conjugated through a lysine residue of the antibody or antigen-binding fragment thereof.

58. The SPAC of any one of claims 1 to 57, wherein the antibody or antigen-binding fragment thereof is conjugated to the stapled peptide via a linker.

59. 59. The conjugate of claim 58, wherein the linker comprises an optionally substituted alkylene, an optionally substituted alkenylene, an optionally substituted alkynylene, an optionally substituted heteroalkylene, an optionally substituted heteroalkenylene, an optionally substituted heteroalkynylene, an optionally substituted carbocyclylene, an optionally substituted heterocyclylene, an optionally substituted arylene, an optionally substituted heteroarylene, an optionally substituted acylene, or any combination thereof.

60. The SPAC of claim 58 or 59, wherein the linker is a cleavable linker.

61. The SPAC of any one of claims 58 to 60, wherein the linker is cleavable by pH or by a protease, an esterase, or intracellular disulfide reduction.

62. The SPAC of claim 61, wherein the linker is cleavable by a protease.

63. The SPAC of any one of claims 58 to 62, wherein the linker is a peptide linker.

64. The peptide linker is -Y A Y B Y C Y D - (SEQ ID NO: 159), where Y A is glycine, glutamic acid, or absent; Y B is valine, phenylalanine, alanine, tyrosine, or glycine; Y C is citrulline, arginine, lysine, alanine, or glycine; and Y D The SPAC of claim 63, wherein is glycine or absent.

65. The SPAC of claim 64, wherein the peptide linker comprises -valine-citrulline-.

66. The linker has the formula: 【Chemistry 9】 (Maleimido-caproic acid-valine-citrulline-para-aminobenzyl), 【Chemistry 10】 (Maleimido-caproic acid-valine-citrulline-glycine), 【Chemistry 11】 (iodoacetamido-(PEG3)-valine-citrulline), 【Chemistry 12】 (iodoacetamido-(PEG3)-valine-citrulline-para-aminobenzyl), 【Chemistry 13】 (Maleimido-2,3-diaminopropionate-valine-citrulline-para-aminobenzyl), 【Chemistry 14】 (Maleimido-caproic acid-valine-citrulline), 【Chemistry 15】 (Maleimido-caproic acid-lysine-valine-citrulline), or 【Chemistry 16】 (Maleimide-caproic acid-(PEG3)-(PEG3)-valine-citrulline) wherein S represents a point of attachment to an antibody or antigen-binding fragment thereof; and N represents a point of attachment to the N-terminus of the stapled peptide.

67. The linker has the formula: 【Chemistry 17】 【Chemistry 18】 【Chemistry 19】 【Chemistry 20】 【Chemistry 21】 【Chemical 22】 where A represents the point of attachment to the antibody or antigen-binding fragment thereof; N represents the point of attachment to the N-terminus of the stapled peptide. The SPAC of any one of claims 58 to 65, comprising one of:

68. The SPAC of any one of claims 1 to 67, wherein the antibody or antigen-binding fragment thereof is conjugated to two or more stapled peptides.

69. The SPAC of any one of claims 1 to 68, wherein the antibody or antigen-binding fragment thereof is conjugated to 2 to 10 stapled peptides, inclusive.

70. 70. The SPAC of any one of claims 1 to 69, comprising an antibody or antigen-binding fragment thereof:staple peptide ratio of about 1:

8.

71. 71. A pharmaceutical composition comprising the SPAC of any one of claims 1 to 70 and a pharma- ceutically acceptable carrier.

72. 71. A method for treating a proliferative disease in a subject, comprising administering to the subject a SPAC according to any one of claims 1 to 70, or a pharmaceutical composition thereof.

73. 73. The method of claim 72, wherein the proliferative disease is cancer.

74. 74. The method of claim 73, wherein the cancer is a HER2-positive cancer.

75. 75. The method of claim 73 or 74, wherein the cancer is colon cancer, breast cancer, gastric cancer, ovarian cancer, or esophageal cancer.

76. The method of any one of claims 73 to 75, wherein the cancer is HER2-positive breast cancer.

77. 74. The method of claim 73, wherein the cancer expresses CD38.

78. 78. The method of claim 73 or 77, wherein the cancer is multiple myeloma, leukemia, or lymphoma.

79. 71. A method of inhibiting tumor growth in a subject, comprising administering to the subject a SPAC according to any one of claims 1 to 70, or a pharmaceutical composition thereof.

80. 71. A method for delivering a stapled peptide to a cell, comprising contacting the cell with a SPAC according to any one of claims 1 to 70 or a pharmaceutical composition thereof.

81. 81. The method of claim 80, wherein the cell is a cancer cell.

82. 82. The method of claim 80 or 81, wherein the stapled peptide has improved cellular uptake compared to the corresponding unconjugated stapled peptide.

83. 71. A method for inducing cancer cell death, comprising contacting a cancer cell with a SPAC according to any one of claims 1 to 70, or a pharmaceutical composition thereof.

84. 84. The method of claim 83 for selectively killing cancer cells in the presence of non-cancerous cells.

85. The method of any one of claims 80 to 84, wherein the cell is in vitro.

86. The method of any one of claims 80 to 84, wherein the cell is in vivo in a subject.

87. 2. The method of any one of the preceding claims, wherein the SPAC is administered intravenously.

88. 13. The method of any one of the preceding claims, wherein the subject is a human.

89. A SPAC according to any one of claims 1 to 70 for use in a method according to any one of the preceding claims.

90. Use of a SPAC according to any one of claims 1 to 70 for the manufacture of a medicament.

91. 71. A kit comprising the SPAC of any one of claims 1 to 70, or a pharmaceutical composition thereof, and optionally instructions for use.